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The development of organisms relies on complex spatial and temporal patterning of gene 
expression to define cell types and facilitate their functions. Cis-regulatory elements in our genome 
are responsible for the control of gene expression across tissues and cell types. Regulation of these 
elements themselves depends on a balance of activation and repression through epigenetic 
modifications and molecular regulatory components. Disruption of cis-regulatory element control 
is emerging as a cause of neurodevelopmental disease. An important contributor to gene regulation 
in development is methylation of cytosine in DNA, disruption of which has been associated with 
disease. Notably, while all cell types employ methylation at CG dinucleotides to control gene 
expression, mammalian neurons contain uniquely high levels of non-CG DNA methylation that 
are critical for proper nervous system function. MeCP2, the protein associated with Rett syndrome, 
in turn binds to non-CG methylation to regulate gene expression. Defining how non-CG 
methylation accumulates in neurons and is read out by MeCP2 will improve our understanding of 
the unique gene-regulatory environment in these cells and can begin to decipher the molecular 
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underpinnings of neurodevelopmental disorders. Here, I explore the role of gene expression and 
genome architecture in establishing patterns of non-CG methylation in neurons and highlight 
emerging mechanistic insights into how non-CG methylation and MeCP2 control transcription 
through neuronal enhancers. I define a nested pattern of methylation by which highly-methylated, 
mega-base scale topologically-associated domains contain genes of high methylation, which 
themselves contain enhancers of high methylation. MeCP2 represses enhancers found in these 
methylation-enriched domains, with the strongest repression occurring for enhancers located 
within genes repressed by MeCP2. I show that loss of methylation-dependent repression of 
enhancers can drive changes in gene expression in models of disease. Finally, I outline preliminary 
findings identifying upstream and downstream mechanisms of enhancer regulation through 
MeCP2 and DNA methylation. These insights provide clues as to how the distinctive epigenome 




Chapter 1: Emerging insights into the 
distinctive neuronal methylome 
 
This chapter is adapted from a review published in Trends in Genetics. 
Clemens, AW., Gabel, HW. Emerging insights into the distinctive neuronal methylome. Trends 




1.1 DNA methylation guides genomic regulation. 
Eukaryotic gene expression is guided by covalent chromatin modifications that facilitate temporal 
and spatial control of transcription in diverse cell types during development and across dynamic 
processes (Zhou et al., 2017). The addition of a methyl group to the 5’ position of cytosine 
nucleotides (mC) is a major epigenetic modification that contributes to gene regulation across 
phylogeny (Zhou et al., 2017). mC can block the binding of gene regulatory proteins such as 
transcription factors, or recruit “reader” proteins that affect chromatin structure and alter 
transcription. There is evidence that DNA methylation participates in both activation and 
repression of gene expression; however, in mammals it is predominantly associated with repeat 
and transposable element silencing, as well as gene repression (reviewed in (Greenberg and 
Bourc’his, 2019)). While mC at CG dinucleotides contributes to gene regulation in all cell types, 
in the last decade it has become clear that DNA methylation has unique and essential roles in the 
nervous system. Here, we review the discovery and characterization of prevalent mC at non-CG 
sequences in neurons and discuss the identification of Methyl CpG-binding Protein 2 (MeCP2), 
the protein disrupted in the neurodevelopmental disorder Rett syndrome (see Glossary), as an 
essential reader of this mark. We explore new results shedding light on mechanisms of 
neurodevelopmental disorders caused by disruption of DNA methylation and gene regulation 
mediated by MeCP2.   
 
1.2 The unique neuronal methylome. 
Classically, DNA methylation in mammals was described almost exclusively at cytosines followed 
by guanines (mCG), with symmetric methylation occurring at cytosines on both strands. mCG is 
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the predominant form of DNA methylation in most tissue types (reviewed in (Greenberg and 
Bourc’his, 2019)). However, in the brain, alternative forms of methylation are abundant. The 
neuronal methylome was first recognized as unique when high levels of oxidation of mCG sites to 
hydroxymethylation (hmCG) were discovered in Purkinje cells of the cerebellum and in brain 
tissue (Endnote 1) (Kriaucionis and Heintz, 2009). More recently, prevalent non-CG DNA 
methylation (mCH; where H=A, C, or T) has been identified, with this methylation primarily 
occurring at cytosines followed by adenine (mCA). mCH is highly enriched in neurons compared 
to other cell types in mouse and humans, and while the methylation rate of CH is lower than that 
of CG, in some classes of neurons the number of modified CH sites (~1.5-3% for 1.1 billion CH 
sites = 16-30 million modified CH sites) is equivalent to, or higher than, total modified CG sites 
(~80% for 21 million CG sites = ~17 million modified CG sites) (Figure 1A; 2A; discussed in 
Endnote 1) (Guo et al., 2014; Lister et al., 2013; Xie et al., 2012).   
 
mCH is deposited by the de novo DNA methyltransferase 3A (DNMT3A) (Endnote 1), which is 
upregulated in neurons at birth and reaches peak expression at ~2 weeks in mice, before declining 
to lower expression levels in adulthood (Gabel et al., 2015; Guo et al., 2014; Lister et al., 2013). 
In frontal cortex, this expression leads to postnatal accumulation of mCH, which plateaus by 4-6 
weeks in mice. In humans, mCH builds up primarily during the first two years, but requires sixteen 
years to fully accumulate (Figure 2B) (Lister et al., 2013). Like mCG, mCH occurs broadly across 
the genome. Postnatal mCH accumulation across the neuronal genome is influenced by pre-
existing gene expression and chromatin structure (Clemens et al., 2020; Lister et al., 2013; Stroud 
et al., 2017). Little to no mCH is deposited at completely silent genes and inaccessible regions of 
constitutive heterochromatin (e.g. olfactory receptor genes clusters) (Lister et al., 2013). Within 
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euchromatic regions, DNMT3A is readily recruited and deposits mCH at repeated sequences, 
extragenic regions, lowly transcribed genes, and inactive regulatory elements. In contrast, 
DNMT3A binding and mCH accumulation are depleted from the transcribed region of highly 
expressed genes and active regulatory elements (Figure 1B; 2C,D) (Kozlenkov et al., 2018; Lister 
et al., 2013; Luo et al., 2017; Mo et al., 2015, 2016; Stroud et al., 2017). Experimental manipulation 
of gene expression in mouse cerebral cortex during the postnatal period indicates that high 
transcriptional activity blocks DNMT3A binding in genes and results in low mCH accumulation, 
which persists throughout adulthood (Stroud et al., 2017). Readout and repression of genes through 
mCH in adult neurons likely reinforces low expression of highly methylated genes, while lowly 
methylated genes escape repression and are highly transcribed (Stroud et al., 2017) (discussed 
below). Genes expressed at moderate levels postnatally build up intermediate levels of mCH, 
resulting in balanced activation by transcription-promoting machinery and repression by mCH in 
adult neurons that may tune gene expression levels (Stroud et al., 2017). 
 
Non-CG methylation depletion at genes and regulatory elements largely parallels patterns of mCG 
at a local scale (kilobase), but mCH shows unique variations on a large scale (megabase) that have 
been linked to the folding of chromosomes within the nucleus (Clemens et al., 2020). Megabase-
sized genomic regions show enrichment and depletion of mCH that correlate with Topologically 
Associating Domains (TADs) of chromatin folding (Clemens et al., 2020). TADs appear to be 
regions of consistent DNMT3A binding and accumulation of mCH, such that sequences found 
within individual TADs share similar mCH levels, or a “mCH set-point”, while sequences in 
neighboring TADs can have very different mCH levels (Clemens et al., 2020). This consistency 
of TAD mCH impacts genes and enhancer elements within TADs. For example, genes and 
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enhancers in a high-mCH TAD tend to have higher methylation than genes and enhancers in a 
low-mCH TAD (Figure 2D) (Clemens et al., 2020). Importantly, these differences in TAD 
methylation influence the regulation of genes in TADs by mCH. More details on the neuronal 
patterning and importance of mCH are further discussed below and within Chapter 2. 
 
While transcription of genes and TAD structure are clearly associated with mCH deposition, 
molecular mechanisms controlling DNMT3A activity to create these patterns are not yet defined. 
Analysis of diverse histone modifications in mouse cortex suggests that chromatin structure 
during early postnatal development impacts mCH deposition (Stroud et al., 2017), and studies of 
mCG deposition by DNMT3A outside the nervous system may provide clues to mCH deposition 
mechanisms within neurons. DNMT3A can bind to unmethylated lysine 4 on histone H3 
(H3K4me0) through its ATRX-DNMT3-DNMT3L (ADD) domain, which releases an auto-
inhibitory conformation to allow cytosine methylation (Guo et al., 2015; Rondelet et al., 2016). 
This mechanism could restrict mCH deposition from active regulatory elements, which are marked 
by H3K4 methylation. The Pro-Trp-Trp-Pro (PWWP) domain of DNMT3A can bind methylated 
lysine 36 on histone H3 (H3K36me) (Dhayalan et al., 2010; Guo et al., 2015). Based on studies of 
the close paralog, DNMT3B, this domain has been thought to bind H3K36me3 (Greenberg and 
Bourc’his, 2019), but recent studies indicate similar or more robust binding to H3K36me2 
compared to H3K36me3. Notably, H3K36me2 has been shown to accumulate in broad 
euchromatic regions and facilitate CG methylation of these domains in dividing mouse and human 
cells (Dukatz et al., 2019; Weinberg et al., 2019; Xu et al., 2020), while H3K36me3 is associated 
with the gene bodies of highly expressed genes. If similar patterns of H3K36me2 exist in neurons, 
DNMT3A may bind to broadly distributed H3K36me2 to guide TAD-scale methylation, while 
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conversion of H3K36me2 to H3K36me3 in the gene body could result in lower levels of 
DNMT3A recruitment and less mCH deposition in highly expressed genes. Future studies 
examining the effects of disruption of these histone marks on DNMT3A localization and activity 
in neurons will help to define the precise mechanisms that govern the deposition of mCH in the 
brain. For instance, it has yet to be determined how the ADD domain functions in neurons and if 
it shares the same auto-inhibitory role suggested from structural analysis. Moreover, it is unknown 
how gene expression, H3K36me2, and H3K36me3 function together to balance to the recruitment 
and repression of DNMT3A to gene bodies within neurons. Identifying these regulatory roles for 
gene expression and DNMT3A within neurons will provide valuable insight into how gene 
expression and chromatin structure dictate the distribution of neuronal DNA methylation. 
 
1.3 mCH as a hallmark of cell types. 
An intriguing feature of non-CG methylation is its high degree of cell-type specificity, both in 
global levels of mCH and in local patterns of demethylation at genes and regulatory elements. In 
both mouse and human, levels of mCH can vary by up to 2-fold between brain regions (Christian 
et al., 2020; Gabel et al., 2015; Guo et al., 2014; Lister et al., 2013; Mellén et al., 2017) and 1.5-
fold among neuron subtypes in the same brain region (Luo et al., 2017; Mo et al., 2015, 2016). For 
example, somatostatin- (SST+) and parvalbumin-positive (PV+) inhibitory interneurons in the 
cerebral cortex are enriched approximately 30% for mCH compared to vasoactive intestinal 
polypeptide-positive (VIP+) neurons (Luo et al., 2017; Mo et al., 2015). mCH is also enriched 30-
50% in deep layer cortical excitatory neurons compared to their upper layer counterparts (Luo et 
al., 2017). These large variations contrast with smaller global differences in mCG across brain 
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regions and cell classes (Figure 2E) (Luo et al., 2017; Mo et al., 2015). Studies of single neuron 
methylomes in hippocampus and cortex suggest that both the subtype of a neuron and its location 
influence mCH levels. For example, inhibitory neuron classes (e.g. PV+) from both cortex and 
hippocampus share similar mCH levels, but total amounts can be different for cells within the same 
class in different layers within a region (Liu et al., 2020; Luo et al., 2017). How these global 
variations in mCH originate has not been determined, but differential expression or activation of 
DNMT3A in cell types during postnatal development is a potential mechanism that future studies 
can explore. In all, the varying global mCH levels across cell types suggest that mCH may play a 
larger regulatory role in some brain regions and neuronal classes compared to others.  
 
The role of MeCP2 in neuronal function has been extensively characterized across multiple brain 
regions through studies of mice carrying knockout, overexpression, and disease-associated 
missense mutations (Gulmez Karaca et al., 2019; L.M. et al., 2015; Lyst and Bird, 2015; Tillotson 
and Bird, 2019). When exogenous MeCP2 is expressed specifically in post-mitotic neurons of a 
mouse lacking MeCP2, the phenotypes associated with the MeCP2 knockout mice are rescued 
back to wild-type (Luikenhuis et al., 2004). However, there is evidence of some importance of 
MeCP2 in glia, in which loss of MeCP2 in glia show a poisoning effect on neurons, which suggests 
that while MeCP2 likely plays an important function in glia, the majority of the phenotypes may 
result from neuronal-dysfunction (Ballas et al., 2009; Jin et al., 2017). Moreover, re-expression of 
MeCP2 in glia or microglia of an MeCP2-null mouse only partially recovers phenotypes, unlike 
restoration of MeCP2 in neurons (Cronk et al., 2015; Nguyen et al., 2013). Researchers have 
remained focused on MeCP2 in neurons, not just because it is enriched in neurons over glia, but 
also because CA methylation does not accumulate in glia like it does in neurons (Lister et al., 
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2013). Additionally, the more prominent effects of MeCP2 disruption in neurons compared to glia 
underlie the importance of the presence of both MeCP2 and mCA to observe the functional effects 
associated with MeCP2.  
 
Differential CG methylation at genes and regulatory sequences has historically been known to 
contribute to differentiation and maintenance of distinct cell types (reviewed in (Greenberg and 
Bourc’his, 2019)). In addition to global variations, local mCH profiles at genomic loci show even 
more robust cell-type specific patterning than canonical mCG (Luo et al., 2017; Mo et al., 2015). 
Gene body mCH patterns across cell types are tightly associated with gene expression (Luo et al., 
2017; Mo et al., 2015; Stroud et al., 2017), such that mCH within genes varies to a greater degree 
and is more highly correlated with cell-type specific expression than mCG or open chromatin 
signatures, which show a less dynamic range in signal at genes across cell types (Luo et al., 2017; 
Mo et al., 2015). Emerging compendiums of single-cell methylomes across multiple mouse brain 
regions are further defining cell-type specific patterns of mCH (Liu et al., 2020; Yao et al., 2020). 
These data show that mCH profiles of individual neurons can be used to predict the precise location 
of a given neuron within one of five different brain regions and the laminar position within that 
region. The data also reveal patterns of gene expression and enhancer activity across increasingly 
refined neuronal subtypes. Cell-type specific mCH patterns appear to be dictated by existing gene 
expression patterns in the early postnatal period through the mechanisms described above (Figure 
2C). Once established, these mCH patterns function with canonical mCG to maintain cell-type 




1.4 Readout of mCH by MeCP2. 
Insights into the functional importance of mCH in the brain have emerged through studies 
establishing MeCP2 as a major reader of this methyl mark. MeCP2 accumulates dramatically in 
neurons during postnatal development in parallel with the build-up of mCH (Figure 2B) (Kishi 
and Macklis, 2004; Shahbazian, 2002; Skene et al., 2010). In mature neurons, MeCP2 protein 
reaches expression levels nearly equivalent to that of histone H4 (Figure 2A) (Skene et al., 2010), 
and the expression of Mecp2 in neurons has been shown to be essential for nervous system function 
(Luikenhuis et al., 2004; Tillotson and Bird, 2019). While MeCP2 was originally identified as a 
reader of mCG sites, the discovery of high levels of mCH in the brain prompted close examination 
of its affinity for this methyl-mark. Indeed, several independent studies identified high-affinity 
binding of MeCP2 to mCH sites, specifically mCA (Chen et al., 2015; Gabel et al., 2015; Guo et 
al., 2014). MeCP2 binds to methylated DNA through its methyl-binding domain (MBD), a motif 
common amongst other methyl-binding proteins (Ginder and Williams, 2018; Hendrich and Bird, 
1998), and shows the strongest binding to mCA compared to the other members of this protein 
family (Ginder and Williams, 2018; Sperlazza et al., 2017). Notably, mCAC is the most common 
site for non-CG methylation in the neuronal genome (Lister et al., 2013; Xie et al., 2012) and is 
the highest affinity trinucleotide non-CG site for MeCP2 binding (Lagger et al., 2017). The 
preference of MeCP2 for the most prevalent mCH site suggests a functional evolution of non-CG 
binding for MeCP2 (Lagger et al., 2017). Further support for readout of mCA as a critical player 
in MeCP2 function comes from an emerging study of mice carrying an engineered MeCP2 protein 
that can bind mCG, but not mCA. These mice recapitulate many neurologic phenotypes and gene 
expression changes seen in MeCP2 knockouts (Tillotson et al., 2020), indicating that mCG binding 
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is not sufficient for normal nervous system function. Together, these studies emphasize readout of 
mCA by MeCP2 as essential in the brain. 
 
Interestingly, the high levels of hydroxymethylation in neurons (Endnote 1) may increase the 
functional importance for mCH as a site of MeCP2 binding. Biochemical and structural studies 
indicate that MeCP2 has a lower affinity for hmCG than mCG, while conversion of mCH to hmCH 
appears to have little effect on MeCP2 binding (Buchmuller et al., 2020; Gabel et al., 2015; 
Hashimoto et al., 2012; Lagger et al., 2017; Mellén et al., 2017; Sperlazza et al., 2017; Valinluck 
et al., 2004). The large-scale conversion of mCG to hmCG (Endnote 1) (Kozlenkov et al., 2018) 
has been proposed to inactivate (“functionally demethylate”) high-affinity CG binding sites of 
MeCP2. Given that the number of MeCP2 molecules in neurons appears to be substantially lower 
than total numbers of mCG and mCH binding sites (Figure 2A, I) (Lister et al., 2013; Skene et al., 
2010), hmCG accumulation could shift MeCP2 binding in favor of mCH or hmCH sites 
(Buchmuller et al., 2020; Gabel et al., 2015; Hashimoto et al., 2012; Lagger et al., 2017; Mellén 
et al., 2017; Sperlazza et al., 2017; Valinluck et al., 2004).  
 
Chromatin-immunoprecipitation-sequencing (ChIP-seq) studies of MeCP2 in mouse and human 
brain and isolated neuronal cell populations have detected extremely broad occupancy of the 
protein across the genome, with relative enrichment of binding at methylated DNA (Baker et al., 
2013; Chen et al., 2015; Cholewa-Waclaw et al., 2019; Cohen et al., 2011a; Gabel et al., 2015; 
Kinde et al., 2016; Lagger et al., 2017; Mellén et al., 2017; Renthal et al., 2018; Rube et al., 2016; 
Skene et al., 2010; Stroud et al., 2017). At approximately 16 million molecules of MeCP2 per 
neuronal nucleus (Skene et al., 2010), there are sufficiently high numbers of MeCP2 molecules to 
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engage a substantial percentage of the ~24-44 million total mCG and mCH binding sites for the 
protein in typical neurons (Endnote 1). Indeed, ChIP signals from multiple studies reflect near-
ubiquitous binding with high levels of enrichment (~10-100 fold) compared to Mecp2 knockout 
controls at all sites in the genome assessed (Boxer et al., 2020; Cohen et al., 2011b). Within the 
context of broad binding, MeCP2 ChIP signal is enriched at regions with high levels of mCG and 
mCH (e.g. extragenic regions) and is depleted at regions with low mCH and mCG and high levels 
of hmCG (e.g. promoters, enhancers, gene bodies for highly expressed genes). However, the 
magnitude of this depletion is minimal (~1-2-fold), even at regions that are essentially devoid of 
mC sites (Baker et al., 2013; Chen et al., 2015; Cholewa-Waclaw et al., 2019; Cohen et al., 2011a; 
Gabel et al., 2015; Kinde et al., 2016; Lagger et al., 2017; Mellén et al., 2017; Renthal et al., 2018; 
Rube et al., 2016; Skene et al., 2010; Stroud et al., 2017). It is unclear if this limited dynamic range 
is a technical limitation of the ChIP method or if it indicates that MeCP2 binds substantially to 
unmethylated DNA in vivo. In vitro studies have shown that MeCP2 is capable of binding 
unmethylated DNA, with a preference for GTG residues, albeit with lower binding affinity than 
methylated DNA (Lei et al., 2019; Meehan et al., 1992). However, recent analyses of MeCP2 
binding in cells indicate that ChIP-seq and footprint signals for MeCP2 are not enriched at 
unmethylated GT-rich DNA sequences (Connelly et al., 2020). A new study suggests that MeCP2 
may undergo phase separation with DNA (Fan et al., 2020; Wang et al., 2020) (discussed below), 
raising the possibility that condensates of MeCP2 may drive multi-valent contacts with regions of 
the genome. These associations may contribute to the observed ubiquitous binding pattern of 
MeCP2, even at sites of low methylation. Together, the largely ubiquitous and low dynamic range 
patterns of MeCP2 ChIP-seq signal have not allowed researchers to definitively classify specific 
“target genes” of MeCP2 based on binding profiles alone. Rather, some genes and regulatory 
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elements display modest enrichment of MeCP2 binding compared to those with modest depletion 
(Baker et al., 2013; Boxer et al., 2020; Clemens et al., 2020; Gabel et al., 2015; Rube et al., 2016). 
This suggests MeCP2 may play a regulatory role at virtually every region of the genome (Endnote 
2).   
 
Despite these challenges, in vitro and in vivo binding studies clearly indicate that MeCP2 binds 
with high affinity to mC and does exhibit enriched binding patterns by ChIP-seq (Gabel et al., 
2015; Guo et al., 2014; Lagger et al., 2017; Rube et al., 2016). Building on this knowledge, 
researchers have employed genomic analysis of high affinity MeCP2 binding sites, mCA and 
mCG, together with transcriptomic studies to establish a functional role of MeCP2 in controlling 
transcription of methylation-rich genes (Baker et al., 2013; Chen et al., 2015; Cholewa-Waclaw et 
al., 2019; Cohen et al., 2011a; Gabel et al., 2015; Kinde et al., 2016; Lagger et al., 2017; Mellén 
et al., 2017; Renthal et al., 2018; Rube et al., 2016; Skene et al., 2010; Stroud et al., 2017). 
 
1.5 Gene regulation by MeCP2 and neuronal DNA 
methylation. 
Since its initial identification as a reader of mCG, a myriad of putative protein binding partners for 
MeCP2 have been identified. These include proteins involved in transcriptional repression and 
activation, splicing regulation, and microRNA processing, suggesting diverse molecular functions 
of MeCP2 (reviewed in (Ip et al., 2018; Tillotson and Bird, 2019)). In addition, MeCP2 is heavily 
phosphorylated in response to neuronal stimulation, which modulates its activity (Yap and 
Greenberg, 2018). A large body of evidence supports gene repression as a major function of 
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MeCP2 (Tillotson and Bird, 2019), and this direct, repressive function of MeCP2 is the focus of 
discussion here. The best characterized interactor for MeCP2 is the Nuclear Co-Repressor 
complex (NCoR). NCoR binding is critical for the repressive function of MeCP2 in in vitro assays, 
and mutations of MECP2 that specifically disrupt this interaction have been shown to drive Rett 
syndrome (Kong et al., 2020; Tillotson and Bird, 2019). Identifying the mechanisms by which the 
MeCP2-NCoR complex affects gene expression is a major outstanding challenge for the field. 
 
The function of MeCP2 in gene regulation has been intensely studied, but remains difficult to 
decode (Lavery and Zoghbi, 2019; Tillotson and Bird, 2019). Hundreds to thousands of genes can 
be detected as significantly dysregulated in transcriptomic studies of brain tissue and isolated cells 
from Mecp2 knockout and missense mutants or MECP2 over-expressing mice, as well as humans 
with Rett syndrome. However, the magnitude of dysregulation for these genes is subtle (less than 
2-fold), and the near-ubiquitous binding patterns of MeCP2 do not provide sufficient evidence to 
suggest that these genes are the exclusive targets of regulation by the protein (Endnote 2).  
 
Since its identification as a high-affinity reader of mCG, multiple lines of evidence have supported 
gene repression as a major function of MeCP2. It is indeed thought that MeCP2 largely functions 
as a repressor due to its observed interaction with the NCoR complex in vitro through MeCP2’s 
NCoR-interacting domain (NID), a critical sequence contained within the transcriptional 
repression domain (TRD) of MeCP2. Notably, the NID contains several sites of mutations 
associated with Rett syndrome, including R306C, the most common mutation observed in Rett 
syndrome that abolishes this NCoR interaction (the MBD also contains a large percentage of Rett-
associated mutations) (Kruusvee et al., 2017; Lyst and Bird, 2015; Lyst et al., 2013). Moreover, 
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the repressive effects of MecP2 have been combined with the repressive KRAB domain in in vitro 
dCas9 experiments to generate more robust repression at targets sites (Yeo et al., 2018).  
 
Recent integrated analysis of whole-genome bisulfite-sequencing DNA methylation maps and 
transcriptomic changes in Mecp2 knockout and missense mutants or MECP2 transgenic mice has 
detected methylation signatures on genes most highly affected by MeCP2 and has provided clues 
to the mechanism of MeCP2-mediated gene regulation (Boxer et al., 2020; Chen et al., 2015; 
Clemens et al., 2020; Gabel et al., 2015; Kinde et al., 2016; Lagger et al., 2017; Lavery et al., 2020; 
Renthal et al., 2018; Rube et al., 2016; Stroud et al., 2017) (Figure 1B). These studies identify a 
reproducible enrichment of mCH compared to the genome average within the gene body and 
flanking sequences of MeCP2-repressed genes, those that show significant increases in 
expression when MeCP2 is disrupted and decreases when MeCP2 is overexpressed. The high 
levels of mCH in and around MeCP2-repressed genes arise from high mCH in the TADs of which 
these genes are found, indicating that genome topology plays a role in establishing high 
methylation at these genes (Clemens et al., 2020). MeCP2-activated genes, those that show 
significant decreases in expression when MeCP2 is lost and increases when it is overexpressed, 
are often found within lower mCH TADs, although they can show moderate gene body mCH 
enrichment in some studies (Figure 1B) (Boxer et al., 2020; Chen et al., 2015; Clemens et al., 
2020). Though it is low in dynamic range, the MeCP2 ChIP-signal in and around MeCP2-repressed 
genes is enriched (Boxer et al., 2020; Chen et al., 2015; Lagger et al., 2017; Renthal et al., 2018), 




The function of mCH in MeCP2-mediated gene repression is supported by studies in which mCH 
accumulation was blocked through perinatal conditional deletion of Dnmt3a in the brain or 
specifically in neurons of mice (Boxer et al., 2020; Clemens et al., 2020; Gabel et al., 2015; Kinde 
et al., 2016; Lavery et al., 2020; Stroud et al., 2017) (Figure 3A). These analyses detected 
alterations in gene expression in the absence of mCH that partially recapitulate the effects observed 
in Mecp2 knockout and missense mutants and demonstrated a loss in MeCP2 ChIP-signal at 
sequences that lose the most mCH upon deletion of Dnmt3a (Clemens et al., 2020; Kinde et al., 
2016). Importantly, because mCG is pre-established early in development by DNMT3A/B and is 
largely maintained in neurons by DNMT1 (Okano et al., 1999), the effects observed after Dnmt3a 
conditional deletion can be attributed to the absence of mCH (Boxer et al., 2020; Clemens et al., 
2020; Gabel et al., 2015; Kinde et al., 2016; Lavery et al., 2020; Stroud et al., 2017). This provides 
substantial in vivo evidence supporting mCH as a key site through which MeCP2 affects 
transcription. 
 
Notably, while signatures of methylation can be detected at lists of genes significantly dysregulated 
in Mecp2 and Dnmt3a mutants, neuronal DNA methylation and MeCP2 are present at every gene 
in the genome to varying degrees, and therefore may impact all genes. Indeed, gradients of gene 
dysregulation associated with genic methylation levels have been detected across all genes genome 
wide in Dnmt3a and Mecp2 knockout, conditional knockout, and missense mutants (Endnote 2) 
(Boxer et al., 2020; Cholewa-Waclaw et al., 2019; Clemens et al., 2020; Gabel et al., 2015; Kinde 
et al., 2016; Lagger et al., 2017; Lavery et al., 2020; Renthal et al., 2018; Stroud et al., 2017). This 
suggests that disruption of mCH or MeCP2 has subtle yet global effects on neuronal transcriptomes 




1.6 Mechanistic insights into gene regulation by neuronal 
methylation and MeCP2. 
The identification of DNA methylation signatures associated with MeCP2-mediated regulation has 
provided a starting point for studies dissecting the mechanism of this regulation. The observation 
that MeCP2-repressed genes are enriched for methylation within the gene body and flanking 
regions, rather than sequences at the transcription start site, has suggested that MeCP2 regulates 
transcription through binding to mC outside of the core promoter region (Figure 1B) (Chen et al., 
2015; Gabel et al., 2015; Kinde et al., 2016). This finding, combined with the fact that MeCP2-
repressed genes also tend to be expressed through extremely long pre-mRNAs, led to the initial 
hypothesis that MeCP2 binds mC and acts as a “speed-bump”, inhibiting processivity of RNA 
polymerase II (RNAPII) (Cholewa-Waclaw et al., 2019; Kinde et al., 2016; Lagger et al., 2017). 
However, recent studies in mice analyzing intronic RNA-seq and GRO-seq data, as well as ChIP-
seq data for RNAPII and histone modifications associated with transcription (H3K4me3, 
H3K27ac, H3K36me3) (Boxer et al., 2020; Clemens et al., 2020) did not support this prediction. 
Rather than finding altered rates of RNAPII processivity, these studies detected altered promoter 
activity and transcription initiation in genes dysregulated upon mutation of Mecp2 (Boxer et al., 
2020; Clemens et al., 2020).  
 
How can binding of MeCP2 to methylation outside of the promoter control transcription initiation? 
One possibility is that MeCP2 bound to mCH and mCG within and outside of genes can loop to 
contact promoters, recruiting the NCoR complex and repressing transcription initiation (Figure 
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3B) (Boxer et al., 2020). In support of this possibility, recent Hi-C analysis in mice indicates that 
contacts between these regions and promoters do occur in the brain (Boxer et al., 2020). Substantial 
additional evidence suggests that MeCP2-NCoR binding to mC at distal sites can broadly block 
histone acetylation (Boxer et al., 2020; Clemens et al., 2020; Shahbazian et al., 2002; Skene et al., 
2010), and genomic looping could bring this function to promoters.  
 
In a parallel mechanism, MeCP2 bound to mC at enhancers locally represses the capacity of these 
elements to activate their cognate genes (Clemens et al., 2020). Loss of Mecp2 in mice leads to an 
increase in histone acetylation at sequences with highly methylated TADs, particularly within 
MeCP2-repressed genes (Boxer et al., 2020; Clemens et al., 2020). These effects are most robust 
at enhancer elements, where de-repression of acetylation in the absence of MeCP2 is correlated 
with the number of mCG and mCH sites. Notably, intragenic enhancers are more highly repressed 
by MeCP2 than extragenic enhancers, providing one explanation for the original identification of 
enriched intragenic methylation in MeCP2-repressed genes. A role for both mCG and mCH in 
mediating these effects at enhancers has been further supported through analysis of Dnmt3a 
conditional knockout mice lacking mCH (Clemens et al., 2020). In addition, a recent study in 
mouse cortex found that DNA methylation accumulates postnatally in embryonic-specific 
enhancers and MeCP2 represses these elements (Stroud et al., 2020). Thus, deacetylation at 
enhancers and potentially other genomic sequences is an important consequence of mC binding 
by MeCP2 that contributes to gene regulation in neurons. 
 
By parsing out the effects of mCH and mCG, a clearer and more definitive understanding of the 
importance of both CH and CG methylation for the function of MeCP2 is revealed. Compared to 
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the effects seen in the MeCP2 KO model, only a partial effect on gene regulation and regulatory 
element activity was observed due to the loss of roughly half of the binding sites of MeCP2 
(Clemens et al., 2020). Since, mCG and MeCP2 both remain at similar levels between the 
DNMT3A cKO and wild-type mice, there were no changes in enhancer activity as a function of 
mCG at enhancers. Conversely, the loss of mCA sites drove changes in enhancer activity as a 
function of mCA levels found at those regions in wild-type mice. Therefore, the partial effects 
seen in the DNMT3A cKO compared to the MeCP2 KO are derived from the persisting mCA-
dependent changes and the lack of mCG-dependent changes. This illustrates that both mCA and 
mCG are important for the full functional activity of MeCP2 and that neuronal DNA methylation 
and MeCP2 have overlapping regulatory functions. Chapter 2 provides a deeper discussion of the 
unique and congruent aspects of DNA methylation, MeCP2, and DNMT3A in neuronal gene 
regulation. 
 
The biological role of NCoR in the context of MeCP2 binding to mC is also coming into focus. 
The NCoR complex is known to possess deacetylase activity mediated by its HDAC3 subunit 
(Guenther et al., 2001). It is therefore intuitive to theorize that this activity could mediate 
repression by MeCP2. Specific disruption of the MeCP2-NCoR interaction through an MeCP2 
point mutation in mice leads to similar effects on histone acetylation and gene expression as the 
Mecp2 knockout, underscoring the role of NCoR in these effects (Boxer et al., 2020; Gabel et al., 
2015). In addition, loss of MeCP2 and loss of HDAC3 result in shared social and motor 
impairments as well as an overlap of dysregulated genes associated with neuronal function in mice, 
supporting a role for HDAC3 in MeCP2-NCoR regulation (Nott et al., 2016). However, a recent 
study tested the importance of NCoR-associated HDAC activity by assessing the severity of 
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phenotypes when Mecp2 is overexpressed in vivo. This study found that introducing an R306C 
missense mutation associated with Rett syndrome into overexpressed MeCP2 disrupts the NCoR-
MeCP2 interaction and blocks the toxicity of MeCP2 overexpression. In contrast, introducing 
mutations into NCoR components that inhibit activation of HDAC3 did not rescue lethality 
(Koerner et al., 2018), suggesting the deacetylase activity of the NCoR complex is not required for 
the key functions of MeCP2-NCoR. This study relied primarily on gross organismal phenotypes 
for its interpretations. Studies directly testing changes in histone acetylation in similar mutants can 
confirm that deacetylation by NCoR is not the direct activity needed for MeCP2’s repressive 
function (Figure 3C). In Chapter 3 of this dissertation, I present initial results probing the 
mechanism by which MeCP2 and NCoR regulate enhancers. These findings suggest that while the 
interaction between MeCP2 and NCoR is critical for gene regulation by MeCP2, NCoR binding 
to the genome does not depend on MeCP2. In addition, these results suggest that MeCP2-NCoR 
act upstream of histone acetylation in the process of enhancer activation and drive downstream 
consequences of enhancer function. I address ongoing studies and future experiments that can 
further elucidate the precise mechanism of enhancer regulation by MeCP2. 
 
A challenge for researchers going forward is to integrate findings on protein-protein interactions 
and chromatin modifying activity of MeCP2-NCoR with potential structural or biophysical roles 
of MeCP2 in chromatin that are re-emerging. Historic findings have shown that MeCP2 localizes 
to regions of heterochromatin and drives nucleosome aggregation in vitro (Agarwal et al., 2007; 
Brero et al., 2005; Nan et al., 1996). Recent studies have shed new light on this activity by showing 
that MeCP2 can undergo liquid-liquid phase separation, forming condensates with nucleosomal 
DNA in vitro (Fan et al., 2020; Wang et al., 2020). Rett syndrome causing mutations of MECP2 
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reduced condensate forming activity, suggesting that MeCP2 might affect compartmentalization 
of heterochromatic droplets in cells and that disruption of this activity may be indicative of MECP2 
inactivation in disease. High resolution nuclear imaging in Mecp2 knockout mice has also 
observed altered heterochromatin volume in neurons lacking MeCP2, suggesting altered 
chromatin condensation (Linhoff et al., 2015). However, these findings have not yet been linked 
to the epigenomic and transcriptomic consequences of mCH-MeCP2 disruption. Recent analyses 
of chromatin looping by 3C and Hi-C detected no dramatic changes in chromosome topology in 
Mecp2 knockout mouse brain tissue (Boxer et al., 2020; Clemens et al., 2020). The lack of changes 
in chromosome topology does not support changes in nuclear compartmentalization occurring 
upon loss of MeCP2, as might be predicted by the phase-separation experiments. However, a study 
of human ES-cell-derived interneurons carrying the MECP2 R133C Rett syndrome mutation 
detected altered global topology (Xiang et al., 2020). Notably, these condensation and human 
topology studies analyzed MECP2 truncation and missense mutants, while the mouse studies 
focused on complete loss of the protein. Different MECP2 mutations result in differential clinical 
severity (Lyst et al., 2013; Tillotson and Bird, 2019), and these differences may account for 
contrasting effects across studies. Additional analysis will be needed to determine how 
condensation characteristics of MeCP2 may impact genome topology and gene expression to 
manifest cellular dysfunction when disrupted. 
 
Future studies can build on these recent findings to further decode the mechanism of gene 
regulation by the mC-MeCP2-NCoR pathway. For example, if epigenomic profiling experiments 
detect alterations in enhancer activation that occur upstream of histone acetylation at highly 
methylated enhancers upon loss of MeCP2 (e.g. transcription factor binding, nucleosome removal, 
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H3K4me1 deposition), it would suggest that MeCP2-NCoR indeed acts outside of histone 
acetylation in controlling chromatin structure. The role of NCoR in enhancer regulation through 
MeCP2 is further discussed in Chapter 3. 
 
1.7 Biological function of mCH-MeCP2-mediated gene 
regulation. 
In addition to these mechanistic insights, recent studies have shed light on the functional impact 
of mCH-MeCP2-mediated gene regulation. The highly cell-type-specific nature of mCH profiles 
suggests an important role for MeCP2 is to mediate neuron subtype-specific gene expression. In 
support of this, an initial study of hand-sorted cell populations from Mecp2 knockout mouse brains 
detected larger changes in mRNA levels in purified cell types compared to whole tissue and 
identified distinct sets of dysregulated genes in different cell types (Sugino et al., 2014). Recent 
integrated analyses of mCH profiles and RNA changes in isolated cell populations (Johnson et al., 
2017; Lavery et al., 2020; Stroud et al., 2017) and single cells (Renthal et al., 2018; Stroud et al., 
2017) from Mecp2 and Dnmt3a knockout, conditional knockout, and missense mouse mutants and 
humans with Rett syndrome have identified cell-type-specific de-repression of genes enriched for 
mCH. Notably, the genes most de-repressed in cell-specific and tissue-based studies of mCH and 
MeCP2 disruption tend to be long genes that encode protein with important roles in the 
establishment and maintenance of synaptic connectivity (e.g. cell-adhesion molecules, ion 
channels, and synaptic receptors) (Boxer et al., 2020; Clemens et al., 2020; Gabel et al., 2015; 
Lagger et al., 2017; Renthal et al., 2018; Sugino et al., 2014). Thus, mCH and MeCP2 appear to 




These recent findings, coupled with the knowledge that MeCP2 reads postnatal mCH patterns to 
repress transcription in the adult, suggest a functional model: During development when MeCP2 
expression is rising and mCH is being deposited in each neuronal subtype, genes and enhancers 
that are robustly expressed escape accumulation of mCH and subsequent repression by MeCP2. 
Conversely, genes that are lowly expressed accumulate mCH and MeCP2, which in turn maintains 
them in a repressed state later in life (Stroud et al., 2017). The absence of mCH-MeCP2 repression 
in the early postnatal period may allow for flexible expression of critical protein components of 
synaptic connectivity, as cells respond to extrinsic cues and integrate into circuits. Build-up of 
mCH and MeCP2 occurs primarily during the closure of postnatal hyperplastic periods, which 
could then maintain these gene expression patterns to allow for consolidation and refinement of 
cellular functions in the circuit. Thus, mCH-MeCP2 repression might effectively close an 
“epigenomic critical period” of plastic gene expression to stabilize functional circuits, in much the 
same way that build-up of extracellular matrix closes critical periods of plastic connectivity in the 
brain during this same period (Picard and Fagiolini, 2019). Once global patterns of mCH are 
established, stimulus-dependent inactivation of MeCP2-NCoR-mediated repression that results 
from MeCP2 phosphorylation (Yap and Greenberg, 2018) and activity-dependent alterations in 
DNA methylation (Bayraktar and Kreutz, 2018) could facilitate more limited, but important, 
dynamic gene expression during adult plasticity. In support of this role for mCH and MeCP2 in 
brain function, loss of MeCP2 disrupts critical period timing and synaptic plasticity (Ip et al., 2018; 




1.8 Expanding roles for mCH and MeCP2 in disease. 
For over a decade, disruption of MeCP2 due to loss-of-function mutations or overexpression has 
been recognized as the cause of Rett syndrome and MeCP2 duplication syndrome, respectively 
(reviewed in (Lavery and Zoghbi, 2019)). The fact that either too much or too little MeCP2 
manifests in severe neurologic dysfunction suggests that circuits require precise, dose-sensitive 
tuning of gene regulation by the mC-MeCP2-NCoR pathway (Lavery and Zoghbi, 2019; Tillotson 
and Bird, 2019) and raises the possibility that this pathway may be susceptible to additional insults 
in disease (Figure 1C). Indeed, exome sequencing studies have recently uncovered mutations in 
individuals with intellectual disability, autism, and related disorders that disrupt this pathway up- 
and down-stream of MeCP2. Heterozygous mutations in DNMT3A cause Tatton-Brown-Rahman 
syndrome and autism (Sanders et al., 2015; Satterstrom et al., 2020; Tatton-Brown et al., 2014). 
Strikingly, Dnmt3a heterozygous knockout mice that model this disorder exhibit ~50% global 
reductions in mCH across multiple brain regions (Christian et al., 2020; Sendžikaitė et al., 2019). 
This reduction in mCH drives alterations in enhancer histone acetylation and gene expression in 
the cerebral cortex that partially recapitulate MeCP2 loss of function (Christian et al., 2020). These 
findings indicate that mCH deposition and its role in neuronal regulation are highly sensitive to 
reduction in DNMT3A protein (Figure 3D).  
 
Mutations of a component in the NCoR complex, TBL1XR1, have also emerged as causal for 
neurodevelopmental disease (Coe et al., 2019; Firth et al., 2009; Satterstrom et al., 2020). Notably, 
some missense mutations identified in TBL1XR1 have been shown to specifically disrupt the 
NCoR-MeCP2 interaction, and a patient with a missense mutation in this interacting domain has 
been diagnosed with Rett syndrome, based on clinical criteria (Kruusvee et al., 2017; Zaghlula et 
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al., 2018). In further support of overlapping pathology arising from an absence of NCoR, loss-of-
function mutations of the Deacetylase Activating Domain of NCOR1 within GABAergic neurons 
resulted in cognitive-, social-, and anxiety- related phenotypes in mice that have some similarities 
with Mecp2 knockout models (Zhou et al., 2019). 
 
It is important to note that mutations in DNMT3A and NCOR1 also manifest multiple distinct 
clinical features from those of Rett syndrome (e.g. overgrowth, heart defects, joint hypermobility). 
Undoubtedly, these factors have gene regulatory roles early in development and outside of the mC-
MeCP2-NCoR axis that contribute to the non-overlapping aspects of these disorders (Tatton-
Brown et al., 2018; Zaghlula et al., 2018) (Figure 3E). The precise degree of overlapping molecular 
etiology between these disorders may have implications for the development of treatments. A 
striking feature of Mecp2 mutations is that reintroduction of exogenous MeCP2 in adults can 
dramatically reverse symptoms in mice (Guy et al., 2007), likely because restored MeCP2 reads 
out mCH and mCG patterns that were appropriately laid down during postnatal development. This 
finding has fueled development of gene therapies for Rett syndrome (Gadalla et al., 2013). If 
DNMT3A mutations cause deficits in DNA methylation during critical temporal windows of 
embryonic and postnatal development, these effects may not be as reversible as the absence of 
MeCP2. Likewise, changes in cellular compositions of the brain or structural changes that occur 
due to loss of early roles for NCoR or DNMT3A may be difficult to reverse later in life. 
Nonetheless, disruption of epigenomic regulation through the mC-MeCP2-NCoR axis in adults is 
likely a shared deficit that contributes to neurologic dysfunction in these disorders and may be a 





1.9.1 Figure 1. Non-CG methylation and MeCP2 in neuronal gene regulation. 
A. Non-CG DNA methylation is enriched in neurons compared to glia and other cell types and 
can show substantial variations in global levels across neuronal subtypes (Lister et al., 2013; 
Luo et al., 2017; Mo et al., 2015). 
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B. Summary of mCH profiles detected at genes most impacted by mCH and MeCP2 mediated 
gene regulation. Two example “meta genes” and TADs depict local depletion of mCH within 
gene bodies and enhancer sequences. MeCP2-repressed genes (red) are enriched for mCH 
within their gene bodies, at associated enhancers, and throughout the TAD they are located 
within, while MeCP2-activated genes (blue) and enhancers associated with them are in regions 
of mCH depletion (Boxer et al., 2020; Clemens et al., 2020; Stroud et al., 2017). 
C. Neuronal gene regulation by the mC-MeCP2-NCoR axis is impacted by disease-associated 
mutations at multiple levels: mCH deposition, MeCP2 expression, and NCoR complex 
components. Dysregulation of enhancers and transcriptional activity resulting from these 
mutations may contribute to disease pathology. The susceptibility of this pathway to disruption 
suggests that it may be affected in additional neurodevelopmental disorders caused by 
mutations of epigenetic regulatory genes. (ASD – Autism Spectrum Disorder; ID – Intellectual 






1.9.2 Figure 2. The unique neuronal epigenome. 
A. Summary of reported levels of DNA modification sites and MeCP2 molecules between 
neurons and non-neural cell types, illustrating that mCH, hmCG, and MeCP2 are uniquely 
enriched within neurons. 
B. During postnatal neuronal maturation, non-CG methylation, hydroxymethylation, and MeCP2 
build up, reaching high levels in mature neurons at the young adult stage. 
C. Left, a model depicting the early postnatal deposition of non-CG methylation by DNMT3A, 
establishing megabase-scale domains of high and low methylation associated with TADs. 
Right, a model illustrating how high levels of gene expression block DNMT3A activity, as 
highly expressed genes exhibit less DNMT3A binding and mCH accumulation compared to 
lowly expressed genes. 
D. Illustration of typical methylation profiles in adult brain tissue. Both mCG and mCH are 
depleted at promoters and enhancers, but only mCH exhibits robust gene body demethylation 
and megabase-scale variations. H3K27ac and H3K36me3 histone modifications illustrate the 
relationship between DNA methylation and regulatory elements and transcriptional activity. 
E. Illustration of differential global levels of mCH detected in subtypes of neurons. A layer V 
excitatory neuron shows substantially more mCH than a layer IV excitatory neuron (Luo et al., 
2017). These differences in methylation, combined with differential methylation of genes, set 
the stage for cell-type specific repressive effects by MeCP2 (e.g. Gene A is more strongly 








1.9.3 Figure 3. Molecular mechanisms of the mC-MeCP2-NCoR axis and its 
disruption in neurodevelopmental disorders. 
A. Top, a model depicting that MeCP2 binds to mCH deposited by DNMT3A. Bottom, upon 
complete or conditional knockout of Dnmt3a, mCH binding sites for MeCP2 are lost, but 
binding of MeCP2 to mCG persists. 
B. Top, model of MeCP2 binding to mC at enhancers and gene bodies to reduce the acetylation 
of enhancers, genes, and promoters, resulting in a reduction of transcription initiation. Bottom, 
upon Mecp2 knockout, restriction on acetylation and transcription are reduced. 
C. Left, the MeCP2-NCoR complex bound to mC represses enhancer acetylation. This may occur 
directly through the HDAC component of the complex or indirectly through other undefined 
activities of NCoR.  Right, loss of MeCP2 can lead to loss of NCoR recruitment to the genome, 
loss of co-repressor activities that result in reduced acetylation, or potentially a mechanism yet 
to be defined. 
D. Schematic depicting a spectrum of disruption for MeCP2 repressive effects at enhancers across 
neurodevelopmental disorders; ranging from hyper repression in MeCP2 duplication, to 
intermediate disruption of repression occurring when heterozygous loss of DNMT3A leads to 
global reduction in mCH, to complete loss of repression when MeCP2 is knocked out. 
E. Venn diagram illustrating mechanistic and phenotypic overlaps of molecular pathologies of 
neurological disorders. Disruption of enhancer repression by the mC-MeCP2-NCoR axis may 
be shared across these disorders and contribute to pathology. Notably, each genetic lesion 
results in unique phenotypes that are likely to drive loss of molecular functions outside of the 
overlapping mC-MeCP2-NCoR axis. (ASD – Autism Spectrum Disorder; ID – Intellectual 
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Disability; MDS – MeCP2 Duplication Syndrome; RTT- Rett Syndrome; TBRS – Tatton-






1.9.4 Figure 4. Neuron-enriched DNA modifications and their enzymes. 
Approximate levels of CG and CH dinucleotides and their levels of modifications across cell types. 
Numbers of mC sites are estimated based on measurements made in (Greenberg and Bourc’his, 
2019; Hon et al., 2014; Kozlenkov et al., 2018; Kriaucionis and Heintz, 2009; Lister et al., 2013; 
Luo et al., 2017; Mellén et al., 2017; Mo et al., 2015; Sardina et al., 2018). mC vs hmC levels are 
inferred by combining results quantifying all modified mC (using bisulfite-sequencing) with 
studies using hmC-sensitive detection methods (TAB-seq, OxBS). Values are based on the mouse 





3C & Hi-C: Chromatin Conformation Capture methods employing crosslinking and proximity 
ligation followed by PCR (3C) or high-throughput sequencing (Hi-C) to map 3D-interactions and 
the architecture of genome folding within the nucleus. 
 
Enhancer: Regulatory element found outside of promoters that recruits transcription factors and 
co-activators and interacts with promoters to drive transcription.  
 
Gene body: Region of the gene from transcription start site (TSS) to transcription end site (TES) 
that is transcribed during pre-mRNA production.  
 
Global run-on sequencing (GRO-seq): Method that utilizes co-transcriptional labeled 
nucleotide incorporation followed by sequencing to directly quantify gene transcription. 
 
Histone modifications: Denoted by histone number, amino acid, and modification (e.g. 
monomethylation, me1; trimethylation, me3; acetylation, ac). Associated with steps in 
transcriptional regulation. 
H3K4me1: Present at active enhancers. 
H3K4me3: Present at active/bivalent promoters and enhancers. 
H3K27ac: Present at active promoters and enhancers. 
H3K36me2: Precursor to H3K36me3; marks open euchromatic regions. 




mCA set-point: Hypothesis that levels of mCA are consistent across discrete mega-base scale 
domains of the genome, but can vary from domain to domain. mCA set-points appear to 
influence the levels of mCA at kilobase-scale sequence elements such as enhancers and gene 
bodies. 
 
MeCP2 duplication syndrome: Neurological disorder caused by genetic duplication of MECP2. 
Causes developmental delay among other severe clinical features. 
 
MeCP2-repressed genes: Genes significantly upregulated when MeCP2 is inactivated, and 
downregulated when MeCP2 is overexpressed. 
 
MeCP2-activated genes: Genes significantly downregulated when MeCP2 is inactivated, and 
upregulated when MeCP2 is overexpressed. 
 
Methyl-binding domain (MBD): Conserved protein domain that binds specifically to 
methylated cytosine. Found in MeCP2 as well as MBD1/2/3/4. 
 
Nuclear Co-Repressor complex (NCoR): A complex comprised of NCoR1 and/or its paralog 
SMRT, with TBL1, HDAC3, and GPS2 as its core components. It is recruited to the genome by 




Rett syndrome (RTT): X-linked recessive neurological disorder predominantly occurring in 
females that is caused by loss of function MECP2 mutations. Typified by phenotypically normal 
early development, followed by regression and decline in brain growth. 
 
Tatton-Brown Rahman syndrome (TBRS): Autosomal dominant neurodevelopmental disorder 
characterized by overgrowth, intellectual disability, and autism. Caused by heterozygous 
mutations of DNMT3A.  
 
Topologically Associating Domains (TADs): Linear regions of the genome that show 
enrichments for interactions in three-dimensional space. Can facilitate and/or result from 
contacts between enhancers and promoters that drive gene expression. 
 
Whole-genome bisulfite-sequencing (WGBS): Base-resolution DNA methylation profiling 
method whereby methylated cytosines are protected from sodium bisulfite conversion to uracil 






Endnote 1: Neuron-enriched DNA modifications and their 
enzymes. 
DNA methylation in mammals is deposited at unmethylated CG and non-CG sites (CH) by the de 
novo methyltransferases DNMT3A and DNMT3B. Additionally, DNMT1 methylates DNA at 
existing hemi-methylated CG sites to maintain symmetric CG methylation after new strand 
synthesis, or to create a fully methylated CG site after de novo methylation of one strand (Gowher 
and Jeltsch, 2018; Hermann et al., 2004). The ten-eleven translocation enzymes (TET 1,2,3) 
oxidize DNA, creating 5-hydroxymethylcytosine (hmC), 5-forymylcytosine (fcC), or 5-
carboxylcytosine (caC). These oxidized forms of DNA can drive active demethylation through the 
base excision repair pathway. However, hmC primarily leads to passive demethylation (dilution) 
in mitotic cells upon DNA replication by blocking DNMT1 from maintaining hemi-methylated 
CG dinucleotides (Wu and Zhang, 2017). 
 
In all cells, CG sites are highly methylated due to early activity of de novo methyltransferases and 
subsequent active maintenance of mCG by DNMT1 (Figure 4) (Hermann et al., 2004). However, 
both mCH and hmC are very low in most dividing cells. This is likely due to both low expression 
of the DNMT3A/B (Okano et al., 1998) and TET (Wu and Zhang, 2017) enzymes and the lack of 
an efficient mechanism to maintain mCH and hmC after DNA replication. In contrast, it appears 
that increased expression of TET (Szulwach et al., 2011) and DNMT3A enzymes (Guo et al., 2014; 
Lister et al., 2013), in conjunction with a lack of DNA replication, leads to accumulation of hmC 
and mCH in neurons. Substantial evidence now suggests that hmC is a stable epigenetic mark in 
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neurons, reaching high levels compared to non-neural cell types (Figure 4) (Globisch et al., 2010; 
Kriaucionis and Heintz, 2009; Lister et al., 2013; Wu and Zhang, 2017). Therefore, while levels 
of modified CG sites are maintained in neurons, TET enzymes drive large scale conversion of 
mCG into hmCG (e.g. total modified CG = mCG + hmCG, Figure 4).  Additionally, there appears 
to be limited turnover of mCH in neurons due to low hmC conversion or active demethylation at 
these sites. 
 
More efficient methylation at CG sites compared to CH sites leads to a substantially higher percent 
of mCG compared to mCH (Figure 4). However, the depletion of CG dinucleotides from the 
genome resulting from mutation of methylated cytosine to thymine over evolution (Bird, 1980) 
results in nearly equivalent numbers of mC events occurring at CG and non-CG sites in neuronal 
genomes (Figure 4) (Lister et al., 2013). Together, the high, stable levels of hmC and mCH create 
a unique environment for epigenetic regulation in neurons that can affect the binding of regulatory 
factors to DNA and impact gene expression. 
 
Endnote 2: Global, graded gene regulation by mC and 
MeCP2. 
Unlike transcription factors, where sparse genomic binding sites can be linked to “target” genes, 
MeCP2 binds to millions of mCH and mCG sites, which are present in varying amounts at every 
gene and regulatory element. This genome-wide binding suggests that MeCP2 influences 
transcription of all genes to some extent. Indeed, genome-wide analysis of RNA changes in Mecp2 
knockout and missense mutants, MECP2 over expressing mice, and brain-specific Dnmt3a 
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conditional knockout mice have detected trends in which the degree of gene dysregulation is 
proportional to the number of mCH and mCG sites found in the gene body (Boxer et al., 2020; 
Clemens et al., 2020; Gabel et al., 2015; Kinde et al., 2016; Lagger et al., 2017; Lavery et al., 2020; 
Renthal et al., 2018; Stroud et al., 2017). In addition, genome-wide upregulation of expression 
associated with gene body length has been detected upon loss of MeCP2 (Gabel et al., 2015; 
Johnson et al., 2017; Kinde et al., 2016; Lagger et al., 2017; Sugino et al., 2014), providing the 
first clues that intragenic binding by MeCP2 is an important aspect of its regulatory mechanism 
(Gabel et al., 2015; Stroud et al., 2017). Care must be taken to ensure that apparent genome-wide 
effects do not result from technical noise (Raman et al., 2018), but studies have now verified these 
trends in large-replicate datasets, using multiple RNA quantification methods (Boxer et al., 2020; 
Cholewa-Waclaw et al., 2019; Clemens et al., 2020; Renthal et al., 2018). Notably, the 
investigation of these trends has led to the generation of new molecular models for gene regulation 
by mCH, mCG, and MeCP2 (Boxer et al., 2020; Cholewa-Waclaw et al., 2019; Clemens et al., 
2020; Renthal et al., 2018; Stroud et al., 2017).  
 
While these global trends provide mechanistic clues, limitations of gene expression analysis also 
present challenges for interpretation of transcriptomic data. For instance, normalization procedures 
used to quantify relative RNA levels between samples assume that no global changes in the 
distribution of gene expression values occur across conditions (Love et al., 2014). As a result, 
genome-wide fold-changes will effectively be re-centered around zero during data processing, and 
this can possibly switch the sign of perceived changes in gene expression. Similar effects can occur 
in RT-qPCR experiments, where total RNA and house-keeping gene normalization are employed. 
Thus, in one plausible model, loss of repression in the Mecp2 knockout leads to upregulation of 
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nearly all genes in the genome, with the most highly methylated regions being most de-repressed. 
However, upon normalization, genes that are lowly methylated and the least de-repressed are re-
centered below zero and quantified as being down-regulated. In such a paradigm, a substantial 
portion of MeCP2-activated genes that appear to decrease in expression when MeCP2 is lost may 
in fact represent genes that normally escape repression by MeCP2 rather than being genes that are 
directly activated by the protein. 
 
In addition to these issues, standard transcriptomic approaches do not detect changes in global 
RNA levels per cell, and several reports indicate that Mecp2-null neurons, which are reduced in 
size, contain less total RNA than normal cells (Lagger et al., 2017; Li et al., 2013). In all, relative 
quantification methods can combine with secondary effects on RNA levels and gene expression, 
as well as disruption of potential direct gene-activating functions for MeCP2 (Ip et al., 2018), to 
result in the overall changes in gene expression observed in MeCP2 mutants. These complexities 
highlight the need to integrate transcriptomic findings with biochemical insights into the direct 








Chapter 2: MeCP2 represses enhancers 
through chromosome topology-associated 
DNA methylation 
 
This chapter is adapted from a manuscript published in Molecular Cell. 
Clemens, AW., Wu, DY., Moore, JR., Christian, DL., Zhao, G., Gabel, HW., MeCP2 Represses 





AWC carried out all of the experiments in collaboration with JRM and DLC and performed ChIP-
seq analysis; DYW performed RNA-seq, Bisulfite-seq, and TAD analysis; GZ and D.Y.W. 
performed the Hi-C analysis; AWC, DYW, and HWG designed the experiments and analysis, and 




The development and function of the mammalian brain requires precise control of gene expression 
to specify neuronal sub-types, form and refine circuits, and respond to dynamic changes in 
neuronal activity (Cholewa-Waclaw et al., 2016; Ebert and Greenberg, 2013; Molyneaux et al., 
2007; Ziats et al., 2015). Emerging evidence indicates that neurons utilize a unique form of DNA 
methylation to regulate these transcriptional programs, with multiple types of CNS neurons 
displaying high levels of cytosine methylation in a non-CG context compared to non-neural cells 
(Guo et al., 2014; Lister et al., 2013; Luo et al., 2017; Mo et al., 2015; Xie et al., 2012). This non-
CG DNA methylation is deposited by the DNA methyltransferase, DNMT3A, and accumulates 
specifically in neurons during the early postnatal period, until the number of methylated cytosines 
in the non-CG context is nearly equivalent to that of canonical methyl-CG sites (mCG) (Guo et 
al., 2014; Kinde et al., 2015; Lister et al., 2013). Disruption of DNMT3A specifically in mouse 
brain completely blocks the accumulation of non-CG methylation, leading to de-repression of 
genes that normally contain high levels of non-CG methylation and resulting in severe neurological 
phenotypes in these mice (Gabel et al., 2015; Nguyen et al., 2007; Stroud et al., 2017). These 
findings underscore the importance of non-CG methylation in neural development, motivating 
efforts to understand how this methylation works together with mCG to control gene expression 
in neurons.  
 
Recent studies have demonstrated that Methyl-CpG binding Protein 2 (MeCP2) binds tightly to 
non-CG methylation, showing a high affinity for methylated cytosines within CA dinucleotides 
(mCA) that is similar to its affinity for its classically defined substrate, mCG (Chen et al., 2015; 
Gabel et al., 2015; Guo et al., 2014; Kinde et al., 2015; Lagger et al., 2017). Inactivation of MeCP2 
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causes the severe neurological disorder Rett syndrome, and duplication of MeCP2 leads to autism 
spectrum disorder (Amir et al., 1999; Chahrour and Zoghbi, 2007; Van Esch et al., 2005; Hagberg 
et al., 1983). While MeCP2 has been proposed to be both a repressor and an activator of 
transcription, biochemical analyses have identified a critical interaction between MeCP2 and the 
NCoR-HDAC3 transcriptional corepressor complex, and in vitro experiments have demonstrated 
that MeCP2 can repress transcription of reporter plasmids. Together these findings indicate that 
MeCP2 plays a critical role in nervous system function, and suggest that one important role for 
MeCP2 is to bind to DNA methylation in neurons and repress gene expression (Ip et al., 2018; 
Lyst and Bird, 2015; Lyst et al., 2013). 
 
Because of its important role in brain function, identifying the genes that MeCP2 directly regulates 
in neurons has been an area of intense investigation. Genomic analyses have revealed that MeCP2 
is expressed at near histone levels and binds extremely broadly across the neuronal genome. In the 
context of this broad binding, enrichment of MeCP2 can be detected in regions with high numbers 
of mCG and mCA sites (Chen et al., 2015; Cohen et al., 2011a; Gabel et al., 2015; Kinde et al., 
2015; Lagger et al., 2017; Skene et al., 2010). Studies of gene expression changes in brain tissue 
from human Rett syndrome patients, MeCP2 knockout mice (MeCP2 KO), and MeCP2 
overexpression mice (MeCP2 OE) detect only subtle changes across many genes upon MeCP2 
disruption, making it difficult to differentiate direct targets of MeCP2 regulation from secondary 
effects on gene expression (Baker et al., 2013; Ben-Shachar et al., 2009; Chahrour et al., 2008; 
Gabel et al., 2015; Kinde et al., 2016; Samaco et al., 2012; Tudor et al., 2002; Zhao et al., 2013). 
Defining the mechanism by which MeCP2 mediates its broad but subtle effects on gene expression 
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has therefore been recognized as an important challenge (Ip et al., 2018; Lyst and Bird, 2015), and 
despite continued studies, has remained difficult to decipher.  
Recent integrated analysis of gene expression and DNA methylation has revealed enrichment of 
methylation at CA dinucleotide sites (mCA/CA) in and around “MeCP2-repressed” genes--those 
genes most significantly upregulated upon loss of MeCP2 and downregulated upon overexpression 
of MeCP2 (Chen et al., 2015; Gabel et al., 2015; Kinde et al., 2016; Lagger et al., 2017). Notably, 
these genes are not substantially enriched for mCA at promoters, a canonical site of action for 
DNA methylation, but instead show high mCA within the transcribed region and flanking 
sequences of the gene. Furthermore, genome-wide analysis has revealed that loss of MeCP2 leads 
to a graded upregulation of genes that is proportional to both the level of DNA methylation within 
the transcribed region of the gene (the “gene body”) and to the length of the pre-mRNA transcript. 
Thus, genes that are very long (e.g. >100kb) and contain high numbers of methylation sites are 
upregulated relative to shorter genes that contain fewer methylation sites (Gabel et al., 2015; Kinde 
et al., 2015, 2016; Lagger et al., 2017; Sugino et al., 2014). This association with gene length, and 
the observation that upregulation of gene expression upon loss of MeCP2 is best correlated with 
the DNA methylation within the gene, has led to the proposal that MeCP2 regulates expression by 
binding to methylated DNA in gene bodies and repressing transcription (Kinde et al., 2016). 
 
While these findings have provided insight into the role of mCA, mCG, and MeCP2 in the brain, 
they raise new questions. For example, high levels of mCA are detected at regions extending 
megabases up- and downstream of MeCP2-repressed genes (Kinde et al., 2016; Lagger et al., 
2017), but it has not been determined what delineates the large regions of mCA enrichment in 
which these genes are found.  In addition, while multiple studies now support a role for MeCP2 in 
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repressing long, highly-methylated genes, it has not been demonstrated that MeCP2 directly affects 
transcription when bound to mCG and mCA within these genes, and alternative post-
transcriptional mechanisms have been proposed (Johnson et al., 2017). Finally, the precise 
mechanism by which binding of MeCP2 to DNA methylation outside of promoter regions results 
in subtle, but functionally critical gene repression has not been determined. 
 
In this study, we have investigated how high levels of CA methylation are established at genes that 
are repressed by MeCP2 and examined how MeCP2 functions with the methylation at these loci 
to control gene transcription. Through integrated genomic analysis we identified an association 
between chromatin folding in the nucleus and the patterning of mCA across the neuronal genome, 
and we show that genes repressed by MeCP2 land within topologically-associating domains 
(TADs) enriched for mCA. We further investigated how the high levels of TAD-associated mCA 
are read out by MeCP2 to control gene transcription, uncovering new evidence that binding of 
MeCP2 to mCA and mCG at enhancer elements controls the activity of these regulatory sequences. 
We find that MeCP2-repressed enhancers tend to be located within the same highly methylated 
TADs as MeCP2-repressed genes, and often reside within these genes. Thus, dysregulation of 
enhancers can contribute to altered transcription that occurs upon mutation of MeCP2. Together, 
our study defines a mechanism that shapes the deposition of neuron-enriched mCA in the genome 
and uncovers a new role for mCA and MeCP2 in the regulation of enhancers. These findings 
provide insight into how disruption of MeCP2 causes altered gene expression to drive neurological 





To probe how high levels of mCA are established at MeCP2-repressed genes and to determine 
how DNA methylation is read out by MeCP2 to control gene expression, we carried out integrated 
genomic analysis in the cerebral cortex, a brain region in which loss of MeCP2 has been shown to 
affect gene expression, alter neuronal morphology, and disrupt physiology (Gabel et al., 2015; 
Kinde et al., 2016; Kishi and Macklis, 2004, 2010; Pacheco et al., 2017; Sceniak et al., 2016; 
Shepherd and Katz, 2011). By studying the cortex, we were able to integrate our genomic datasets 
with a compendium of data on gene expression, DNA methylation, chromatin structure, and 
genome topology for this brain region compiled across multiple studies (Dixon et al., 2012; 
ENCODE Consortium, 2012; Mo et al., 2015; Shen et al., 2012; Sloan et al., 2016; Stroud et al., 
2017). This allowed us to explore features of the genome and chromatin structure that are 
associated with high mCA levels at MeCP2-repressed genes. While we focused on patterns of 
mCA, the most prevalent and highest affinity non-CG methylation site for MeCP2 binding (Gabel 
et al., 2015; Lagger et al., 2017), we obtained similar results when we included minor forms of 
non-CG methylation, mCT and mCC, in analysis throughout our studies. 
 
To identify the genes most robustly dysregulated upon disruption of MeCP2 in the cortex, we used 
combined RNA-seq analysis of MeCP2 KO and MeCP2 OE mice, an approach that has been 
powerful for detecting MeCP2-regulated genes in other brain regions (Ben-Shachar et al., 2009; 
Chahrour et al., 2008; Chen et al., 2015). Differential mRNA expression analysis of cortex from 
six MeCP2 KO-wild-type and five MeCP2 OE-wild-type littermate pairs identified 884 “MeCP2-
repressed genes” that are significantly upregulated upon loss of MeCP2 and downregulated upon 
overexpression of MeCP2, and 843 “MeCP2-activated genes” that are significantly downregulated 
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upon loss of MeCP2 and upregulated upon overexpression of MeCP2 (Figure 1A; Table S1). These 
genes significantly overlap with genes identified through meta-analysis of MeCP2 mutant gene 
expression studies across multiple non-cortical brain regions (Gabel et al., 2015), indicating that a 
substantial number of MeCP2-regulated genes are shared across functionally distinct brain regions 
made up of diverse neuronal subtypes (Figure S1A,B).  
 
We then assessed the characteristics of MeCP2-regulated genes, including gene length and DNA 
methylation levels as measured by whole-genome bisulfite sequencing (Stroud et al., 2017, see 
methods). In agreement with previous studies (Gabel et al., 2015; Kinde et al., 2016; Lagger et al., 
2017; Renthal et al., 2018; Stroud et al., 2017; Sugino et al., 2014), MeCP2-repressed genes in the 
cortex are significantly longer than the genome average (Figure S1D). These genes are also 
enriched for CA methylation (mCA/CA, referred to as “mCA level”) in the gene body and 
surrounding the gene, but show little to no mCA enrichment at the transcriptional start site (TSS) 
(Figure 1B,C; S1C). As previously observed, we find a global gene-length- and mCA-associated 
relative upregulation of genes in MeCP2 KO cortex and a reciprocal relative downregulation in 
the MeCP2 OE cortex (Figure S1E,F). Analysis of expression changes in all genes showed that 
the degree of dysregulation in MeCP2 KO and MeCP2 OE cortex genome-wide was more highly 
correlated with gene body DNA methylation than it was with gene-flanking regions (Figure 
S1G,H). We did not detect evidence of enriched mCG levels in and around MeCP2-repressed 
genes, and MeCP2-activated genes displayed limited differences in gene length and mCA or mCG 
profiles compared to the genome average or control sets of unchanged genes (Figure 1B; S1C). 
These results validate conclusions from previous studies that MeCP2 preferentially represses long 
genes that contain high levels of methylation within their gene body (Gabel et al., 2015; Kinde et 
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al., 2016; Lagger et al., 2017; Renthal et al., 2018; Stroud et al., 2017; Sugino et al., 2014) and 
provide a high confidence set of MeCP2-regulated genes in the cerebral cortex to facilitate our 
further analyses.  
 
2.2.1 Large-scale non-CG DNA methylation profiles are linked to chromatin 
topology.  
Having established that MeCP2-repressed genes in the cerebral cortex are enriched for mCA in 
and around the gene, we explored how patterns of high mCA may be established at these loci. 
Broad-scale analysis of mCA around MeCP2-repressed genes revealed that, like gene-sets 
identified in other brain regions (Kinde et al., 2016; Lagger et al., 2017), enrichment of this 
methylation can extend megabases away from the gene (Figure 1B,C). This suggested that high 
regional methylation might be associated with chromosomal features that vary at the hundred-
kilobase to megabase scale. We therefore searched the compendium of datasets for transcription 
factor binding, chromatin structure, and chromosome topology in the cerebral cortex (Dixon et al., 
2012; ENCODE Consortium, 2012; Lister et al., 2013; Shen et al., 2012; Stroud et al., 2017) 
looking for sequence features or epigenetic marks that correlate with the large-scale patterns of 
mCA observed at MeCP2-repressed genes and across the genome. Examination of high-
throughput chromatin conformation capture (Hi-C) interaction maps of nuclear topology generated 
for the mouse cerebral cortex (Dixon et al., 2012, 2016) revealed notable instances in which a 
region of high mCA surrounding MeCP2-repressed genes dropped off at transition points in Hi-C 
interactions, similar to those that delineate topologically associating domains (TADs) (Figure 1D) 




TADs are defined in Hi-C analysis as stretches of the genome that are enriched for cis interactions 
compared to background (Dixon et al., 2012). TAD structures delineate interactions between cis-
regulatory enhancer elements and genes, such that enhancer elements within a TAD are more likely 
to interact with promoters of genes within the same TAD than they are to interact with promoters 
of genes outside of the TAD (Spielmann et al., 2018). A correlation between mCA patterns and 
TAD structure would implicate genome folding in the deposition of this unique methylation, and 
could have important implications for regulation of gene expression through methylation at 
promoters and enhancer elements within each TAD. We therefore computationally defined TAD 
structures in the genome of adult mouse cerebral cortex (Dixon et al., 2012) using the TADtree 
algorithm (Weinreb and Raphael, 2016) and systematically examined DNA methylation in regions 
containing MeCP2-repressed genes (Table S2). TADs defined in the cerebral cortex by this method 
are ~400kb on average and range in size from ~160kb to ~2mb, a scale that is similar to regions 
that we observed with enriched mCA levels. 
 
Analysis of mCA levels across TADs revealed that MeCP2-repressed genes are found within 
TADs that are significantly enriched for mCA compared to TADs genome-wide (Figure 1E). We 
observed a significant drop-off of mCA levels at the boundaries of TADs containing MeCP2-
repressed genes that was not observed for control TADs that were generated by shuffling TADs 
across the genome (Figure 1F; S2B,C). While the shift in methylation across all of these boundaries 
was a return toward the genome average (Figure 1F), more dramatic step-changes in methylation 
occurring specifically at the boundary could be detected in genomic regions where a high-mCA 
TAD containing an MeCP2-repressed gene was juxtaposed with a genomic region with 
substantially lower mCA levels (Figure 1G). Such strong enrichments in mCA and discrete step-
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changes in signal at boundaries were not observed when TAD locations were shuffled and these 
resampled boundaries were examined (Figure 1F,G; S2B, see methods). In addition, similar signals 
could not be detected in coverage rates for Bisulfite-sequencing or GC composition of the 
sequences on either side of TAD boundaries (Figure S2B), indicating that the patterns we observed 
were specific to TAD boundaries and are not likely to be driven by sequencing biases.  
 
To further test if TAD structures impact the patterns of mCA at MeCP2-repressed genes and 
throughout the genome, we performed genome-wide, cross-correlation analysis of mCA levels 
within and across TAD boundaries using a procedure similar to analysis carried out for histone 
modifications (Rao et al., 2014, see methods). We found that the mCA levels for genomic regions 
located within the same TAD are more highly correlated with each other than they are with regions 
in neighboring TADs (Figure 1H). This relationship was prominent for high-mCA TADs that 
contain MeCP2-repressed genes, but also robustly detectable when examining all TADs in the 
genome. Similar signals of correlation within the TAD were not detected when analyzing shuffled, 
control TADs randomly placed throughout the genome (Figure 1H, see methods). These findings 
suggest that TADs are units of organization for mCA levels across the genome and that MeCP2-
repressed genes often occupy TADs with high levels of mCA.  
 
In contrast to MeCP2-repressed genes, MeCP2-activated genes reside in TADs that have lower 
mCA levels compared to the genome average (Figure 1E; S2A). This finding is consistent with the 
limited enrichment of mCA in gene-flanking sequences that we and others observe for these genes 
(Kinde et al., 2016; Lagger et al., 2017). mCG levels across the genome do not exhibit prominent 
megabase-scale variation. No clear enrichment of mCG levels was detectable for TADs that 
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contain MeCP2-repressed genes, and a subtle depletion of mCG was present in TADs that contain 
MeCP2-activated genes (Figure 1D; S2A,B). Some evidence of more consistent mCG levels 
within TADs compared to across TAD boundaries was observed however, suggesting that while 
TADs do not vary dramatically in average mCG levels, TAD structures are associated with the 
modest fluctuations in the levels of regional mCG that do exist (Figure S2B). 
 
As an additional test of the association between chromosome topology and regional mCA levels, 
we analyzed high-resolution Hi-C data generated from an independent study of the cerebral cortex 
in early development (Bonev et al., 2017), prior to the deposition of mCA. We defined TAD-
related “contact domains” of interaction across the genome using the Arrowhead algorithm as 
previously described (Rao et al., 2014) (Table S3). These analyses of mCA revealed similar 
enrichments of mCA levels in contact domains that contain MeCP2-repressed genes, a drop-off of 
mCA levels at the boundaries of domains containing MeCP2-repressed genes, and consistent levels 
of mCA across contact domains (Figure S2E-H). This shows that regions of close chromatin 
folding early in development are predictive of mCA patterns in the adult cortex. We further 
assessed if these findings can be generalized by repeating our analysis using an independently 
derived cortical DNA methylation dataset (Lister et al., 2013), as well as Hi-C and DNA 
methylation from the cerebellum (Mellén et al., 2017; Yamada et al., 2019). This analysis detected 
similar topology-associated mCA patterns (Figure S2I-K).  These findings demonstrate a 
reproducible association between genome topology and large-scale mCA levels in the brain that is 
not dependent on analysis algorithms that are employed or the brain regions analyzed, suggesting 
that the topological structure that is established in neurons early in development influences the 




We next probed the mechanism by which mCA levels are established within TADs during 
development. Previous studies have demonstrated that the de novo methyltransferase DNMT3A 
increases in expression and deposits mCA across the genome during the postnatal period in mice 
from birth to six weeks of age (Gabel et al., 2015; Guo et al., 2014; Lister et al., 2013). Consistent 
with its role in patterning methylation during this time, binding of DNMT3A across kilobase-scale 
regions of the genome at two weeks is predictive of mCA levels in the cortex at eight weeks of 
age (Figure S3A; Stroud et al., 2017). We therefore investigated whether hundred-kilobase- to 
megabase-scale patterns of DNMT3A binding during the early postnatal period support our finding 
that mCA levels are associated with TAD structures. Analysis of DNMT3A ChIP-seq signal in the 
cortex at two weeks showed that DNMT3A binding is more highly correlated within TADs than 
across TAD boundaries (Figure 2A). Levels of binding for DNMT3A within TADs at two weeks 
are well correlated with levels of mCA observed at eight weeks (Figure 2B).  Consistent with the 
idea that TAD boundaries delineate regions of higher and lower DNMT3A binding, aggregate 
DNMT3A ChIP signal showed distinct reductions at the boundaries of TADs containing MeCP2-
repressed genes (Figure 2C). This signal was specific to DNMT3A ChIP, as no such profile was 
observed for sequencing of the input controls (Figure S3B). 
 
The association between DNMT3A binding and mCA levels for TADs called in the postnatal 
cortex is also present in contact domains identified in embryonic neurons (Figure S3C, S3D). 
Notably, the low level of DNMT3A that is expressed in the cortex and bound to the genome at 
eight weeks is also consistent across TAD structures (Figure S3E), but the degree of binding is not 
as closely associated with mCA levels in TADs compared to DNMT3A at two weeks (Figure S3F). 
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These findings indicate that the level of DNMT3A that is recruited to the genome during mCA 
accumulation is shaped by established TAD structures, and they suggest that the activity of this 
enzyme in a TAD during postnatal development defines a long-term “set-point” for mCA across 
this region into adulthood.  
 
To examine the consequences of TAD-associated mCA patterns on MeCP2 binding and function 
we quantified MeCP2 ChIP-seq signal (Kinde et al., 2016) across TADs in the adult cortex. MeCP2 
ChIP signal is specific for MeCP2 but extremely broad and shows only very modest fluctuations 
across the genome (Chen et al., 2015; Gabel et al., 2015; Lagger et al., 2017). In the context of 
these small fluctuations however, we found that the level of MeCP2 for TADs is associated with 
mCA levels within each TAD (Figure 2D). In addition, MeCP2 signal shows higher cross-
correlation within TADs compared to across TAD boundaries (Figure S3G). To test the importance 
of mCA for MeCP2 binding we examined how patterns of MeCP2 binding change when mCA is 
completely blocked from building up in neurons by conditional deletion of DNMT3A from the 
brain (DNMT3A Nestin-cKO) during the perinatal period (Figure S3H) (Kinde et al., 2016). This 
analysis revealed that TADs that normally contain high mCA levels in wild-type conditions 
displayed subtle reductions in MeCP2 binding in the DNMT3A mutant compared to TADs that 
contain lower mCA levels in wild-type conditions (Figure S3I). This indicates that high mCA 
levels in TADs are associated with some enrichment of MeCP2 binding, and upon loss of mCA 
from the neuronal genome, large-scale MeCP2 profiles are measurably altered.  
 
We next considered how TAD-associated mCA levels across the genome could influence gene 
regulation within each TAD. Given that TADs coordinate the function of regulatory elements and 
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genes within a genomic region, we investigated if the set-point level of mCA within a TAD could 
influence the methylation of these sequences. Levels of methylation for regulatory elements and 
genes are primarily thought to be established locally, with the methylation status determined by 
sequence features and the activity level at these sites (Lister et al., 2013; Schübeler, 2015). 
However, the differences in set-point mCA between TADs could act on top of these local 
determinants of mCA, driving consistently higher or lower mCA across all of the smaller scale 
elements within each TAD. In this way, the TAD mCA set-point could affect the regulation of 
genes by MeCP2.  
 
We therefore investigated if set-point mCA level in each TAD is associated with mCA at these 
smaller scale genomic elements within the TAD. For this analysis, we defined TSS regions and 
gene bodies based on Ensembl gene models (see methods). Enhancers are distal regulatory 
sequences that are bound by transcription factors and can loop to interact with promoters, activating 
gene transcription (Bulger and Groudine, 2010; Heintzman et al., 2007; Rada-Iglesias et al., 2011). We 
defined enhancers as sequences that show peaks of ChIP-seq signal for the enhancer-associated 
Histone H3 lysine 27 acetylation (H3K27ac) and Histone H3 lysine 4 monomethylation 
(H3K4me1) and do not overlap with known TSS regions or ChIP-seq peaks for promoter-
associated Histone H3 lysine 4 trimethylation (H3K4me3) (see methods). We then quantified mCA 
and mCG levels at these genomic elements and examined whether these levels correlate with the 
average mCA and mCG levels across the TADs in which they reside. Strikingly, this analysis 
detected a robust correlation between the set-point level of mCA across each TAD and the mCA 
level for gene bodies and enhancers found inside the TAD (Figure 2E). This correlation occurred 
only for elements found within the TAD, breaking down for elements found immediately outside 
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of the TAD (Figure S3J). Correlations in mCA levels between elements found within the same 
TAD were also stronger than for elements found on different sides of a TAD boundary (Figure 
S3K), underscoring that boundaries delineate regions of similar mCA levels for these sequences.   
 
In contrast to gene bodies and enhancers, mCA levels in TSS regions showed much more limited 
correlation with overall TAD mCA levels, suggesting that these elements largely escape the TAD-
associated mCA set-point. Control analysis in which we resampled the location of TADs genome 
wide, confirmed that TAD boundaries delineate transitions between TAD mCA set-points for 
enhancers and genes (Figure S3J,K). Randomizing the location of TSS-, gene-, and enhancer-sized 
sequences within TADs showed that that these small-scale random regions are correlated with 
TAD mCA levels, and only true TSS regions escape TAD mCA levels (Figure S3M). In contrast 
to mCA, mCG levels did not show strong TAD-associated signals (Figure S3L,M). Together these 
findings indicate that mCA levels at enhancers and genes within the TAD are linked to the mCA 
set-point for each TAD, while TSS regions are protected from these effects. By influencing mCA 
at genes and enhancers, high TAD-associated mCA levels may directly impact mCA- and MeCP2-
mediated regulation of genes within a TAD. 
 
 
2.2.2 Loss of MeCP2 leads to promoter-associated transcriptional activation. 
We next investigated the mechanism by which methylation in high-mCA TADs is read out by 
MeCP2 to affect mRNA expression. Consistent with our TAD methylation analysis above (Figure 
2E), we find that the high TAD mCA set-point for MeCP2-repressed genes is associated with high 
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mCA in and around the genes, but little to no signature of mCA enrichment is observed at their 
TSS (Figure 1B; S1C) (Gabel et al., 2015; Kinde et al., 2016; Lagger et al., 2017). This finding 
suggests that regulation of these genes occurs through binding of MeCP2 to methylation at regions 
outside of the proximal promoter. Based on the long length of MeCP2-repressed genes and the 
observation that the levels of mCA within gene bodies are better correlated with dysregulation of 
RNA expression upon disruption of MeCP2 compared to extragenic regions (Figure S1D,G,H) 
(Kinde et al., 2016), we considered several different mechanisms by which MeCP2 might repress 
transcription. For example, one possible explanation is that binding of MeCP2 to methylation 
within the gene body inhibits transcriptional elongation by interfering with transcribing RNA 
polymerase II, resulting in premature termination and reduced production of mature mRNA. 
Alternatively, binding of MeCP2 to methylation within the gene body could act at a distance to 
repress transcription initiation or polymerase release occurring near promoter elements. To test 
these and other possible mechanisms of action, we carried out integrative genomic analyses of the 
cerebral cortex from MeCP2 KO and wild-type mice, assessing changes in intronic RNA and histone 
marks associated with gene transcription. 
 
Because intronic RNA is quickly destroyed after pre-mRNA transcription and splicing, analysis of 
reads corresponding to introns in RNA-seq data can provide read-outs of changes in different stages 
of transcription (Boswell et al., 2017; Gray et al., 2014). For example, if MeCP2 reduces the 
processivity of RNA polymerase II leading to a significant level of premature termination under wild-
type conditions, knockout of MeCP2 could lead to more efficient completion of transcription 
elongation and result in an increase in intronic reads at the 3’ end of the pre-mRNA transcript in the 
MeCP2 knockout, but cause little to no change in intronic reads at the 5’ end. If MeCP2 represses or 
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activates promoters to modulate transcription, knockout of MeCP2 would result in a consistent change 
in levels of intronic reads starting at the beginning of MeCP2-repressed genes and continuing along 
their entire length. Alternatively, if transcription is not upregulated for these genes upon loss of MeCP2, 
as suggested by one study (Johnson et al., 2017), we would expect no increase or even a reduction in 
intronic RNA corresponding to these genes. 
 
To determine if these or other effects on transcription can be observed upon mutation of MeCP2 we 
carried out RNA-seq analysis of intronic RNA in MeCP2 KO and wild-type controls, assessing the 
direction and distribution of changes in pre-mRNA transcripts. Nuclear RNA was isolated from the 
cerebral cortex to enrich for short-lived, intron-containing transcripts and total RNA sequencing was 
performed (Figure 3A). We found that changes in nascent intronic RNA are highly concordant with 
exonic RNA, both for genes called as significantly dysregulated at the exon level and all genes genome-
wide (Figure 3B; S4A,B). Robust coverage of intronic RNA in these data also allowed us to perform 
differential expression analysis, defining genes that are significantly dysregulated at the intron RNA 
level upon loss of MeCP2 (Table S1). We find that these dysregulated genes significantly overlap with 
genes identified by quantification of exonic reads in whole tissue RNA-seq (Figure S4B). In addition, 
genome-wide changes in nuclear intronic RNA as a function of gene length and gene body mCA levels 
mirror those observed for total cell exonic reads, with long and highly methylated genes displaying 
intronic RNA upregulation relative to shorter and lower methylated genes (Figure S4C-F). To examine 
if MeCP2 regulates transcription initiation or successful completion of transcription elongation, we 
assessed changes in intronic RNA across the length of genes that are significantly upregulated at the 
intronic level in the MeCP2 KO. We observed a consistent increase of intronic reads across these long, 
highly-methylated genes in the MeCP2 KO (Figure 3C; S4G,H). These results suggest that subtle 
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changes in mRNA observed in the MeCP2 KO result from a concomitant subtle change in pre-mRNA 
transcription and that promoter-associated transcriptional activation, rather than RNA polymerase II 
processivity, is increased in MeCP2-repressed genes upon loss of MeCP2.  
 
We further examined the effects of MeCP2 disruption on transcription by performing ChIP-seq 
analysis of the cerebral cortex in wild-type and MeCP2 KO mice, assessing histone modifications that 
report on promoter activity and transcription through the gene. To determine if promoters of MeCP2-
regulated genes are affected upon loss of MeCP2 we examined profiles of H3K27ac and H3K4me3, 
two marks closely associated with promoter activation (Heintzman et al., 2007; Santos-Rosa et al., 
2002; Schübeler et al., 2004). To test if transcription through genes is altered, we profiled Histone H3 
lysine 36 trimethylation (H3K36me3), a modification that is closely associated with levels of 
transcription (Bannister et al., 2005; Guenther et al., 2007; Krogan et al., 2003). Quantification of 
changes in gene body-associated H3K36me3 revealed that MeCP2-repressed genes display a subtle 
but significant increase in this signal upon loss of MeCP2 (Figure 3A,D) that is consistent with the 
magnitude of the increased mRNA expression that occurs for these genes. H3K27ac and H3K4me3 at 
the TSS of these genes showed comensurately subtle, but significant upregulation in the MeCP2 KO 
(Figure 3A,D). Together with our analysis of intronic RNA changes, these findings support a model in 
which loss of MeCP2 leads to promoter activation of long, highly methylated, MeCP2-repressed genes. 
 
Given the small magnitude of the effects of MeCP2 disruption on gene expression, we sought to further 
test the consequences of MeCP2 disruption on transcription in an independent set of analyses. In light 
of the opposite effects on mRNA levels that we and others observe in the MeCP2 OE compared to the 
MeCP2 KO, we predicted that intronic RNA and transcription-associated chromatin marks should be 
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reciprocally affected in the MeCP2 OE. We therefore repeated our integrated RNA-seq and ChIP-seq 
analyses in the MeCP2 OE mice, examining how genes identified as dysregulated in the MeCP2 KO 
are affected in this strain. Consistent with our predictions, analysis of intronic RNA, H3K27ac, 
H3K4me3, and H3K36me3 profiles in the MeCP2 OE revealed reciprocal effects on promoter activity 
and transcription compared to the MeCP2 KO (Figure 3E-G; S4I, Table S1). These findings serve as 
independent validation that MeCP2 represses long, highly-methylated genes through down-regulation 
of promoter activity. 
 
2.2.3 MeCP2 represses enhancers that are enriched for mCA and mCG 
binding sites. 
We next considered how binding of MeCP2 to high levels of methylation found outside of the TSS 
could impact promoter-associated transcriptional activation. One mechanism by which sequences 
outside of the TSS can impact transcription is through enhancers. Activation of enhancers is associated 
with high levels of H3K27ac at these sequences, and changes in acetylation are linked to increases and 
decreases in enhancer activity (Creyghton et al., 2010; Malik et al., 2014; Rada-Iglesias et al., 2011; 
Spiegel et al., 2014). Our TAD methylation analysis indicates that the high mCA set-point of TADs 
that contain MeCP2-repressed genes is likely associated with high mCA at the enhancers within the 
TAD (Figure 1E; 2E). Binding of MeCP2 at these highly methylated enhancers and repression of their 
activity could result in reduced activation of the MeCP2-repressed genes the enhancers regulate. To 
date however, no study has examined the effects of loss of MeCP2 on enhancer activity. Notably, 
visualization of putative enhancers in the vicinity of promoters of MeCP2-repressed genes showed that 
these regions displayed subtly higher levels of H3K27ac signal in the MeCP2 KO cortex compared to 
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wild type (Figure 4A), further suggesting that the activity of these elements may be affected by MeCP2. 
We therefore systematically assessed the effects of loss of MeCP2 on enhancer activity genome-wide.  
 
Through combined analysis of differential H3K27ac ChIP-seq signal for MeCP2 KO and MeCP2 OE 
cortex samples at enhancer-associated H3K27ac peaks (see methods), we identified enhancers that are 
significantly altered in the MeCP2 KO and MeCP2 OE cerebral cortex relative to controls (Figure 4B; 
S5A; Table S4). To assess if the presence of mCA or mCG at enhancers might drive their regulation 
by MeCP2, we quantified DNA methylation at these sequences. We detected an enrichment of mCA 
levels at MeCP2-repressed enhancers compared to the genome average and a relative depletion of 
mCA levels at MeCP2-activated enhancers. mCG levels showed limited enrichment and depletion in 
MeCP2-repressed and MeCP2-activated enhancers respectively (Figure 4C; S5B). 
 
Given the well-established high affinity of MeCP2 for mCG (Meehan et al., 1989), but the lack of 
robust enrichment of mCG/CG levels at MeCP2-regulated enhancers, we further investigated if the 
presence of mCG sites at enhancers is associated with MeCP2-mediated repression. The number of 
mC binding sites for MeCP2 within an enhancer region is determined by both per-base cytosine 
methylation at CA and CG dinucleotides (e.g. mCA/CA) and the frequency of each dinucleotide 
sequence that occurs in the enhancer region. The contribution of dinucleotide frequency to mC site 
abundance is particularly relevant for mCG, because CG dinucleotides are depleted from the genome 
and non-uniform in their distribution (Bird, 1980; McClelland and Ivarie, 1982). We therefore 
examined the number of mC binding sites per kilobase (mC/kb), or “density” of mC sites at enhancers 
(Figure 4C). In comparison to the limited signal for mCG levels (mCG/CG) at dysregulated enhancers, 
the density of mCG sites at these enhancers showed more robust association with repression and 
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activation (Figure 4C; S5B). The larger enrichment and depletion of mCG density compared to mCG 
levels was driven primarily by enrichment of CG dinucleotides at repressed enhancers (Figure S5B). 
Our findings therefore suggest a role for both mCA and mCG sites in enhancer regulation by MeCP2, 
but while enrichment for mCA sites is largely driven by high per-base methylation (mCA/CA), 
enrichment of mCG sites is primarily driven by higher frequencies of CG dinucleotides (CG/kb) at 
these sequences. 
 
While mCA is the highest affinity non-CG dinucleotide binding site for MeCP2 (Gabel et al., 2015; 
Lagger et al., 2017), a recent study has indicated that the third nucleotide in the mCNN context can 
also affect MeCP2 binding, with mCAC sites showing the highest affinity for MeCP2 binding amongst 
non-CG sites, and other trinucleotides showing lower affinity (Lagger et al., 2017). We reasoned that 
if MeCP2 directly binds enhancers to repress their activity, then repressed enhancers should be most 
robustly enriched for mCAC sites compared to other mC trinucleotide contexts. We therefore 
quantified the relative enrichment of all mCNN trinucleotide sites at significantly dysregulated 
enhancers, comparing them to control sets of enhancers. We find that mCAC, of all mC trinucleotides, 
is most significantly enriched and depleted in MeCP2-repressed and MeCP2-activated enhancers 
respectively (Figure 4D; S5C). This enrichment of the highest affinity non-CG site for MeCP2 further 
supports a role for MeCP2 binding in regulation of these enhancers. Consistent with these patterns of 
high affinity binding sites for MeCP2 at dysregulated enhancers, MeCP2 ChIP-seq signal is enriched 
at MeCP2-repressed enhancers (Figure 4E). Analysis of a subset of high-stringency MeCP2-repressed 
enhancers that are selected based on enrichment for MeCP2 binding yields similar changes in histone 





While the enhancers that are significantly dysregulated upon loss of MeCP2 are enriched for mCA, 
mCG, and MeCP2 binding, the levels of methylation at enhancers genome-wide occur in a continuous 
distribution (Figure S5D), and MeCP2 binds broadly across the genome at enhancers and other regions 
(Chen et al., 2015; Gabel et al., 2015; Kinde et al., 2016; Lagger et al., 2017). This raises the possibility 
that every enhancer may be regulated by MeCP2 to some degree, with the number of mC sites 
determining the level of repression. To examine this possibility, we performed analysis of H3K27ac 
changes at all enhancers genome-wide, assessing if the levels of mC at these regulatory regions are 
correlated with the degree of H3K27ac dysregulation observed in the MeCP2 KO and MeCP2 OE. In 
this “unthresholded” analysis, we observed a genome-wide association between mCA and mCG sites 
at enhancers and the dysregulation of H3K27ac at these regulatory elements. This effect is positively 
correlated in the MeCP2 KO and negatively correlated in the MeCP2 OE (Figure 4F,G). We noted that 
mCA and mCG density is enriched in and around MeCP2-repressed enhancers (Figure 4C), but if 
binding of MeCP2 to methylation specifically at the enhancer is required for repression of these 
elements, we reasoned that the methylation of the enhancer sequence itself should be most predictive 
of enhancer de-repression upon loss of MeCP2. We therefore examined the correlation between the 
density of mCA and mCG sites and change in H3K27ac at enhancers at 500bp spatial resolution. We 
observe that the degree of H3K27ac upregulation of enhancers in the MeCP2 KO is most robustly 
correlated with the density of mCA and mCG sites occurring at the centers of the enhancers (Figure 
4H), and the reciprocal relationship is observed in the MeCP2 OE (Figure 4I). This finding points to 
methylation specifically within the regulatory sequence itself as the primary determinant of regulation 
by MeCP2. Together, these findings support a model in which binding of MeCP2 to mCA and mCG 
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sites within enhancers genome-wide leads to downregulation of acetylation that is proportional to the 
density of methyl sites at each sequence. 
 
Examination of profiles of increased acetylation in the MeCP2 KO suggested some increases in signal 
occurred at sites outside of our stringently defined enhancer regions (Figure S5E). We therefore further 
investigated the potential for sub-threshold regulation of H3K27ac at putative regulatory sites that were 
not detected by our initial peak calling. Examination of a comprehensive set of possible regulatory 
elements defined using a compendium of ATAC-seq peaks across cells types from 13 different mouse 
tissues (Cusanovich et al., 2018) showed that these sites often overlap with high-confidence enhancer 
peaks (97.1% of enhancers contain an ATAC peak) and are measurably enriched for acetyl signal 
above control, non-peak regions (Figure S5E,F). Comparison of acetylation in MeCP2 KO and MeCP2 
OE to controls at these ATAC-peaks genome-wide revealed noisier, but detectable changes in 
acetylation that were associated with mCA and mCG density (Figure S5F,G,H). These findings 
indicate that MeCP2 also regulates histone acetylation at these sub-threshold putative regulatory sites. 
Given the higher level and larger absolute change of H3K27ac that we observe in the MeCP2 KO and 
MeCP2 OE at enhancers compared to sub-threshold regions (Figure S5F), the dysregulation of called 
enhancers is likely to have the largest impact on gene expression. However, alterations in acetylation 
at sub-threshold sites may also contribute to the transcriptional effects observed in MeCP2 mutants.  
 
To directly examine the importance of methylation in enhancer repression and dissect the contribution 
of mCA and mCG in these effects, we next investigated the effects of selective disruption of mCA on 
enhancer activity. Disruption of DNA methylation by conditional knockout of DNMT3A using brain-
specific Nestin-Cre leads to overlapping, but more limited effects on MeCP2-repressed genes than 
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those seen in MeCP2 mutants (Gabel et al., 2015). Given that conditional deletion of DNMT3A leads 
to loss of mCA, but leaves mCG largely intact (Gabel et al., 2015), we reasoned that these partial 
effects on gene expression might arise due to loss of mCA-mediated enhancer repression, but 
preservation of mCG-mediated effects. To test this hypothesis, we assessed the effects of conditional 
deletion of DNMT3A specifically from post-mitotic neurons (DNMT3A Baf53-cKO, see methods). 
Bisulfite-seq of cerebral cortex from these mice revealed ablation of mCA, but retention of the majority 
of mCG at genomic elements, including TADs and enhancers (Figure 5A, S6A-C). Total RNA-seq 
analysis detected significant, but partial dysregulation of MeCP2-regulated genes (Figure 5B) that is 
consistent with previous DNMT3A brain-specific Nestin-cKO studies (Gabel et al., 2015). 
Quantification of H3K27ac signal at enhancers genome wide, similarly detected robust, but partial, 
dysregulation of MeCP2-repressed and –activated enhancers in DNMT3A mutants (Figure 5B). 
Analysis of normal methylation levels at enhancers defined as significantly dysregulated in the 
DNMT3A Baf53b-cKO mice revealed enrichment for mCA at upregulated enhancers, while mCG 
was equivalent between up and downregulated enhancers (Figure 5C, S6D,E). In genome-wide, 
unthresholded analysis, we detected an association between the change in H3K27ac signal and wild-
type mCA levels at enhancers that is similar to the trends observed in MeCP2 mutant mice (Figure 
5D). In contrast, no robust association was detected for mCG at enhancers (Figure 5D). Together these 
findings support the role for mCA in the repression of MeCP2-regulated neuronal enhancers. 
Furthermore, the lack of mCG-associated changes in the DNMT3A Baf53b-cKO mice, together with 
the quantitatively lower dysregulation of MeCP2-repressed genes and enhancers compared to MeCP2 
mutants, supports an important role for mCG in MeCP2-mediated enhancer regulation.  
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2.2.4 MeCP2-mediated enhancer repression is associated with gene regulation. 
We next examined if the effects we observe on enhancers can explain changes in gene transcription in 
the MeCP2 KO. Interactions of promoters and enhancers are enriched within TADs, such that 
enhancers tend to interact with, and activate, promoters within the same TAD (Bell et al., 1999; Ong 
and Corces, 2014). We reasoned therefore that if MeCP2-repressed enhancers regulate MeCP2-
repressed genes they should be found within the same TAD as these genes. In addition, based on our 
analysis of TAD methylation above (Figure 2E), we predicted that the high mCA set-point in TADs 
that contain MeCP2-repressed genes would result in high levels of mCA at enhancers within these 
TADs. Indeed, we found that enhancers within TADs that contain MeCP2-repressed genes are more 
highly methylated as a population than the genome average (Figure 6A), supporting the notion that 
these enhancers are likely to be repressed by MeCP2. To directly examine the link between enhancer 
dysregulation in TADs and changes in gene expression, we analyzed the distribution of MeCP2-
regulated enhancers in TADs across the genome. We found that MeCP2-repressed enhancers are 
significantly more likely than by chance to be found within TADs that contain MeCP2-repressed genes 
(Figure 6B). MeCP2-repressed enhancers are also significantly associated with MeCP2-repressed 
genes by GREAT analysis (McLean et al., 2010) and are more likely to show enrichment of 
interactions with promoters of MeCP2-repressed genes by Hi-C analysis (Figure 6B). Because our 
unthresholded analysis of H3K27ac changes revealed a genome-wide association between DNA 
methylation levels and repression of H3K27ac at enhancers (Figure 4F,G), we considered that highly-
methylated enhancers linked to MeCP2-repressed genes may display widespread upregulation of 
H3K27ac in the MeCP2 KO that is below the statistical threshold for significance. Indeed, inspection 
of changes in acetylation at enhancers in TADs that contain prominent MeCP2-repressed genes 
showed that while only some were called as significantly changed by our differential acetylation 
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analysis, many of these enhancers display a trend toward upregulation. Conversely, this pattern did not 
hold within TADs devoid of MeCP2-repressed genes (Figure 6C). Quantification of acetylation 
changes for the population of enhancers found in TADs containing MeCP2-repressed genes confirmed 
this observation, revealing that the H3K27ac signal in this population of enhancers is significantly 
upregulated in the MeCP2 KO (Figure 6D). Analysis of MeCP2 OE mice further showed reciprocal 
downregulation of acetylation for the population of enhancers found within TADs that contain MeCP2-
repressed genes (Figure 6D). 
 
This analysis links dysregulation of enhancers to changes in gene expression upon loss of MeCP2. We 
next wanted to understand if regulation of enhancers by MeCP2 can explain our previous finding that 
the levels of methylation within gene bodies are better correlated with changes in mRNA expression 
upon disruption of MeCP2 compared to regions flanking genes (Figure S1F-H; S4E,F) (Kinde et al., 
2016). We reasoned that the gene-body-associated signal we have detected may in part reflect the 
regulation of enhancers located within genes, and that MeCP2 may preferentially repress intragenic 
enhancers. Indeed, examination of enhancers within TADs containing prominent MeCP2-repressed 
genes (e.g. Zmat4, Auts2) revealed that enhancers within repressed genes show a stronger trend toward 
dysregulation upon loss or overexpression of MeCP2 compared to enhancers found outside these genes 
(Figure 6C). Analysis of all MeCP2-repressed enhancers showed that they are preferentially found 
within genes (Figure 6E), and significantly enriched in MeCP2-repressed genes (Figure 6B). In 
contrast, MeCP2-repressed enhancers are depleted from MeCP2-activated genes (Figure 6B). 
Examination of all enhancers located within MeCP2-repressed genes revealed that they are more 
robustly upregulated as a population in the MeCP2 KO and downregulated in the MeCP2 OE 
compared to enhancers within the same TAD as these genes (Figure 6D). Furthermore, analysis of 
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enhancer changes genome-wide revealed that while changes in acetylation of both intragenic and 
extragenic enhancers are correlated with mCA and mCG sites at these enhancers, for a given level of 
methylation, intragenic enhancers show more upregulation than extragenic enhancers (Figure 6F). 
Thus, intragenic enhancers appear to be more susceptible to repression by MeCP2 than enhancers 
outside of genes. 
 
Given the susceptibility of intragenic enhancers to repression by MeCP2, we investigated the degree 
to which these enhancers interact with the promoters of their cognate genes and whether disruption of 
MeCP2 affects the strength of these interactions to affect gene expression. Interrogation of Hi-C 
interaction maps revealed that intragenic sequences preferentially interact with promoters compared to 
extragenic sequences (Figure 6G), and intragenic enhancers make more contacts with promoters of the 
gene they reside in than enhancers that are equidistant from the promoter but extragenic (Figure 6H). 
This suggests that intragenic enhancers are privileged compared to extragenic enhancers for regulation 
of their cognate genes. We next examined if disruption of MeCP2 alters enhancer-promoter 
interactions. Quantitative 3C analysis of a representative set of enhancers that are altered in MeCP2 
mutants and associated with MeCP2-regulated genes showed no evidence of changes in interaction 
frequencies between these enhancers and their target promoters upon disruption of MeCP2 (Figure 
S5I). This suggests that MeCP2 does not regulate the contact frequencies between enhancers and 
promoters, but rather the degree to which enhancers drive gene activation once looped to their target 
promoter.  
 
If the repression of genes by MeCP2 is mediated through repression of intragenic enhancers, then we 
reasoned that gene body methylation and upregulation of gene expression in the MeCP2 KO cortex 
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should be more tightly linked for genes that contain enhancers than genes that do not contain enhancers. 
Because long genes are more likely to contain enhancers than shorter genes (Figure S5J), robust 
regulation of intragenic enhancers by MeCP2 binding could also help to explain the global trend toward 
upregulation of longer genes with high gene body mCA levels upon loss of MeCP2 that we and others 
have observed (Figure S1F-H) (Gabel et al., 2015; Kinde et al., 2016; Lagger et al., 2017; Rube et al., 
2016; Sugino et al., 2014). We therefore examined the effects of MeCP2 knockout and MeCP2 
overexpression on gene expression for genes that do or do not contain intragenic enhancers. We find 
little to no correlation between dysregulation of gene expression and the density of gene body mCA 
sites for genes that do not contain enhancers, but we observe a robust correlation for genes containing 
one or more intragenic enhancer (Figure 6I, S5L). Importantly, these effects were seen even when we 
controlled for gene length in this analysis (Figure S5K). Consistent with the idea that enhancers 
substantially contribute to the gene-body mCA signature that we have previously observed for MeCP2-
repressed genes, we found that the H3K27ac changes in intragenic enhancers was more predictive of 
the change in gene expression in MeCP2 mutants than H3K27ac changes in intragenic non-peak 
sequences (Figure S5M). These results point to dysregulation of intragenic enhancers as an underlying 
cause for the dysregulation of long, highly methylated genes that we and others have observed in 
MeCP2 mutant mice. 
 
2.3 Discussion 
The recent discovery of high levels of non-CG methylation in neurons and the realization that MeCP2 
can bind to this neuron-enriched methyl-mark have uncovered a new pathway of gene regulation that 
is critical for neuronal function. However, our understanding of how patterns of non-CG methylation 
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are established across the neuronal genome is still in its infancy. In this study, we have uncovered a 
link between genome topology in the nucleus of neurons and the levels of mCA occurring at the 
hundred-kilobase to megabase scale. Our findings suggest a model in which TAD structures in neurons 
dictate the distribution of DNMT3A across the genome during early postnatal development to establish 
higher or lower mCA set-points for genes and enhancers within each TAD (Figure 7A). In mature 
neurons, MeCP2 then reads-out this methylation to repress histone acetylation at enhancer elements 
and control gene expression. Because MeCP2 most potently represses highly-methylated, intragenic 
enhancers, its repressive effects have the largest impact on genes that contain multiple enhancers and 
lie within high-mCA TADs. Upon disruption of MeCP2 or loss of mCA, dysregulation of intragenic 
enhancers leads to altered expression of these genes, driving nervous system dysfunction (Figure 7B). 
The varying levels of CA methylation in TADs appear to be facilitated by the dynamic and unimodal 
distribution of mCA across the genome that allows for large relative fluctuations in levels between 
megabase scale TADs and contrast with megabase scale mCG levels, which tend to be very high and 
consistent across domains. The consistently high levels of DNMT3A recruitment and resulting high 
set-point of CA methylation that we observe in TADs that contain MeCP2-repressed genes provide 
insight into the origin of high mCA that we and others have previously observed at these genes (Kinde 
et al., 2016; Lagger et al., 2017). Future studies will be needed to determine how DNMT3A recruitment 
and mCA becomes associated with TAD structures during postnatal development. 
 
Our finding that the mCA set-point for TADs correlates well with the mCA levels for enhancers and 
genes in each domain suggests that, while sequence features and the regulatory state of each enhancer 
are known to affect their methylation status (Schübeler, 2015), regional mCA levels also influence 
total levels of mCA at these important regulatory elements. In contrast, mCA levels at TSSs are 
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generally extremely low and are not well correlated with TAD-associated mCA levels. Thus, while 
TSSs are not likely to be directly affected by TAD-associated mCA, enhancers within high-mCA 
TADs are enriched for mCA and are more likely to be repressed by MeCP2 compared to enhancers 
within low-mCA TADs. In this way, TADs can dictate mCA patterns across the genome and set the 
stage for MeCP2-mediated gene regulation in the brain.  
 
Previously, based on the long length of MeCP2-repressed genes, as well as the observed correlation 
between gene-body methylation and changes in gene expression upon loss of MeCP2 (e.g. Figure 1B; 
S1D,G,H), we had proposed a mechanism whereby binding of MeCP2 within genes interrupts RNA 
polymerase II processivity to downregulate expression (Kinde et al., 2016). Surprisingly, our analysis 
here did not uncover evidence of altered polymerase processivity or termination for long, highly-
methylated genes in the MeCP2 mutants, but instead pointed to changes in promoter activation for 
these MeCP2-repressed genes. In parallel with our study, Boxer, Renthal, Greenberg, and colleagues 
(Boxer et al., co-submitted) have employed several high-resolution methodologies to examine 
alterations in gene expression in MeCP2 mutants on multiple levels (e.g. initiation, elongation, 
splicing). This analysis identified alterations in transcription initiation as the primary change in 
MeCP2-regulated genes upon loss of MeCP2, which is consistent with our findings here. Our search 
for how mCA and mCG sites found outside the TSS of the gene can affect promoter activation led to 
the identification of intragenic enhancers that are dysregulated in MeCP2 mutants, and showed that the 
methylation of these enhancers is most tightly linked to changes in gene expression (Figure 6I, S5J-
M). Hence, our new findings support the model in which MeCP2 preferentially represses long, highly-
methylated genes through binding within the gene body, but provide an unexpected mechanism of 




While MeCP2 has been shown to act as a transcriptional repressor in vitro, the protein binds nearly 
ubiquitously across the genome in vivo and its most relevant sites of action have not been clear. 
Through genome-wide analysis of changes in histone acetylation, we have uncovered a role for mCA, 
mCG, and MeCP2 in enhancer regulation. Multiple biochemical studies have shown that MeCP2 binds 
with high affinity to both mCG and mCA, suggesting that each of these marks are important for gene 
regulation by MeCP2 (Chen et al., 2015; Gabel et al., 2015; Guo et al., 2014; Lagger et al., 2017). 
Previous genomic analyses have primarily detected enrichments of per-cytosine mCA levels 
(mCA/CA) at sequences in and around MeCP2-repressed genes however (Chen et al., 2015; Gabel et 
al., 2015; Kinde et al., 2016; Lagger et al., 2017), with limited evidence of higher mCG levels 
(mCG/CG) at these genes. Our findings show that TAD-scale fluctuations in mCA/CA are a major 
determinant of the number of mCA sites at enhancers that are repressed by MeCP2. In contrast, 
fluctuations in the number of CG dinucleotides present in enhancer sequences, rather than mCG/CG, 
primarily contribute to the enrichment of mCG sites found at MeCP2-repressed enhancers. Thus, our 
findings uncover a novel function for MeCP2 in regulating enhancers and support a role for the high 
affinity of MeCP2 to both mCG and mCA in its repressive function at these sites. 
 
Consistent with some role for mC sites in recruiting MeCP2 to the genome, MeCP2 ChIP-seq profiles 
show a measurable association with mCA and mCG binding sites (Figure 2D, S3I). However, the 
binding of the protein is very broad and signal is present at highly demethylated sites. Therefore, it is 
possible that the presence or absence of mC binding sites for MeCP2 may modulate its repressive 
activity, rather than serving as a strict determinant of its binding. Future analyses will be necessary to 




Our identification of genes and enhancers defined as changed in MeCP2 mutants using statistical 
thresholds revealed critical determinants for enhancer regulation by MeCP2 (e.g. number of mCA and 
mCG sites, presence within a gene), but our findings suggest that these lists of significantly altered 
enhancers represent only the extreme examples in a continuum of genome-wide effects. DNA 
methylation and MeCP2 binding occur nearly ubiquitously across the genome and show only limited 
fluctuations in levels from region to region. Our unthresholded, genome-wide analysis of enhancer 
methylation supports a graded repressive effect of MeCP2 that is proportional to the number of mC 
sites at each enhancer. Thus, nearly every gene-regulatory element may be regulated to some extent 
by MeCP2. Alterations in this pervasive tuning of enhancers may explain why disruption of non-CG 
methylation or MeCP2 leads to profound nervous system dysfunction, despite the small magnitude of 
gene expression effects that are observed for individual genes. 
 
Analysis of more than a dozen human and mouse MeCP2 mutant datasets carried out across multiple 
laboratories support a role for MeCP2 in repressing long, highly methylated genes (Gabel et al., 2015; 
Kinde et al., 2015, 2016; Lagger et al., 2017; Rube et al., 2016; Sugino et al., 2014). The mechanism 
by which this repression occurs has been an area of open investigation however, and two recent studies 
have suggested that a model of direct transcriptional repression of these genes requires further testing. 
One study proposed that upregulation of long genes upon loss of MeCP2 is a consequence of post-
transcriptional effects rather than disrupted transcriptional repression (Johnson et al., 2017), while 
another suggested that the subtle dysregulation of long genes observed in individual MeCP2 mutant 
datasets does not reach a threshold for statistical significance (Raman et al., 2018). Here, we have 
addressed these issues by confirming these effects in a new set of MeCP2 KO and MeCP2 OE RNA-
72 
 
seq analyses and by using ChIP-seq analysis to independently assess effects on transcription-associated 
histone modifications. Our new findings further support the conclusion that MeCP2 mediates 
methylation-associated transcriptional repression that preferentially influences long genes. Notably, 
parallel analyses from an independent laboratory using multiple methodologies to assess 
transcriptional changes in large-replicate-number MeCP2 mutant datasets (Boxer et al., co-submitted), 
have further verified that mutation of MeCP2 leads to bona fide gene-length- and methylation-
associated dysregulation of gene transcription. Our additional insights implicating enhancers in this 
gene regulation not only validate these effects, but also provide one mechanism by which MeCP2 can 
carry out this regulation. 
 
While our study focuses on understanding the origin and function of mCG and mCA at MeCP2-
repressed genes, our findings suggest that enhancer repression by MeCP2 may also influence MeCP2-
activated genes. A distinguishing feature of MeCP2-activated enhancers identified in this study is that 
they are depleted of mCA and mCG sites compared to the genome average (Figure 4C; S5B-D). This 
suggests that acetylation changes that we observed for these activated enhancers may actually reflect 
a relative lack of de-repression upon loss of MeCP2 and an escape from repression upon increased 
MeCP2 levels, respectively. Notably, MeCP2-activated enhancers are significantly associated with 
MeCP2-activated genes (Figure 6B). This raises the possibility that a lack of de-repression at some 
enhancers upon loss of MeCP2 drives the apparent relative downregulation of MeCP2-activated genes 
that is detected. Future studies will be necessary to further delineate whether the downregulation effects 
that we observe upon loss of MeCP2 are caused by a lack of de-repression at MeCP2-activated 




Previous studies have implicated the interaction between MeCP2 and the NCoR histone deacetylase 
co-repressor complex as critical for MeCP2 to mediate gene repression (Ebert et al., 2013; Kokura et 
al., 2001; Lyst et al., 2013; Nott et al., 2016). Indeed, analysis from Boxer, Renthal, and colleagues 
(Boxer et al., co-submitted) shows that specific disruption of the MeCP2-NCoR interaction in the 
MeCP2 R306C mutant mouse leads to similar effects on transcription and chromatin as deletion of 
MeCP2. Our findings detecting regulation of enhancers by MeCP2 suggest an important site of action 
for the MeCP2-NCoR complex. In one model, recruitment or regulation of enhancer-associated NCoR 
by MeCP2 induces histone deacetylation to block the activating effect of the enhancer on its target 
promoter. Alternatively, MeCP2 may modulate NCoR activity on non-histone proteins. Stimulus-
dependent phosphorylation of MeCP2 may selectively disrupt the MeCP2-NCoR interaction and 
modulate NCoR function at enhancers. Such a mechanism could facilitate de-repression of enhancer 
activity upon neuronal activation, and help drive activity-dependent gene expression in the brain (Ebert 
et al., 2013; Yap and Greenberg, 2018).  
 
Our quantification of H3K27ac shows that its highest signal is located at enhancers and promoters and 
indicates that robust mCA- and mCG-associated changes occur at enhancers in MeCP2 mutants. 
MeCP2 binds broadly across the genome however, including at non-regulatory sequences, and 
disruption of MeCP2 has effects on acetylation in broad domains that are not strictly confined to our 
stringently defined enhancer sequences (Figure S5E) (Boxer et al., co-submitted). Our analysis of 
ATAC-seq peaks suggest that additional regulatory sequences that were not detected as H3K27ac 
ChIP-seq peaks may be regulated by MeCP2, and that acetylation changes in enhancers and these 
regions contribute to increases in gene body acetylation detected. However, MeCP2 is likely to have 




A striking feature of the enhancer repression that we observe is that MeCP2 appears to have larger 
repressive effects on intragenic enhancers compared to extragenic enhancers, and de-repression of 
intragenic enhancers upon loss of MeCP2 is closely linked to upregulation of the gene in which the 
enhancers reside. Our analysis of Hi-C data further suggests that, in general, intragenic enhancers more 
readily contact and regulate their cognate promoters than extragenic enhancers, making the 
dysregulation of intragenic enhancers in MeCP2 mutants particularly impactful for gene expression. 
Notably, the larger MeCP2-mediated effects on intragenic enhancer acetylation and preferential Hi-C 
interactions that we observe provide an explanation for previous observations in which the mC sites 
specifically within longer genes are most tightly linked to the level of repression imposed on the gene 
by MeCP2 (Kinde et al., 2016; Lagger et al., 2017). Future studies to examine the mechanism by which 
MeCP2 preferentially represses intragenic enhancers will allow us to further understand the origins of 
these effects.  
 
Our findings have important implications for the molecular etiology of Rett syndrome and MeCP2 
duplication disorders. Our results indicate that when MeCP2 is lost or overexpressed in disease, this 
disrupts the precise control of enhancers normally maintained by MeCP2 through its interaction with 
genome-topology-associated DNA methylation. The resulting dysregulation of enhancers that occurs 
can contribute to altered gene expression, driving disease pathology. In this way, our study suggests 
that Rett syndrome and MeCP2 duplication syndrome are disorders that stem in part from disruption 




2.4 STAR Methods 
2.4.1 Key Resources Table 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
Rabbit polyclonal anti-Histone H3 (acetyl K27) Abcam Cat# ab4729; 
RRID:AB_2118291 
Mouse monoclonal anti-Histone H3 (tri methyl K4) Abcam Cat# ab1012; 
RRID:AB_442796 
Rabbit polyclonal anti-Histone (tri methyl K36) Active Motif Cat# 61101; 
RRID:AB_2615073 
Bacterial and Virus Strains  
Biological Samples   
Chemicals, Peptides, and Recombinant Proteins 
OptiPrep Density Gradient Medium Sigma-Aldrich Cat#: D1556 
IGEPAL CA-630 Sigma-Aldrich Cat#: I8896 
Critical Commercial Assays 
RNeasy Micro Kit Qiagen Cat#: 74004 
NEBNext Ultra Directional RNA Library Prep Kit 
for Illumina 
NEB Cat#: E7420S 
NEBNext Mulitplex Oligos for Illumina (Index 
Primers Set 1) 
NEB Cat#: E7335S 
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NEBNext rRNA Depletion Kit 
(Human/Mouse/Rat) 
NEB Cat#: E6310L  
Ovation Ultralow Library System V2 NuGEN Cat#: 0344-32 
Ovation Ultralow Methyl-Seq Library System NuGEN Cat# 0535-32 
2S Set A Indexing Kit Swift Biosciences Cat#: 26148 
Deposited Data 
RNA-sequencing data This paper GEO: GSE123373 
ChIP-sequencing data (H3K27Ac, H3K4Me3, 
H3K36me3) 
This paper GEO: GSE123373 
ENCODE H3K4me1 ChIP-seq ENCODE GEO: GSM769022 
Bisulfite-sequencing data This paper GEO: GSE123373 
MeCP2 ChIP-seq (Kinde et al., 2016) GEO: GSE90704 
DNMT3A ChIP-seq, Bisulfite-seq (Stroud et al., 2017) GEO: GSE104298 
Dixon Hi-C contact matrices (Dixon et al., 2012) http://chromosome.
sdsc.edu/mouse/hi-
c/cortex.norm.tar.gz 
Bonev Hi-C data (Bonev et al., 2017) GEO: GSE96107 
Bisulfite-seq (Lister et al., 2013) GEO: GSE47966 
Bisulfite-seq (Mellén et al., 2017) GEO: GSE95628 





Mus musculus mm9 genome assembly UCSC http://hgdownload.s
oe.ucsc.edu/golden
Path/mm10/ 
Ensembl gene models UCSC https://genome.ucsc
.edu/cgi-
bin/hgTables 
Experimental Models: Cell Lines 
Experimental Models: Organisms/Strains 












Mouse: DNMT3A Baf53b-cKO: Dnmt3afl/fl 
Tg(Actl6b-cre)4092Jiwu/J 
Derived from 
DNMT3A fl/fl strain 
(described in 
(Kaneda et al., 
2004), mice 
provided by M. 
Goodell) and 
Baf53b-Cre (Zhan et 
al., 2015) , mice 









Mouse: DNMT3A Nestin-cKO: Dnmt3afl/fl Tg(Nes-
cre)1Kln/J 
Derived from 
DNMT3A fl/fl strain 
(described in 
(Kaneda et al., 
2004), mice 
provided by M. 
Goodell) and Nes-
Cre (Tronche et al., 
1999), mice obtained 





(Gabel et al., 2015) 
Oligonucleotides 
Zmat4 anchor primer: 
GGCTGTTTGGAAATGTAGCC 
IDT Custom 
Zmat4 – e1 primer: 
GGGTGAGAAGGGAAGAGACA 
IDT Custom 
Zmat4 – e2 primer: 
ATCTTGCCAGCTCCTGTCTTT 
IDT Custom 





Zmat4 – e1 negative region primer: 
CGTGAATGCCAATGTGTTTC 
IDT Custom 
Zmat4 – e2 negative region primer: 
CAAGGCTGGGCACTCTCTGT 
IDT Custom 
Zmat4 – e3 negative region primer: 
ACAGTATTGTGTGGGCATTCAG 
IDT Custom 
Efna5 anchor primer: 
TGCTACCGTTGTTTGGTTTG 
IDT Custom 
Efna5 – e1 primer: 
CCCTAAATGTCTCAGAACTGTGG 
IDT Custom 
Efna5 – e2 primer: 
GCTGAGCCTGCTGAAATATGTA 
IDT Custom 
Efna5 – e1 negative region primer: 
GCCCAAGGTGATTCTAAACTGT 
IDT Custom 
Efna5 – e2 negative region primer: 
TTGCTTTCAAGAACTCCTATTTCA 
IDT Custom 
Snx24 anchor primer: 
TAGAAACCACAGATGGTCTGGA 
IDT Custom 
Snx24 – e1 primer: 
GGCTAAGTGTAGTCCCAGCAC 
IDT Custom 





Tshz1 anchor primer: 
ATGTCCCAAATGTCCTGTGTTT 
IDT Custom 
Tshz1 – e1 primer: 
CCAGGCTTGAAGTAGTTTCTGG 
IDT Custom 
Tshz1 – e2 primer: 
ACAGTGCCAGCAAGGGTATG 
IDT Custom 
Tshz1 – e1/e2 negative region primer: 
TTGAAAACAAAATGTCATCCAG 
IDT Custom 
Actb anchor primer: 
TGTTACCAACTGGGACGACAT 
IDT Custom 
Actb – e1 primer: 
AGACATGCCAGAAGAGCGTGT 
IDT Custom 
Actb – e1 negative region primer: 
TAGACTTAGCCAGCCTGGAACT 
IDT Custom 
Ank2 anchor primer: 
GGCACTCACTCTGTCTATGAGG 
IDT Custom 
Ank2 – e1 primer: 
ATATGTGTTAGGGGCCAGTGTC 
IDT Custom 
Ank2 – e1 negative region primer: 
ACGGTTTTCTGCTGCAGTTAGT 
IDT Custom 





Zfp60 – e1 primer: 
GGTGGTCATCTATAACTGTCTTGAG 
IDT Custom 




Zmat4 BAC: RP23-21B20 Life Technologies Cat#: Clone Id 
21B20 RPCI-23 
MM BAC CLONE 
Zmat4 BAC: RP23-320D14 Life Technologies Cat#: Clone Id 
320D14 RPCI-23 
MM BAC CLONE 
Efna5 BAC: RP23-51F6 Life Technologies Cat#: Clone Id 
51F6 RPCI-23 MM 
BAC CLONE 
Efna5 BAC: RP23-309F7 BACPAC Resources Cat#: RP23-309F7 
Snx24 BAC: RP23-207I5 BACPAC Resources Cat#: RP23-207I5 
Tshz1 BAC: RP23-153P8 BACPAC Resources Cat#: RP23-153P8 
Actb BAC: RP23-35M10 BACPAC Resources Cat#: RP23-35M10 
Ank2 BAC: RP23-399L5 BACPAC Resources Cat#: RP23-399L5 
Zfp60 BAC: RP23-181E8 BACPAC Resources Cat#: RP23-181E8 
Software and Algorithms 
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MACS2 (v2.1.0) (Zhang et al., 2008) https://github.com/t
aoliu/MACS 









Juicer (Durand et al., 2016) https://github.com/t
heaidenlab/juicer 
BS-seeker2 (Guo et al., 2013) https://github.com/
BSSeeker/BSseeker
2 






Contact for Reagent and Resource Sharing 





2.5 Experimental Model and Subject Details 
Mice 
MeCP2 knockout mice (B6.129P2(C)-MeCP2tm1.Bird/J) were obtained from The Jackson 
Laboratory. Female heterozygous mice (MeCP2-/+) were crossed with C57BL/6J male mice to 
generate hemizygous male knockout mice (MeCP2-/y) and wild-type male litter mates (MeCP2+/y). 
MeCP2 overexpression mice (FVB-Tg(MECP2)3Hzo/J) were cryo-recovered from The Jackson 
Laboratory. Female heterozygous mice (MeCP2Tg3/+) were crossed with FVB/NJ male mice to 
generate hemizygous male transgenic mice (MeCP2Tg3/y) and wild-type male litter mates 
(MeCP2+/y). Female Dnmt3afl/fl were provided by M. Goodell and crossed to male B6.Cg-Tg(Nes-
cre)1Kln/J (Nestin-Cre+/-) to generate Dnmt3afl/+; Nestin-Cre+/. Male Dnmt3afl/+; Nestin-Cre+/- 
were then crossed to female Dnmt3afl/fl to generate Dnmt3afl/fl Tg(Nes-cre)1Kln/J conditional 
knockout mice (DNMT3A Nestin-cKO) (Gabel et al., 2015). To generate Dnmt3afl/fl Tg(Actl6b-
cre)4092Jiwu/J conditional knockout mice (DNMT3A Baf53b-cKO), Dnmt3afl/fl were crossed to 
Tg(Actl6b-cre)4092Jiwu/J (Baf53b-Cre+/+) to generate Dnmt3afl/+; Baf53b-Cre+/-.  Dnmt3afl/+; 




Topologically associated domain analysis 
Topologically associating domains were called using TADtree on interaction matrices from (Dixon 
et al., 2012), with the following parameters: gamma (Sensitivity vs specificity tradeoff) = 200, M 
(Number of hierarchical layers) = 1, p and q (minimum scale of interaction shift) = 3 and 12 
respectively, and N (maximum number of TADs detected) = 500. To allow for manual model 
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selection, TADtree also computes TADs for the range of 1:500, in this case. We leveraged this to 
apply an additional filter for consistency, wherein we selected for TADs that are called in at least 
30% of all runs. When we applied this filter, we found that the effects of changing gamma were 
moderated, and the program performed consistently at many ranges of sensitivity vs specificity. 8-
week cortex Hi-C data was obtained as pre-processed observed/expected contact matrices, from 
http://chromosome.sdsc.edu/mouse/hi-c/download.html (Dixon et al., 2012). For analysis of 
neocortex Hi-C data from Bonev and colleagues (Bonev et al., 2017), raw FASTQ files were 
downloaded from GEO. HiC-Pro (Servant et al., 2015) was used to generate contact matrices using 
the mm10 mouse genome as reference. Juicer (Durand et al., 2016) was then run on the contact 
matrices to generate Hi-C contact matrices at 1.5kb, 5kb, and 40kb resolutions using KR 
normalization. Arrowhead domains were then called on the data within Juicer. 
For cerebellum analysis, contact domains called from 10kb-resolution Hi-C data were used 
(Yamada et al., 2019). 
 
Total and nuclear RNA isolation 
Cerebral cortex was dissected on ice in phosphate buffered saline from 1) MeCP2 knockout and 
wild-type male litter mates at 7-8 weeks old, 2) MeCP2 overexpression and wild-type male litter 
mates at 7-10 weeks old, and 3) DNMT3A Baf53b-cKO and control mice at 7-8 weeks old. Total 
RNA was extracted from 1/16th of a whole cortex using RLT buffer following RNeasy Micro Kit 
(Qiagen). Nuclear RNA was isolated following a modified version of the protocol described by 
(Mo et al., 2015). Briefly, half of a cortex was homogenized in 0.25M sucrose, 25mM KCl, 5mM 
MgCl2, 20mM Tricine-KOH using a glass dounce homogenizer. Nuclei were isolated via 
centrifugation at 10,000g for 18 minutes at 4°C (Sorvall HB-4) by pelleting through a 30% 
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iodixanol density gradient (Sigma D1556). RNA was isolated from nuclei by resuspending pellet 
in RLT buffer following the RNeasy Micro Kit (Qiagen). 
 
RNA sequencing 
RNA libraries were generated from 250ng total and nuclear RNA with NEBNext Ultra Directional 
RNA Library Prep Kit for Illumina (NEB) using a modified amplification protocol (37°C, 15 
minutes; 98°C, 30 seconds; (98°C, 10 seconds; 65°C, 30 seconds; 72°C, 30 seconds)x13; 72°C, 5 
minutes; 4°C hold. RNA libraries were pooled at a final concentration of 8-10nM and sequenced 
using Illumina HiSeq 2500 or 3000 with the Genome Technology Access Center (GTAC) at 
Washington University in St. Louis, typically yielding 20-30 million single-end reads per sample.  
 
RNA sequencing analysis 
Raw FASTQ files were trimmed with Trim Galore, using a quality filter of 20, then rRNA 
sequences were filtered out using Bowtie, using rRNA sequences from Mus Musculus obtained 
from the NCBI sequence database (see Key Resources Table). The unaligned reads from this step 
were then aligned to mm9 using STAR (Dobin et al., 2013), using the default parameters. Reads 
mapping to multiple regions in the genome were then filtered out, and uniquely mapping reads 
were converted to BED files. Intronic and exonic reads were then separated. To do this, splice-site 
reads were first filtered out of the BED read files, then reads that mapped entirely within exons 
were added to the splice-site reads to make the exonic read file. All remaining reads that 
overlapped introns were considered intronic reads. Finally, reads were assigned to genes using 




For gene annotation we defined a "flattened" list of longest transcript forms for each gene, 
generated on Ensgene annotations, obtained from the UCSC table browser. For each gene, ensembl 
IDs were matched up to MGI gene names. Then, for each unique MGI gene name, the most 
upstream Ensgene TSS and the most downstream TES were taken as that gene's start and stop. 
 
Chromatin immunoprecipitation protocol 
Cerebral cortex was dissected on ice in phosphate buffered saline from 1) MeCP2 knockout and 
wild-type male litter mates at 7-8 weeks old, 2) MeCP2 overexpression and wild-type male litter 
mates at 7-10 weeks old, 3) DNMT3A Baf53b-cKO and control mice at 7-8 weeks old. The tissue 
was flash-frozen in liquid nitrogen and stored at -80°C. ChIP experiments were performed on half 
a cortex as previously described (Cohen et al., 2011a), using an alternative chromatin 
fragmentation method. Chromatin were fragmented with Covaris E220 sonicator (5% Duty 
Factory, 140 Peak Incidence Power, 200 cycles per burst, milliTUBE 1mL AFA Fiber). ChIP was 
performed with H3K27ac (0.025-0.1µg; Abcam ab4729), H3K4me3 (2µg; Abcam ab1012), 
H3K36me3 (0.2µg; Active Motif 61101). ChIP libraries for H3K27ac, H3K4me3, and H3K36me3 
were generated using Ovation Ultralow Library System V2 (NuGEN). Libraries were pooled to a 
final concentration of 8-10nM and sequenced using Illumina HiSeq 3000 with GTAC, yielding 
15-30 million single-end reads per sample. 
 
Chromatin immunoprecipitation analysis 
Sequenced reads were mapped to the mm9 genome using bowtie2 alignment, and reads were 
extended based on library sizes and deduplicated to consolidate PCR duplicate reads. Deduplicated 
reads were used to quantify read density normalized by the number of reads per sample and by 
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read length in basepairs. Bedtools coverage –counts was used to quantify ChIP signal at the 
transcriptional start site (TSS), gene body (GB), and transcriptional end site (TES). For consistency 
with methylation analysis, the TSS was defined as a 1kb region surrounding the TSS (+/-500bp), 
the GB was defined as 3kb downstream of the TSS to the end of the transcript, and the TES was 
defined as 2kb upstream through 3kb downstream of the end of the transcript. edgeR was then 
used to determine differential ChIP-signal across genotypes. 
 
Whole-genome bisulfite sequencing 
Cerebral cortex was dissected from DNMT3A Nestin-cKO or DNMT3A Baf53-cKO and controls 
at 7-8 weeks, flash-frozen in liquid nitrogen, and stored at -80°C. DNA extraction and bisulfite 
conversion were performed as in (Gabel et al., 2015). Briefly, genomic DNA was extracted and 
bisulfite libraries were generated using the Ovation Ultralow Methyl-Seq Library System 
(NuGEN).  Libraries were pooled and sequenced using Illumina MiSeq 2x150 with the Spike-In 
Cooperative at Washington University in St. Louis.  
 
Chromatin conformation capture 
3C assays were adapted from previously described procedures (Kim and Dekker, 2018; 
Lieberman-Aiden et al., 2009; Yamada et al., 2019). Half of a cerebral cortex was dounced 10x 
with a loose pestle in cross-linking buffer (50mM Hepes-KOH, pH 7.9; 100mM NaCl; 1mM 
EDTA; 0.5mM EGTA) with 1% formaldehyde at room temperature for 15 minutes. Formaldehyde 
was quenched with 125mM glycine and incubated for 5 minutes at room temperature. The 
suspension was pelleted at 1150xg for 5 minutes at 4°C and the pellet was subsequently washed 
with PBS and frozen at -80°C. The frozen pellet was thawed and lysed (10mM Tris-HCl, pH 8; 
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10mM NaCl, 0.2% IGEPAL-630, Protease Inhibitor (Complete Protease Inhibitor Cocktail, 
Roche)) for 15 minutes followed by douncing 25x with a loose pestle on ice. The lysed cells were 
strained through a 70um cell strainer (Falcon) and pelleted at 200xg for 5 minutes at 4°C. Nuclei 
were resuspended in 1mL of 0.5% SDS and incubated at 62°C for 10 minutes to permeabilize the 
nuclei. 25ul (approx. 90-100k nuclei) were used for the 3C library construction, and SDS was 
quenched with Triton X-100 (1% Triton, 1x NEB 3.1 Buffer). Nuclei were digested overnight at 
37°C with 200U of BglII. The digested nuclei were incubated at 65°C for 15 minutes to inactivate 
the enzyme. Samples were then ligated for 6 hours at 16°C with 4000U of T4 DNA ligase (NEB 
Ligase Buffer, 0.1mg/ml BSA, Triton X-100, NEB T4 ligase). Digested and ligated 3C samples 
were pelleted at 3500rpm for 5 minutes at 4°C and resuspended in 200ul NEB 3.1 Buffer and 
brought to 1% SDS, 250mM NaCl. 3C libraries were de-crosslinked overnight at 65°C. They were 
then incubated with 40ug RNase A at 37°C for 1 hour, followed by 80ug of Proteinase K at 55°C 
for 1 hour. The samples were purified with Phenol/Chloroform/Isoamyl Alcohol (25:24:1) and 
subsequently ethanol precipitated (100mM Sodium Acetate) overnight at -20°C. Control libraries 
were generated from Bacterial Artificial Chromosomes (BACs) as previously published (Kim and 
Dekker, 2018). BACs (see STAR methods) were isolated using PureLink HiPure Plasmid 
Maxiprep Kit (Invitrogen), following the modified protocol for BAC isolation. 
 
Quantification and Statistical Analysis 
Whole-genome bisulfite analysis 
Bisulfite-sequencing cannot distinguish between hydroxymethylation and methylation at 
cytosines, detecting both only as modified sites during sequencing. Thus, measures of methylation 
included in this study represent the aggregate of both forms of methylation at sites across the 
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genome. Bisulfite data for the DNMT3A Nestin-cKO and DNMT3A Baf53b-cKO, and data 
obtained from GEO as FASTQ files, were adapter-trimmed, mapped to mm9, then deduplicated 
and called for methylation using BS-seeker2 (with bowtie2). Nonconversion rate was set to be (--
XS=.3,2), and default settings were used otherwise. The methylation levels for genes and regions 
was assessed by summing up the number of reads mapping to Cs that supported mC and dividing 
that by the number of reads mapping to Cs that supported non-mC, using bedtools map -o sum. 
This allows sites with more read information to contribute more in determining the methylation 
level of the surrounding region. In order to avoid confounding effects of promoter-associated 
depletion of methylation, genic methylation was assessed 3kb downstream of promoters, to the 
TES. In order to assess any potential for C site coverage bias influencing TAD-associated 
Bisulfite-seq results, a bed file of every C/G in the genome was generated, and bedtools coverage 
-counts was run on it. Bisulfite coverage bias was assessed on informative sites for methylation 
with bedtools map -o mean on the number of reads mapping to Cs in the region. 
 
RNA-sequencing quantification 
MeCP2-repressed and activated genes were identified by quantitative analysis of exonic reads 
from total RNA from the MeCP2 KO and OE. For this analysis we applied an approach similar to 
previous studies of other brain regions that combined results of gene expression in these two strains 
in order to identify the most-robustly MeCP2-regulated genes (Ben-Shachar et al., 2009; Chahrour 
et al., 2008; Chen et al., 2015). DESeq2 was run using default parameters on exonic reads from 
MeCP2 KO and their littermate control animals (n=6 per genotype). Separately, we ran DESeq2 
analysis on exonic reads from MeCP2 OE and their littermate control animals (n=5). The nominal 
p-values output by DESeq2 for each gene in each mutant-control comparison were then combined 
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using the Fisher method (log-sum). The resulting combined p-values were then Benjamini-
Hochberg corrected, and genes with a q-value < .1 and a log2 fold-change > 0 in the KO and a 
log2 fold-change < 0 in the OE were labeled as MeCP2-repressed, while genes with a q-value < .1 
and a log2 fold-change < 0 in the KO and a log2 fold-change > 0 in the OE were labeled as MeCP2-
activated. Notably, similar results for enrichment of mCA, and gene length were observed when 
examining lists of genes called as significantly dysregulated in the MeCP2 KO and OE on their 
own. However, a smaller gene list was identified in each independent analysis, likely due to the 
reduced statistical power. For comparison between changes in intronic RNA and changes in exonic 
RNA (Figure 3; S1) a list of significantly changed genes in the MeCP2 KO compared to littermate 
controls based on intronic fold-changes was generated by applying the same DESeq2 analysis to 
intronic reads derived from total RNA-seq of nuclear RNA.  
 
RNA-seq aggregate plots examining changes in expression over lengths of genes (Figure S4G-I) 
were performed by binning genes into 1kb windows, then calculating nuclear intronic coverage 
over each bin using bedtools coverage -hist. Each gene was then normalized by the median amount 
of combined coverage from the MeCP2 KO and wild-type. Finally, genes were aligned by their 
TSS's, and median expression levels were plotted for each bin. For any given graph, the genes are 
filtered such that the lengths of genes plotted is equal to or greater than the aggregate length being 
plotted (Boswell et al., 2017; Gray et al., 2014). Termination ratios (adapted from (Boswell et al., 
2017)) were calculated in a manner similar to the aggregate plots of expression. Windows were 
made for every gene longer than 100kb, from the TSS to 25kb downstream of the TSS (window 
A), and from the TES to 25kb upstream of the TES (window B). Coverage over these windows 
was calculated with bedtools coverage -hist, then coverage of window A was divided by the 
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coverage of window B, within each sample. Then, wild type/MeCP2 KO samples were divided 
against each other, and a normalized metric for each wild type/MeCP2 KO replicate was generated. 
Finally, median metrics were plotted for each wild type/MeCP2 KO replicate. Simulated metrics 
were generated by progressively applying exonic fold-changes to the wild-type expression 
throughout the gene. For example, a gene 50kb long, with an observed exonic log2 fold-change 
(MeCP2 KO/wild type) of -1 would be divided into 50 1kb bins. A simulated KO expression 
pattern would then be generated by progressing down each of the 50 bins, applying a fold-change 
of 1/50 * -1, 2/50 * -1, etc, to the expression of the corresponding bin in the WT. 
 
TAD boundary analysis  
For Figures 1F, 2C, S2B, and S2F, all TADs that intersected MeCP2-repressed, MeCP2-activated, 
and unchanged genes were selected, boundaries phased, and values for mC/C, coverage, GC 
percent, or ChIP/Input plotted in aggregate using R, python, and bedtools. Shuffling analysis was 
performed in these cases by moving each TAD randomly around their target genes (TADs 
containing MeCP2-repressed genes were shuffled around MeCP2-repressed genes, etc.). This was 
done once to generate a single example (e.g. Figure 1F), or up to 20 times to generate a resampling 
ribbon (e.g. Figure S2B).  Figures 1G and S2K were generated by selecting boundaries through 
the following method: TADs were assigned a score, based on the difference between its mCA level 
and the mCA level of the next downstream TAD. Then, the top 33% top scoring TADs were taken 
and plotted in aggregate analysis. For shuffled TAD control plots, TAD locations were randomized 
and the selection process for these shuffled TADs was repeated. We note that because both true 
TADs and shuffled TADs in these plots were selected based on high differences in average 
methylation between them, a reduction of signal going from left to right is predicted. However, 
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true TADs display two aspects of mCA/CA signal that are not present in shuffled TADs, which 
demonstrate the organizing effects associated with TAD boundaries: 1) True TADs are more 
highly enriched for mCA, showing that resampling TADs eliminates an organized enrichment of 
mCA/CA in specific regions of the genome. 2) A steep step-down in mCA/CA occurs at true TAD 
boundaries, while a more gradual fall off in signal occurs at reshuffled boundaries. These two 
differences illustrate that ~30% shifts in mCA/CA levels are common between adjacent TADs, 
and they demonstrate that TAD boundaries delineate a sharp transition between mCA/CA levels 
at these regions. Plotted in all figures is the average of the upstream and downstream TAD 
boundaries, taking into account TAD orientation. Upstream boundaries (where the TAD would be 
on the right, instead of the left), have their orientation flipped horizontally along the boundary. 
The value plotted is the mean of the flipped upstream boundaries and the unflipped downstream 
boundaries.  
 
TAD methylation cross-correlation 
Cross-correlation matrices (e.g. Figure 1H) were generated by dividing each domain into 10 
equally-sized bins, then prepending and appending 10 identically sized bins up and down-stream 
of the domain, making a number of domains x 30 matrix. Each column of this matrix was then 
correlated against each other column, making a 30 x 30 correlation matrix, which was plotted in 
heatmap form. Shuffled TADs were generated as a negative control by randomly placing TAD-
sized regions around the genome, separated from each other by similar distances as actual TADs 




In order to calculate heatmaps of correlations between mCA/CA levels of genomic elements in 
and outside of TADs and mean TAD mCA/CA levels (Figure S3J), TADs were again divided into 
10 equally sized bins, with equal-sized regions placed upstream and downstream the domain. 
Enhancers, genes, and TSSs in the genome were then intersected with these regions, and spearman 
correlations between TAD methylation (subtracting out the methylation of the element if 
necessary) and element methylation within each region were calculated.  
 
To assess the similarity of mCA levels between individual elements inside and outside of the same 
TAD (i.e. TSS regions, enhancers, gene bodies; Figure S3K), each element was paired to each 
other element on the same chromosome. Each pair was then assessed if they paired within, or 
between TADs. Because mCA varies with genomic distance, each intra-TAD pair was matched to 
the extra-TAD pair with the most similar distance between elements, and Spearman correlations 
were calculated on the two distance-matched sets. 
 
Identification of enhancers 
Bed files of H3K27ac and H3K4me3 ChIP-seq were pooled by replicate. Peaks of H3K27ac and 
H3K4me3 ChIP-seq were identified using the MACS2 peak calling algorithm on the pooled bed 
files using the pooled ChIP Input as background signal (macs2 callpeak --nomodel -q 0.05). 
MeCP2 KO and wild type peak files were then combined using bedtools unionbedg, and 
overlapping peaks were merged into single peaks using bedtools merge. Bedtools intersect was 
used to identify H3K27ac peaks that did not overlap with gene promoter regions (1kb around 
annotated TSS) or with H3K4me3 peaks from MACS2. These non-overlapping H3K27ac peaks 
were then further filtered for landing within an H3K4me1 peak, as called in the ENCODE-
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generated broadpeak file for H3K4me1 ChIP from 8-week old cortex. All H3K27ac peaks that 
remained after these rounds of filtering were defined as enhancers. 
 
To identify the enhancers most robustly regulated by MeCP2, we used combined analysis of the 
MeCP2 KO and OE, similar to the approach used for determining gene-expression changes. We 
ran differential ChIP-seq analysis on H3K27ac from the MeCP2 KO and their littermate control 
animals (n=5), and from the MeCP2 OE and their littermate controls (n=3). Reads were quantified 
in all merged acetyl peaks, and edgeR was used to calculate nominal p-values and fold-changes 
for these peaks. These p-values were then combined using the Fisher method (log-sum), and were 
Benjamini-Hochberg corrected. Acetyl peaks with a combined q-value < 0.1, and a log2 fold-
change > 0 in the KO and a log2 fold-change < 0 in the OE were called as MeCP2-repressed peaks, 
while peaks with a combined q-value < 0.1, and a log2 fold-change < 0 in the KO and a log2 fold-
change > 0 in the OE were called as MeCP2-activated peaks.  
 
Enhancers were also called as misregulated in the DNMT3a Baf53b-cKO, using edgeR. H3K27ac 
ChIP-seq reads from the DNMT3A Baf53-cKO and control (n=6) were quantified in the merged 
acetyl peaks called from the MeCP2 KO/control. edgeR was then run on these regions, and peaks 
with a q-value < 0.1 were called as misregulated in the DNMT3a Baf53-cKO. 
 
ATAC peak analysis 
To sensitively detect sub-peak-threshold histone acetylation signal that could correspond to 
putative regulatory elements, a compendium of all ATAC peaks detected in the genome was 
obtained from http://atlas.gs.washington.edu/mouse-atac/data/ 
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(atac_matrix.binary.qc_filtered.peaks.txt) and acetylation was quantified in these regions. ATAC 
peaks which landed within 1kb of a TSS were filtered out, and methylation and acetylation analysis 
was performed on them as described for enhancers. Equal-sized control regions for enhancers and 
ATAC peaks were generated through a structured resampling approach. Enhancers and ATAC 
peaks, if located within a gene, are shuffled within that gene. If the peak is extragenic, it is shuffled 
between the nearest upstream and downstream enhancer/gene/ATAC peak. In each case, enhancers 
and ATAC peaks are restricted from landing within existing enhancers and ATAC peaks. 
Normalized pseudocounts of acetylation for enhancers, ATAC peaks, and resampled ATAC peaks 
were generated from edgeR common dispersions, running on each dataset and mouse strain 
separately.  
 
Associations between enhancers and genes using Hi-C and GREAT 
GREAT 3.0 (McLean et al., 2010) was used to determine potential enhancer-promoter interactions. 
NCBI build 37 of Mus Musculus was used as the species assembly, and bed files of enhancer 
regions were uploaded into the web tool. Enhancer-promoter interactions were identified for 
MeCP2-repressed, MeCP2-activated, and all other enhancers. All identified genes linked to these 
enhancers were used for further analysis. To link enhancers to promoters by Hi-C, 
intrachromosomal Hi-C matrices (KR-normalized) were extracted at 1.5 kb resolution using Straw 
(Durand et al., 2016), and mean average interactions for all distances were calculated per-
chromosome. Each matrix was then filtered down to only interactions between promoters and 
enhancers within 3mb of each other, and enhancers-promoter pairs with greater than 3 observed 
interactions and an observed/expected ratio over 1.5 were linked, making Hi-C-linked enhancers. 
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Enhancers that were linked to promoters of MeCP2-repressed or MeCP2-activated genes were 
then used in analysis in Figure 6B. 
 
For analysis of intragenic versus extragenic contact frequencies (Figure 6G), the same normalized 
contact matrices were analyzed. Genes greater than 50kb were extended on either side by their 
respective gene lengths, and contacts were mapped to them using bedtools intersect -wao -F 1. 
Each region was then split into 60 equally-sized bins (20 upstream, 20 intragenic, 20 downstream), 
making 3600 possible regions of interactions. Average interaction frequencies within these regions 
were calculated from the interaction matrix, and each gene’s intragenic and extragenic interactions 
were aggregated by calculating the mean of each bin of interaction.  
 
For Figure 6H, intragenic and extragenic enhancer-promoter interactions were distance matched 
to control for the greater number and variability of extragenic interactions. To do this, a similar 
resampling approach to Figure S3K was used: for each intragenic interaction, an extragenic 
interaction with a similar distance was selected for comparison. 
 
To assess the relationship between enhancer acetylation fold-change and gene fold-change (Figure 
S5M), partial correlations between enhancer/control region acetyl fold-change and gene fold-
change were calculated by averaging the acetyl fold-changes of elements within the gene and 
correlating this aggregate value to that gene’s fold-change. 
 
Quantitative 3C analysis 
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Quantitative PCR was employed, as previously described (Joo et al., 2016; Schaukowitch et al., 
2014; Tolhuis et al., 2002), to determine enhancer-promoter interactions of enhancers using the 
primers listed (see STAR Methods). Negative regions were selected from genomic restriction 
fragments that did not contain detectable enhancer sequences and were located nearby to the 
enhancer being tested but in closer proximity to the anchor TSS. Relative concentrations of 
enhancers and corresponding negative regions were calculated from a standard curve of BAC 3C 
libraries containing the targeted loci. Enrichments of interactions were then calculated as the 
relative concentration of targeted enhancers divided by the relative concentration of the nearby 
negative region. 
 
mC context enrichment analysis 
Trinucleotide contexts and methylation status (a rational number determined through bisulfite 
coverage - # of Cs mapping to site / # of Ts mapping to site) were determined for each cytosine 
and guanine in the genome, and then sites were assigned to enhancers based on proximity (a site 
was assigned to an enhancer if it was within 1 kb of the enhancer’s center). T-tests were then run 
for each context, summing up methyl-weighted or unweighted (for total mC per kb / C sites per 
kb respectively), or averaging methylation statuses (for percent mC), comparing test sets 
(up/downregulated enhancers, or enhancers within certain genes) to a set of resampled control 
enhancers with similar acetylation levels 5 times the size of the test set. 
 
mC vs acetylation change local correlation analysis at enhancers 
For both enhancers and gene local correlation analysis, 1 kb-sized bins were assessed for average 
methylation around and within enhancers/genes, making an N x M sized matrix of methylation, 
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where N = # of enhancers/genes, and M = # of bins. Each column of this matrix was then correlated 
against the matching enhancer/gene’s fold-change in the MeCP2 KO/MeCP2 OE. For enhancers, 
correlation analysis was centered on summits of wild-type acetylation and MeCP2 KO acetylation 
and analyzed separately through MACS2. 
 
Running-average plots 
Running-average plots of mCA/CA and genic fold-change, as well as total mC sites and genic 
fold-change were generated from means of 201 gene bins, with a 1 gene step, using the rollMean 
command in the zoo package of R. Length-controlled resampling was performed by selecting a 
gene within .75 – 1.25 times the length of each gene in the test set. 
 
Data and Software Availability 










2.6.1 Figure 1. Regional non-CG methylation patterns are associated with 
domains of chromatin folding. 
A. Left, heatmap of changes in exonic RNA for genes detected as significantly dysregulated (FDR 
<0.1) in combined analysis of total RNA-seq from MeCP2 KO and MeCP2 OE cerebral cortex 
(grey indicates no data for replicate). Right, fold-change of exonic RNA in MeCP2 KO or OE 
vs wild-type control for an example MeCP2-repressed gene, Sdk1. ***, Benjamini-Hochberg 
adjusted pvalue < 10-8 DESeq2 Wald test. 
B. Aggregate plot of cerebral cortex mCA/CA levels for MeCP2-repressed, MeCP2-activated, 
and all other genes. Mean mCA/CA for 1kb bins in the TSS and regions surrounding genes is 
shown at kilobase (left) and megabase (right) scale. For “Metagene” region, mean mCA/CA 
was calculated for 50 equally-sized bins within the gene bodies. 
C. DNA methylation levels around the Sdk1 gene as assessed by bisulfite-sequencing of the 
cerebral cortex.  
D. Hi-C interaction matrix data from cerebral cortex for a genomic region including two MeCP2-
repressed genes, Sdk1 and Auts2 (red), above mCA/CA and mCG/CG levels. Blue highlights 
indicate regions within TAD-like structures that are visible in the interaction matrix. 
E. A boxplot of mCA/CA levels of TADs that contain MeCP2-repressed genes or MeCP2-
activated genes, or TADs that do not contain dysregulated genes. Notches estimate the 95% 
confidence interval for the median (see methods). ***, p < 10-8 Wilcoxon rank sum test. 
F. Aggregate plot of mean mCA/CA for 4kb bins, phased on boundaries of TADs that contain 
MeCP2-repressed genes. Red, analysis of true TADs; pink, analysis repeated on shuffled TAD 
boundaries (see methods). Drop off in mCA/CA at boundaries is significantly different from 
TAD boundaries shuffled around MeCP2-repressed genes, p < 10-3 (see Figure S2C, methods). 
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G. Aggregate plot of mean mCA/CA phased on boundaries that contain the top 33% most 
differential levels of mCA/CA between TADs that contain MeCP2-repressed genes and 
neighboring TADs. Red, true TADs; pink, shuffled TAD boundaries. 
H. Cross correlation analysis of mCA/CA signal within and outside of TADs. mCA/CA values 
were calculated for 10 intra-domain regions and 10 equally-sized regions up and downstream 
of each TAD. Correlation between mCA/CA in these regions across TADs containing MeCP2-
repressed genes, all genes, and shuffled control TADs is shown.  
 
Data from cerebral cortex of 7-10 week old animals. n=6 per genotype (MeCP2 KO, wild type) 
and n=5 per genotype (MeCP2 OE, wild type) for RNA-seq, n=2 wild type for DNA methylation 






2.6.2 Figure 2. Domain-associated recruitment of DNMT3A defines megabase- 
and kilobase-scale mCA levels. 
A. Cross correlation within and outside of TADs for DNMT3A ChIP signal from the cerebral 
cortex at 2 weeks of age. DNMT3A ChIP/Input values were calculated for 10 intra-domain 
regions and 10 equally-sized regions up and downstream of each TAD. Correlation between 
these regions for all TADs is shown (see methods). 
B. Density scatter plot of DNMT3A ChIP/Input signal at 2 weeks of age and mCA/CA levels at 
8 weeks of age for each TAD. Spearman rho shown for correlation between DNMT3A signal 
and mCA/CA levels within TADs. ***, p < 10-8. 
C. Aggregate plots of ChIP/Input for DNMT3A at 2 weeks phased on boundaries of TADs that 
contain MeCP2-repressed genes. Black line and ribbon for each plot indicates the mean and 
standard deviation of 20 sets of resampled boundaries generated by shuffling TADs in the 
genome (see methods). 
D. Boxplot of MeCP2 ChIP/Input signal within TADs, split up by quartile of TAD mCA/CA. 
Spearman correlation shows significant association between these signals. ***, p < 10-8. 
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E. Density scatter plots of TAD mCA/CA levels and mCA/CA levels at various kilobase-scale 
genomic elements in the cerebral cortex at 8 weeks of age. Values for every TSS, gene body, 
or enhancer in the genome are plotted against the value for the TAD in which the element 
resides. Data is subtracted from TADs such that element methylation does not contribute to 
plotted TAD methylation. Spearman rho shown for the mCA/CA levels of each genomic 
element vs the mCA/CA level of the TAD that the element is in. ***, p < 10-8. 
 
Data from cerebral cortex of 2 or 8 week old animals. n=2-3 per time point for DNMT3A ChIP-





2.6.3 Figure 3. Loss of MeCP2 leads to promoter-associated transcriptional 
activation of MeCP2-repressed genes. 
A. Left, genome browser view of nuclear total RNA-seq coverage, as well as H3K36me3, 
H3K4me3, and H3K27ac ChIP-seq signals from the MeCP2 KO and wild type at an example 
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MeCP2-repressed gene, Zmat4. Right, close-up view of overlaid MeCP2 KO and wild type 
aggregate signal illustrating subtle increases in RNA-seq and ChIP-seq signal in regions 
indicated in blue at left.   
B. Boxplot of fold-changes in gene expression for MeCP2 KO versus wild type for MeCP2-
repressed, MeCP2-activated, and all other genes defined in combined analysis of total RNA 
from MeCP2 KO and MeCP2 OE versus wild type cerebral cortex (see Figure 1A). Shown are 
fold changes as measured by RNA-seq quantification of exonic regions from whole cortex 
RNA (Exonic) or intronic regions of genes for RNA from isolated nuclei (Intronic). ***, p < 
10-8 Wilcoxon rank-sum test. 
C. Profile of intronic expression and median fold-change for the first 100kb of genes identified as 
upregulated in intronic RNA analysis of MeCP2 KO versus wild type cortex (Figure S4B). 
Normalized median expression of one hundred 1kb bins in the wild type and MeCP2 KO is 
plotted for genes >100kb (see methods). The fold-change of the median expression of the bins 
between the MeCP2 KO versus wild type is shown in orange. The consistent differences 
between MeCP2 KO and wild type across the length of these genes suggests there is promoter-
associated upregulation of transcription for these genes in the MeCP2 KO (see also Figure 
S4G,H). 
D. Boxplots of mean fold-changes in ChIP signal for MeCP2 KO versus wild type at indicated 
regions of MeCP2-repressed, MeCP2-activated, and all other genes (defined by analysis of 
intronic RNA sequencing from MeCP2 KO and wild type cortex).  Value for Zmat4 gene 




E. Boxplots of fold-changes in gene expression for MeCP2 OE versus wild type for gene sets 
defined in combined analysis of total RNA from MeCP2 KO and MeCP2 OE versus wild type 
cerebral cortex (see Figure 1A). Fold-changes of reads corresponding to exonic or intronic 
RNA are shown. ***, p < 10-8 Wilcoxon rank-sum test. 
F. Profile of intronic expression and fold-change in the MeCP2 OE versus wild type as in 3C. 
The consistent differences between MeCP2 OE and wild type across the length of these genes 
suggests there is promoter-associated downregulation of transcription for these genes in the 
MeCP2 OE (see also Figure S4I). 
G. Boxplots of mean fold-changes in ChIP-signal for MeCP2 OE versus wild type as in panel D. 
*, p < 0.05 ; **, p<10-3 ; ***, p < 10-8 Wilcoxon rank-sum test. 
 
Data generated from cerebral cortex of 7-10 week old animals. For MeCP2 KO analysis: n=6 per 
genotype for RNA-seq, n=3 per genotype for H3K36me3, n=4 per genotype for H3K4me3, n=5 
per genotype for H3K27ac. For MeCP2 OE analysis: n= 5 per genotype for RNA-seq, n=2 per 





2.6.4 Figure 4. MeCP2 represses enhancers that are enriched for mCA and 
mCG binding sites. 
A. Left, genome browser view of overlaid wild type and MeCP2 KO aggregate H3K27ac ChIP-
seq signal, H3K4me1 ChIP-seq peaks, and H3K27ac peaks called as enhancers at two example 
MeCP2-repressed genes, Zmat4 and Efna5. Right, relative scale and close-up view of 
enhancers indicated in blue at left.  
B. Heatmap of per replicate fold-changes of H3K27ac ChIP signal between MeCP2 KO and 
MeCP2 OE, for enhancers identified as significantly changed (FDR < 0.1) in combined 
analysis of H3K27ac ChIP-seq from MeCP2 KO and MeCP2 OE. 
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C. Aggregate plots of mCA/CA or mCG/CG levels (left) or number of mCA and mCG sites per 
kilobase (right) of MeCP2-repressed, MeCP2-activated, and all other enhancers. Plots are 
centered at the midpoint for each enhancer. Average values for 100 bp bins are shown. 
D. Heatmap of enrichment significance for methylated trinucleotide sites in MeCP2-repressed and 
MeCP2-activated enhancers. Significance of enrichment or depletion was calculated by 
comparing mC sites per kb in the enhancers to resampled sets of enhancers that are not 
significantly changed (see methods).   
E. Boxplots of MeCP2 ChIP/Input signal in MeCP2-repressed, MeCP2-activated, and all other 
enhancers. ***, p < 10-8 Wilcoxon rank-sum test.                                                                                                                             
F. Boxplots of fold-changes of H3K27ac ChIP signal in MeCP2 KO versus wild type across 
deciles of mCA/kb (left) and mCG/kb (right) for all enhancers genome-wide. Spearman rho 
shown for correlations of each methylation mark with the change in H3K27ac at enhancers. 
***, p < 10-8. 
G. Boxplots of fold-changes of H3K27ac ChIP signal in MeCP2 OE versus wild type for all 
enhancers across deciles of mCA/kb (left) and mCG/kb (right). Spearman rho shown for the 
correlation of each methylation mark with the change in H3K27ac at enhancers. ***, p < 10-8. 
H. Plot of spearman correlations between H3K27ac fold-change at enhancers in the MeCP2 KO 
and mC/kb for 500bp bins in and around the enhancers. Plots are centered at the summit of 
enhancer H3K27ac ChIP peaks. 
I. Plot of spearman correlations for H3K27ac fold-change at enhancers in the MeCP2 OE and 




Data from cerebral cortex of 7-10 week old animals. For MeCP2 KO: n=5 per genotype for 
H3K27ac. For MeCP2 OE: n=3 per genotype for H3K27ac. n=2 wild type for DNA methylation 





2.6.5 Figure 5. mCA-associated de-repression of enhancers in DNMT3A 
Baf53b-cKO.  
A. Quantification of mCG/CG and mCA/CA levels in enhancers genome-wide for wild type and 
DNMT3a Baf53b-cKO cerebral cortex. Error bars = SEM, **, p < 10-3 , ***, p < 10-8 two-
tailed t-test. 
B. Fold-change for mRNA of MeCP2-regulated genes (left) and H3K27ac for MeCP2-regulated 




C. Profiles of mC/C and mC/kb for enhancers detected as significantly dysregulated in the 
DNMT3A Baf53b-cKO (see Figure S6D).  
D. Boxplots of fold-changes of H3K27ac ChIP signal in DNMT3A Baf53b-cKO versus wild type 
across deciles of mCA/kb (left) and mCG/kb (right) for all enhancers genome-wide. Spearman 
rho shown for correlations of each methylation mark with the change in H3K27ac at enhancers. 
* p < 0.05, ***, p < 10-8. 
 
Data from cerebral cortex of 7-10 week old animals. n=6 per genotype for DNA methylation, n= 







2.6.6 Figure 6. MeCP2-repressed enhancers are linked to MeCP2-repressed 
genes. 
A. Boxplot of enhancer mCA/kb for enhancers within TADs containing MeCP2-repressed genes, 
MeCP2-activated genes, or no dysregulated genes. **, p < 10-3, ***, p < 10-8 Wilcoxon rank-
sum test.  
B. Heatmap of enrichment for the associations between MeCP2-repressed and MeCP2-activated 
enhancers with MeCP2-repressed and MeCP2-activated genes. Comparisons are for enhancers 
within the same TAD as MeCP2-repressed/activated genes (“Same TAD”), assigned to 
MeCP2-repressed/activated genes by GREAT analysis (McLean et al., 2010) (“GREAT”), 
enriched for enhancer promoter contacts by Hi-C (Bonev et al., 2017) (“Hi-C-linked”), or 
found within MeCP2-repressed/activated genes (“Intragenic”). Significance of enrichment or 
depletion was calculated from the median p-value of multiple Fisher's exact tests on 1000 sets 
of resampled, acetylation-matched control enhancers (see methods). Value shown for each 
comparison is the median log2 enrichment (odds ratio) for the overlap of true MeCP2-regulated 
enhancers compared to the overlap of control enhancers. 
C. Barplots of log2 fold-changes of H3K27ac ChIP-signal in MeCP2 KO versus wild type for 
enhancers near MeCP2-repressed genes, Zmat4 and Auts2. TAD regions overlapping the 
MeCP2-repressed genes are indicated in blue above. Red bars, enhancers within MeCP2-
repressed gene; pink bars, other enhancers within the same TAD as MeCP2-repressed gene; 
gray and black bars, extragenic and intragenic enhancers in other TADs. *, indicates enhancers 
identified as significantly changed in genome-wide analysis (FDR < 0.1). 
D. Boxplots of fold-changes in H3K27ac ChIP signal in the MeCP2 KO (top) and the MeCP2 OE 
(bottom) for enhancers within TADs that contain MeCP2-repressed, MeCP2-activated genes, 
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or no dysregulated genes (“Same TAD”, left), and for enhancers found within these genes 
(“Intragenic”, right). ***, p < 10-8 Wilcoxon rank-sum test. 
E. Pie charts displaying intragenic and extragenic distributions of MeCP2-repressed, MeCP2-
activated, and all other enhancers. **, p < 10-3, ***, p < 10-8 chi-squared test comparing 
distribution of dysregulated enhancers to distribution of enhancers that are not significantly 
changed. 
F. Boxplots of fold-changes of H3K27ac ChIP signal in MeCP2 KO (top) or MeCP2 OE (bottom) 
versus wild type for intragenic and extragenic enhancers across deciles of enhancer mCA/kb 
(left) and mCG/kb (right). Spearman rho shown for correlations of each methylation mark in 
enhancers and their change in H3K27ac. ***, p < 10-8. 
G. Heatmap of aggregate observed/expected Hi-C interaction frequencies for regions inside and 
outside of genes, genome-wide (see methods). 
H. Boxplot of observed/expected Hi-C interactions detected for enhancers and promoters 
genome-wide, comparing enhancers found within (Intragenic) and outside (Extragenic) of 
genes (see methods). To facilitate comparison, distances of enhancer-promoter interactions 
were controlled for (see methods). ***, p<10-8 Wilcoxon rank-sum test. 
I. Running-average plot of fold-change in intronic RNA expression in the MeCP2 KO (top) and 
MeCP2 OE (bottom) versus mCA/kb for genes containing various numbers of enhancers. 
Mean fold-changes are plotted for genes sorted by level of gene body mCA/kb. Mean shown 
for bins of 201 genes with a 1-gene step. 
 
Data from cerebral cortex of 7-10 week old animals. For MeCP2 KO: n=6 per genotype for RNA-
seq, n=5 per genotype for H3K27ac. For MeCP2 OE: n=3 per genotype for H3K27ac, n= 5 per 
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genotype for RNA-seq. n=2 wild type for DNA methylation (Stroud et al., 2017). Hi-C interaction 





2.6.7 Figure 7. TAD-associated mCA dictates enhancer repression by MeCP2. 
A. During early postnatal development, TAD structures in neurons dictate DNMT3A activity 
leading to the establishment of higher or lower mCA set-points within each TAD.  
B. In mature neurons, MeCP2 reads-out this methylation, repressing histone acetylation at enhancer 
elements. MeCP2 most strongly represses highly-methylated intragenic enhancers, resulting in 
repression of genes that contain multiple enhancers and lie within high mCA TADs. Upon 
disruption of MeCP2 or loss of mCA, dysregulation of intragenic enhancer activity leads to altered 






2.6.7 Figure S1. Identification of MeCP2-regulated genes in the cerebral 
cortex by combined RNA-seq analysis of MeCP2 KO and MeCP2 OE. Related 
to Figure 1. 
A. Venn diagram of the overlap between genes identified as MeCP2-repressed and MeCP2-
activated in combined analysis of MeCP2 KO and OE versus wild type cerebral cortex and 
genes previously identified as consistently dysregulated across multiple datasets and brain 
regions (Gabel et al., 2015). ***, p < 10-8 hypergeometric test. Analysis was performed using 
coding genes found in annotation sets of both studies (see methods). 
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B. Boxplot of fold-changes in exonic RNA in the cortex of MeCP2 KO and wild type mice, for 
genes previously identified as consistently dysregulated across multiple datasets and brain 
regions (Gabel et al., 2015). ***, p < 10-8 Wilcoxon rank-sum test. 
C. Boxplots of mCA/CA and mCG/CG levels at the TSS (left) and gene bodies (right) of MeCP2-
repressed, MeCP2-activated, and all other genes. Light colored boxplots are plots generated 
for a control set of genes matched for the distribution of gene expression for each dysregulated 
gene set (see methods). * p < 0.05 ; **, p <10-3; ***, p < 10-8 Medians of Wilcoxon rank-sum 
tests on 100 gene-set resamplings. 
D. Boxplot of gene lengths for MeCP2-repressed, MeCP2-activated, and all other genes identified 
in combined analysis of total RNA-seq from MeCP2 KO and OE cerebral cortex. ***, p<10-8 
Wilcoxon rank-sum test. 
E. Running average plots of exonic RNA fold-changes versus gene length, for MeCP2 KO (left) 
and OE (right) versus wild type. Mean fold-changes are plotted for bins of 201 genes sorted 
by gene length with a 1-gene step (see methods). 
F. Running average plots of exonic RNA fold-change vs gene body mCA/CA for the MeCP2 KO 
(left) and OE (right) versus wild type. mCA/CA levels are calculated for the gene body defined 
as +3kb from the TSS to the TES. Mean fold-changes are plotted for bins of 201 genes sorted 
by mean mCA/CA per gene with a 1-gene step (see methods). 
G. Plot of genome-wide correlations between methylation levels for 1kb regions in and around 




H. Plot of genome-wide correlations between methylation levels for 1kb regions in and around 
genes and fold-changes in exonic RNA expression in the MeCP2 OE versus wild type for each 
gene.  
 
Data from cerebral cortex of 7-10 week old animals. n=6 per genotype for RNA-seq (MeCP2 KO, 
wild type), n=5 per genotype for RNA-seq (MeCP2 OE, wild type), n=2 wild type for DNA 
methylation (Stroud et al., 2017). In G and H analysis was carried out for genes over 75kb to 







2.6.8 Figure S2. Chromatin topology is associated with non-CG DNA 
methylation in the cerebral cortex. Related to Figure 1. 
A. Boxplots of mCA/CA and mCG/CG within TADs that contain MeCP2-repressed genes, 
MeCP2-activated genes, or no dysregulated genes. ***, p < 10-8 Wilcoxon rank-sum test.  
B. Aggregate plots of mCA/CA (left), mCG/CG (center), and BS-sequencing coverage rates and 
GC composition (right) phased on boundaries of TADs defined in Hi-C data from the cerebral 
cortex at eight weeks of age. TADs containing MeCP2-repressed (red), MeCP2-activated 
(blue), or all other genes (purple) are shown. “Inside” indicates TADs containing genes of 
interest. Black line and ribbon for each plot indicates the mean and standard deviation of 20 
sets of resampled boundaries generated by shuffling TAD locations in the genome (see 
methods).  
C. A histogram of -log10 p-values for paired t-tests, comparing the difference in DNA 
methylation on either side of the TAD boundaries or 1000 resampled TAD boundaries as in B. 
Histogram shows the distribution of p-values for resampled TADs, red line indicates p-value 
for true TADs.  
D. Cross correlation analysis of mCG/CG signal within and across TAD boundaries for all genes. 
mCG/CG values were calculated for 10 intra-domain regions and 10 equally-sized regions up 
and downstream of each TAD. Correlation between these regions across all TADs is shown 
(see methods). 
E. Boxplots of mCA/CA and mCG/CG within contact domains that contain MeCP2-repressed 
genes, MeCP2-activated genes, or no dysregulated genes. Contact domains were defined by 
analysis of Hi-C data generated from cerebral cortex neurons isolated from fetal brain (Bonev 
et al., 2017).  **,p < 10-3; ***, p < 10-8 Wilcoxon rank-sum test. 
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F. Aggregate plots of mCA/CA (left), mCG/CG (center), and BS-sequencing coverage rates and 
GC composition (right) phased on boundaries of contact domains defined in Hi-C data from 
fetal cortical neurons. Presented as in panel B. 
G. A histogram of -log10 p-values for paired t-tests, comparing the difference in DNA 
methylation on either side of contact domain boundaries or 100 resampled contact domain 
boundaries as in panel F. Histogram shows the distribution of p-values for resampled contact 
domains, red line indicates p-value for true contact domains.  
H. Cross correlation analysis of mCA/CA and mCG/CG signal within and outside of contact 
domains as in panel D. Resampling was performed by shuffling contact domain-sized regions 
around the genome and repeating the analysis of all genes (see methods).  
I. Boxplots of mCA/CA within TADs defined in cerebral cortex (top) and cerebellum (bottom) 
that contain MeCP2-repressed genes, MeCP2-activated genes, or no dysregulated genes. ***, 
p < 10-8 Wilcoxon rank-sum test. Cerebral cortex TADs were compared to genes from this 
study. Cerebellum TADs were compared to genes previously identified as misregulated in the 
cerebellum and multiple other brain regions (Gabel et al., 2015). 
J. Cross correlation analysis of mCA/CA signal within and outside of TADs defined in cerebral 
cortex (top) and cerebellum (bottom), as performed in panel H. 
K. Aggregate plots of mCA/CA from frontal cortex (top) and granule neurons (bottom) phased 
on boundaries of MeCP2 repressed TADs defined in cerebral cortex (top) and cerebellum 
(bottom). Analysis performed on TADs with highly differing mCA levels as in Figure 1G.  
 
A-D analysis of Hi-C interaction data (Dixon et al., 2012), and DNA methylation, n=2 (Stroud et 
al., 2017) from the cerebral cortex at 8 weeks of age. E-H analysis of Hi-C interaction data from 
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neurons isolated from E14.5 cortex (Bonev et al., 2017), and DNA methylation, n=2  (Stroud et 
al., 2017) from the cerebral cortex at 8 weeks of age. I-K analysis of bisulfite data from 6-week 
frontal cortex and granule neurons isolated from 7-12 week old cerebellum (Lister et al., 2013; 
Mellén et al., 2017)(Mellén et al., 2017). Hi-C data from 6-8 week old Cerebellum (Yamada et al., 







2.6.9 Figure S3. Binding of DNMT3A and recruitment of MeCP2 are shaped 
by topologically-associating domains. Related to Figure 2. 
A. Density scatter plot of DNMT3A ChIP/Input signal at 2 weeks of age and mCA/CA levels at 
8 weeks of age for random 1kb regions of the genome. Spearman rho shown for the correlation 
between DNMT3a signal and mCA/CA level. ***, p < 10-8.  
B. Aggregate plot of Input CPM at 2 weeks phased on boundaries of TADs that contain MeCP2-
repressed genes (TADS from cerebral cortex at eight weeks of age). Black line and ribbon for 
each plot indicates the mean and standard deviation of 20 resampled boundaries generated by 
shuffling contact domain locations in the genome (see methods). 
C. Cross correlation analysis of DNMT3A ChIP-seq signal at 2 weeks of age for contact domains 
defined in fetal cortical neurons. DNMT3A ChIP/Input values were calculated for 10 intra-
domain regions and 10 equally-sized regions up and downstream of each domain. Correlation 
between these regions across all domains is shown (see methods). 
D. Density scatter plot of DNMT3A ChIP/Input signal at 2 weeks of age and mCA/CA levels at 
8 weeks of age for contact domains defined in fetal cortical neurons. Spearman rho shown for 
the correlation between DNMT3a signal and mCA/CA level. ***, p < 10-8. 
E. Cross correlation analysis (performed as in panel C) for DNMT3A ChIP-seq signal at 8 weeks 
of age in TADs defined in the cortex at 8 weeks of age. 
F. Density scatter plot of DNMT3A ChIP/Input signal at 8 weeks of age and mCA/CA levels at 
8 weeks of age for TADs defined in the cortex at 8 weeks of age. Spearman rho shown for the 
correlation between DNMT3a signal and mCA/CA level. ***, p < 10-8.  
G. Cross correlation analysis (performed as in panel C) for MeCP2 ChIP/Input signal at 8 weeks 
of age in TADs defined in the cortex at 8 weeks of age. 
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H. Barplots of genome-wide mC/C levels in a DNMT3A Nestin-cKO and control cerebral cortex 
at 8 weeks of age. *, p < 0.05 two-tailed t-test. 
I. Boxplot of fold-changes in MeCP2 ChIP-seq signal within TADs upon ablation of mCA in the 
DNMT3A Nestin-cKO. Change in signal is shown for TADs separated by quartiles of 
mCA/CA (left) and mCG/CG (right) under wild-type conditions. Spearman rho shown for the 
correlation between DNMT3a signal and mCA/CA level. *** p < 10-8. 
J. Heatmap of correlation between mCA/CA levels of gene body (top), enhancer (middle), and 
TSS (bottom) regions found inside and outside of TADs and the average mCA/CA level for 
each TAD. Distinct drop off in correlation coefficient for these elements when they are found 
outside the TAD boundary illustrates influence of intra-TAD mCA/CA consistency. Similar 
correlation level and drop-off in signal is not seen for resampled TADs, placed in randomized 
positions in the genome (see methods).  
K. Barplots of correlations of mCA/CA levels for gene bodies (left), enhancers (middle) and TSSs 
(right), located in either the same TAD or separate TADs. To facilitate comparison, distances 
between pairs of elements in different TADs was matched to distances between pairs of 
elements in the same TAD (see methods). 
L. Density scatter plots of TAD methylation levels and methylation at kilobase-scale genomic 
elements in the cerebral cortex at 8 weeks of age. Values for every TSS, gene body, or enhancer 
in the genome are plotted against the TAD in which the element resides. As in Figure 2E, data 
is subtracted from TADs such that element methylation does not contribute to plotted TAD 
methylation. Spearman rho shown for the methylation levels of each genomic element versus 
the methylation levels of the TAD that the element is in. ***, p < 10-8. 
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M. Density scatter plots of TAD methylation levels and methylation at resampled random 
locations for regions size-matched to kilobase-scale genomic elements (as in panel L). Values 
for every resampled TSS-, gene body-, or enhancer-sized region in the genome are plotted 
against the TAD in which the element resides. Spearman rho shown for the methylation levels 
of each randomized genomic element versus the methylation levels of the TAD that the 
element is in. ***, p < 10-8. 
 
 
A,C,D Analysis of Hi-C interaction data from neurons isolated from E14.5 cortex (Bonev et al., 
2017), DNA methylation, n=2, from the cerebral cortex at 8 weeks of age, and DNMT3A ChIP-
seq data, n=3, from the cerebral cortex at 2 weeks of age (Stroud et al., 2017). B,E-G,I-M Analysis 
of Hi-C interaction data (Dixon et al., 2012), DNA methylation (n=2 wild type), DNMT3A ChIP-
seq data, (n=2 wild type), (Stroud et al., 2017), and MeCP2 ChIP-seq data (n=2 per genotype) 
(Kinde et al., 2016) from the cerebral cortex at 8 weeks of age. H n=2 per genotype for DNA 
methylation DNMT3A Nestin-cKO versus wild-type, 8 weeks of age. Note that some panels from 





2.6.10 Figure S4. Changes in intronic RNA are consistent with promoter-
associated transcriptional upregulation of long, highly methylated, MeCP2-
repressed genes in the MeCP2 KO. Related to Figure 3. 
A. Scatterplot of the log2 fold-changes in the MeCP2 KO versus wild type for exonic RNA 
measured by total RNA sequencing of cerebral cortex tissue compared to intronic RNA 
measured by total RNA sequencing of isolated nuclei from this tissue. Genes identified as 
MeCP2-repressed and MeCP2-activated in combined analysis of exonic RNA in MeCP2 KO 
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and MeCP2 OE mice (Figure 1; S1) are indicated by red and blue dots respectively, all other 
genes indicated as gray points. 
B. Left, heatmap of changes in intronic RNA for genes detected as significantly dysregulated 
(FDR <0.1) in nuclear RNA-seq from MeCP2 KO cerebral cortex (grey indicates, no data for 
replicate). Right, venn diagram of the overlap between genes called as MeCP2-repressed or 
MeCP2-activated in analysis of nuclear intronic RNA expression in the MeCP2 KO (pale 
colors) with genes called as dysregulated in combined analysis of exonic RNA in the MeCP2 
KO and MeCP2 OE mice (dark colors) (Figure 1; S1). ***, p < 10-8 hypergeometric test. 
C. Aggregate plot of cerebral cortex mCA/CA levels for MeCP2-repressed, MeCP2-activated, 
and all other genes defined by analysis of intronic RNA in the MeCP2 KO (see panel B). Mean 
mCA/CA for 1kb bins in the TSS and regions surrounding genes is shown. For “Metagene” 
region, mean mCA/CA was calculated for 50 equal-sized bins within the body of each gene. 
D. Boxplot of gene lengths for MeCP2-repressed or MeCP2-activated, and all other genes called 
by analysis of nuclear intronic RNA in the MeCP2 KO and wild type mice.  *, p < 0.05; ***, 
p < 10-8 Wilcoxon rank-sum test.  
E. Running-average plot of fold-changes in intronic RNA expression in the MeCP2 KO and wild 
type versus mean gene length (top) or mean gene body mCA/CA (bottom). Mean fold-changes 
are plotted for bins of 201 genes sorted by length of mCA/CA per gene with a 1-gene step (see 
methods). 
F. Plot of spearman correlations between fold-changes in intronic RNA expression in the MeCP2 
KO and wild type versus mCA/CA or mCG/CG for regions in and around genes. Analysis 
performed for 1kb bins across 200kb (top) and 2 Mb (bottom) regions. 
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G. Scheme to assess changes in pre-mature transcription termination in the MeCP2 KO versus 
wild type. Similar to analysis carried out by Boswell et al., 2017, a “termination ratio” for each 
gene above 50kb in each sample is defined as the ratio of read counts in the first 25kb of each 
gene to the read counts in the last 25 kb of that gene. The mean fold-change in the ratios 
between MeCP2 KO and wild type is calculated across all genes in paired replicates.  
H. Dotplot showing the change in termination ratio between the nuclear intronic RNA-seq data in 
the MeCP2 KO and wild type for genes that are not significantly changed and MeCP2-
repressed genes. A prediction for the change in this ratio that would be expected if the effects 
on mRNA in the MeCP2 KO were due entirely to changes in transcription termination rate was 
generated for comparison, “Predicted” (see methods).  
I. Dotplot as in panel H, showing the change in termination ratio between the intronic RNA-seq 
in the MeCP2 OE and wild type for genes that are not significantly changed and MeCP2-
repressed genes. 
 
Data from cerebral cortex of 7-10 week old animals. For MeCP2 KO: n= 6 per genotype for RNA-
seq; for MeCP2 OE: n=5 per genotype for RNA-seq; n=2 wild-type for DNA methylation (Stroud 








2.6.11 Figure S5. Analysis of enhancers dysregulated in MeCP2 mutants. 
Related to Figure 4 and Figure 6. 
A. Boxplot of fold-changes in H3K27ac ChIP signal in MeCP2 KO and OE (left) and MeCP2 
ChIP/Input signal (right) for enhancers identified with combined ChIP-seq analysis in KO and 
OE as MeCP2-repressed, MeCP2-repressed with high MeCP2/Input (see methods), MeCP2-
activated, or all other enhancers. Fold-changes were calculated by edgeR analysis of H3K27ac 
ChIP-seq signal at enhancer regions (see methods). Significantly dysregulated enhancers were 
defined as FDR < 0.1. *, p < 0.05, ***, p < 10-8 Wilcoxon rank-sum test.                                                                                                                             
B. Left, boxplots of mC/C, mC/kb, and C sites/kb at MeCP2-repressed, MeCP2-repressed with 
high MeCP2, MeCP2-activated, and all other enhancers, as displayed in panel A. Right, 
heatmap of enrichments for median levels of mC/C, mC/kb, and C sites/kb for MeCP2-
repressed and MeCP2-activated enhancers compared to all other enhancers. *, p < 0.05, **, p 
< 10-3; ***, p < 10-8 Wilcoxon rank-sum test. 
C. Heatmap of enrichment significance for number of mC sites (mC/kb, left), methylation level 
(mC/C, middle) and sequence occurrence (right) for trinucleotide sites in MeCP2-repressed 
and MeCP2-activated enhancers. Significance of enrichment or depletion was calculated by 
comparing occurrences of mC/kb, mC/C, or sequence alone for each trinucleotide in the 2kb 
region surrounding enhancers to resampled sets of enhancers that are not significantly changed 
and matched to changed enhancers for H3K27ac signal (see methods).   
D. Histograms of mCA/kb and mCG/kb in enhancers (black). Blue and red lines indicate the 




E. Genome browser view of an example MeCP2-repressed gene, Zmat4 (as in Figure 4A), 
showing overlaid wild-type and MeCP2 KO aggregate H3K27ac ChIP-seq signal, H3K4me1 
ChIP-seq peaks, H3K27ac peaks called as enhancers, and peaks from a compendium of ATAC-
seq peaks identified across 13 mouse tissues. Blue highlights ATAC-seq peaks that correspond 
to sub-thresholded enrichment of H3K27ac, not identified in peak calling analysis of H3K27ac 
ChIP-seq.  
F. Boxplots of H3K27ac ChIP signal in MeCP2 KO versus wild type (left) and MeCP2 OE vs 
wild type (right) for enhancers defined in this study, a compendium of detectable ATAC-seq 
peaks, and non-peak regions that are sized matched to ATAC-peaks but selected to not overlap 
enhancers of ATAC-seq peaks. Values for the highest mCA/CA decile are shown for each 
class, illustrating total levels of H3K27ac and mCA-dependent dysregulation ***, p < 10-8 
Wilcoxon rank-sum test. 
G. Boxplots of fold-changes of H3K27ac ChIP signal in MeCP2 KO versus wild type across 
deciles of mCA/kb (left) and mCG/kb (right) for ATAC-peaks described in panel E. Spearman 
rho shown for correlations of each methylation mark with change of H3K27ac at enhancers. 
***, p < 10-8 Wilcoxon rank-sum test. 
H.  Boxplots of fold-changes of H3K27ac ChIP signal in MeCP2 OE versus wild type across 
deciles of mCA/kb (left) and mCG/kb (right) for ATAC-peaks described in E. Spearman rho 
shown for correlations of each methylation mark with change of H3K27ac at enhancers. ***, 
p < 10-8. 
I. Quantitative 3C analysis of enhancers found in MeCP2 repressed genes, or control loci. No 
significant factors were detected in a 2-way ANOVA, using enhancer locations and genotype.. 
136 
 
J. Density scatter plot of log10 number of intragenic enhancers versus log10 gene length for all 
genes in the genome. Spearman rho shown for the number of intragenic enhancers and gene 
length for all genes with at least 1 enhancer. ***, p < 10-8. 
K. Running-average plot of fold-change in intronic RNA expression in the MeCP2 KO or MeCP2 
OE versus mCA/kb for genes containing enhancers (red line) and length-matched sets of genes 
that do not contain enhancers (gray lines). Mean fold-changes are plotted for bins of 201 genes 
sorted by mCA/kb with a 1-gene step (see methods).  
L. Local correlation analysis correlating mCA/kb (left) and mCG/kb (right) for 1 kb windows in 
and around genes to intronic RNA fold-changes for the gene in the MeCP2 KO (top) and OE 
(bottom). Genes at least 75kb in length are analyzed to allow visualization of correlations in 
gene bodies. Genic windows of methylation go from the TSS to 75kb downstream. 
M. Heatmap of correlation between fold-change in H3K27ac at intragenic regions and gene 
expression fold-change for MeCP2 KO and MeCP2 OE mice. Values are calculated as partial 
correlation for enhancers or control non-enhancer regions of the same size, removing the signal 
from the other class of element (see methods). Larger correlation for enhancers over control 
regions illustrates the link between enhancer regulation and transcriptional control. 
 
Data from cerebral cortex of 7-10 week old animals. For MeCP2 KO: n=5 per genotype for 
H3K27ac, n=6 per genotype for RNA-seq; for MeCP2 OE: n=3 per genotype for H3K27ac, n= 5 
per genotype for RNA-seq; n=2 wild-type for DNA methylation (Stroud et al., 2017). ATAC-seq 






2.6.12 Figure S6. Transcriptomic and epigenomic analysis of DNMT3A 
Baf53b-cKO. Related to Figure 5. 
A. Barplots of genome-wide methylation levels in the DNMT3A Baf53b-cKO at different CN 
dinucleotides. *, p < 0.05, **, p < 10-3; ***, p < 10-8 two-tailed t-test. 
B. Barplots of mCG (left) and mCA (right) levels in the DNMT3A Baf53b-cKO at genes, 
enhancers, and TSSs. **, p < 10-3; ***, p < 10-8 two-tailed t-test. 
C. Boxplots of mCG (left) and mCA (right) levels in the DNMT3A Baf53b-cKO within TADs 
that contain MeCP2-repressed genes, MeCP2-activated genes, or no dysregulated genes. ***, 
p < 10-8 Wilcoxon rank-sum test. 
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D. Heatmap of H3K27ac fold-changes for enhancers detected as significantly dysregulated in 
DNMT3A Baf53b-cKO mice by edgeR analysis (see methods). 
E. Heatmap of enrichment significance for the number of mC sites (mC/kb) within enhancers 
detected as significantly dysregulated in the DNMT3A Baf53b-cKO. Significance of 
enrichment or depletion was calculated by comparing occurrences of mC/kb for each 
trinucleotide in the 2kb region surrounding enhancers to resampled sets of enhancers that are 
not significantly changed but matched to changed enhancers for H3K27ac signal (see 
methods).   
F. Plot of spearman correlations between H3K27ac fold-change at enhancers in the DNMT3A 
Baf53b- cKO and mC/kb levels in the wild-type brain for 500bp bins in and around the 
enhancers. Plots are centered at the summit of enhancer H3K27ac ChIP peaks.  
 
Data from cerebral cortex of 7-10 week old animals. n=6 per genotype for Bisulfite-seq 





Chapter 3: Probing the mechanism of 




Experiments and analysis discussed in this chapter were done in collaboration between Nicole 
Hamagami (NH) and myself (AWC). AWC carried out all of the ChIP-seq and ATAC-seq 





MeCP2 and methylation-dependent regulation of enhancer activity has been identified in mouse 
cerebral cortex (Clemens et al., 2020). However, the direct mechanism by which MeCP2 mediates 
changes in H3K27ac to regulate enhancers remains to be determined. As discussed in Chapter 1, 
mutations of MeCP2 within the NID, particularly R306C, demonstrate the importance of NCoR 
for the regulatory function of MeCP2. This implicates the NCoR complex in the dysregulation of 
enhancer activity and gene expression that have been observed in studies of MeCP2 mutants. 
However, whether NCoR is directly responsible for controlling H3K27ac levels or a secondary 
aspect of enhancer activity remains to be determined. In the primary model that has been proposed 
(Tillotson and Bird, 2019), MeCP2 is required to recruit NCoR to sites of the genome in order to 
mediate histone deacetylation and gene repression. However, these studies are based on 
heterologous assays in non-neuronal cells (Lyst et al., 2013), and no studies have examined how 
NCoR recruitment to the genome is affected by MeCP2 mutations in vivo. Furthermore, a recent 
study testing the role of HDAC3 activity in MeCP2-NCoR mediated effects provides evidence of 
a mechanism for repression that occurs outside of the NCoR-associated deacetylase activity 
(Koerner et al., 2018). This study dissected the impacts of mutations of the catalytic site of HDAC3 
within the NCoR complex and found that loss of HDAC3 deacetylase activity did not rescue 
phenotypes in mice caused by overexpression of MeCP2. The lack of rescue by reduced 
deacetylation suggests that the regulatory effects of MeCP2-NCoR are not directly associated with 
the deacetylase activity (Koerner et al., 2018). Thus, the recruitment and deacetylation model for 
MeCP2-NCoR may not fully explain the results to date, and additional studies will be needed to 




Progress towards understanding where in enhancer regulation MeCP2-NCoR acts can be made by 
assessing which steps in enhancer activation are affected by loss of MeCP2. Enhancer activation 
is thought to be initiated by binding of pioneering transcription factors, enabling the recruitment 
of chromatin remodelers and histone modifying enzymes. Nucleosome eviction through 
modifications and chromatin remodeling allows for additional transcription factors and cofactors 
to bind, leading to the deposition of histone H3K4me1 at enhancers “poised” for activation (Local 
et al., 2018; Pundhir et al., 2015; Vernimmen and Bickmore, 2015). Histone acetyl transferase 
enzymes are then recruited to deposit H3K27ac, which mark active enhancers (Creyghton et al., 
2010; Lai et al., 2017). Once marked for activation, BRD4 co-activator interacts with acetylated 
histones, which then drives further co-activator recruitment (Calo and Wysocka, 2013; Lee et al., 
2017). Mediator is a critical cofactor recruited to active enhancers by BRD4 (Lee et al., 2017; 
Quevedo et al., 2019), which then functions as an anchor protein at enhancers and super enhancers 
to recruit transcription factors and other cofactors (Allen and Taatjes, 2015). Cohesin is one 
cofactor that interacts with Mediator at enhancers to in turn drive enhancer-promoter looping to 
connect active enhancers to their target gene and activate transcriptional initiation (Kagey et al., 
2010; Quevedo et al., 2019; Vernimmen and Bickmore, 2015). This multi-step process of enhancer 
activation creates many potential regulatory targets for MeCP2. 
 
If MeCP2-NCoR mediates deacetylation as a repressor of enhancer activity, it would be predicted 
that steps upstream of this process might not be affected by loss of MeCP2. Alternatively, changes 
upstream in enhancer activation may drive the changes of H3K27ac previously observed at 
enhancers. If these alterations are observed, it would support a model in which MeCP2-NCoR acts 
at a step before histone deacetylation, instead of directly deacetylating histones itself. To 
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understand how loss of MeCP2 repression affects gene expression, it is important to assess how 
direct or indirect alterations in H3K27ac cause downstream changes in coactivator binding and 
chromosome architectural proteins, linking enhancer activation to gene activation. Therefore, 
interrogation of each of the steps both upstream or downstream of H3K27ac, upon MeCP2 
mutation may provide further information on the mechanism of gene regulation by the mC-
MeCP2-NCoR pathway. For example, measuring upstream changes of chromatin accessibility or 
H3K4me1 of primed enhancers and downstream changes of binding profiles of BRD4, Mediator, 
Cohesin, and other cofactors in MeCP2 mutants, will provide direct readouts of epigenetic changes 
that occur outside of H3K27ac dysregulation. 
 
To date, limited analyses have been performed to assess which steps in enhancer regulation are 
affected by MeCP2 disruption, but some analyses suggest selective effects. For example, changes 
in promoter-enhancer interactions were not observed genome-wide from Hi-C or in targeted 
analysis of de-repressed enhancers with 3C upon loss of MeCP2 (Boxer et al., 2020; Clemens et 
al., 2020), so measuring changes in enhancer activation may provide insight into the regulatory 
role of MeCP2 outside of alterations in genomic architecture. By dissecting multiple steps of 
enhancer activation, we can develop a clear indication of how each step is affected by MeCP2-
NCoR, thereby predicting a more accurate model of gene regulation. 
 
Here, we perform systematic chromatin analyses to examine the mechanism of enhancer regulation 
by MeCP2. We interrogate how genomic binding of the NCoR complex is affected by loss and 
overexpression of MeCP2 and which steps in enhancer activation are altered by MeCP2 disruption. 
We show that NCoR binds to the genome independent of MeCP2 and that multiple steps in 
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enhancer activation are regulated by MeCP2, including chromatin accessibility, H3K4me1 
presence, and Mediator binding. However, Cohesin binding remains largely unchanged by MeCP2 
disruption. These findings suggest a model in which MeCP2 regulates the pre-bound NCoR 
complex to modulate enhancer activation directly at the regulatory element, but that this regulation 
occurs independent of alterations in enhancer-promoter looping. 
 
3.2 Results 
3.2.1 NCoR binding to regulatory elements in the brain is not dependent on 
MeCP2. 
To directly test the model that MeCP2 is required for NCoR recruitment, we examined if changes 
in levels of MeCP2 drive differences in binding profiles of the NCoR complex through ChIP-seq 
in adult cerebral cortex of MeCP2 mutants. If MeCP2 is required for NCoR recruitment, we would 
expect that ChIP-seq signal for NCoR1, a core component of the NCoR complex,  would follow 
patterns of MeCP2, where sites normally enriched for methylation and MeCP2 would show loss 
of signal upon loss of MeCP2 and gain in signal with overexpressed MeCP2. Alternatively, if 
recruitment is not affected by MeCP2 presence, we would not expect significant changes in 
NCoR1 ChIP-seq signal with MeCP2 mutants compared to wild-type cortex, potentially invoking 
an alternative regulatory mechanism outside of MeCP2-mediated recruitment. We performed 
ChIP-seq for NCoR1 in 8-week cortex of Mecp2 knockout, MECP2 overexpression, and wild-type 




MeCP2 binds broadly across the genome in a pattern that mirrors DNA methylation, and is 
depleted from, although still present at, lowly methylated, highly active regulatory elements. Thus, 
MeCP2-dependent binding of NCoR would be expected to show similar patterns as MeCP2 and 
DNA methylation across the genome. Surprisingly however, genome-wide binding profiles of 
NCoR1 heavily overlap with regulatory elements, with nearly half of NCoR1 peaks corresponding 
with defined enhancers in the cortex (Figure 1B). In fact, patterns of total NCoR1 binding across 
genotypes significantly correlate with the total amount of H3K27ac (Figure 1C). This finding is 
supported by previous studies that show ChIP-seq signal for NCoR and other co-repressors are in 
fact found at active promoters and enhancers, invoking an unknown and paradoxical mechanism 
of recruitment for co-repressors at sites of high activity (Siersbæk et al., 2017; Whyte et al., 2012). 
The profiles of NCoR1 suggest that MeCP2 is not a major determinant of NCoR complex binding 
across the genome, but rather the complex occupies active regulatory regions. 
 
To directly interrogate the impact of MeCP2 disruption on NCoR complex binding, we examined 
how NCoR profiles change in Mecp2 knockout and MECP2 overexpression mice. If MeCP2 was 
necessary for recruitment of the NCoR complex, we would observe decreased ChIP signal of 
NCoR1 at enhancers most misregulated by MeCP2 mutations. Instead we observe the opposite 
finding, where at MeCP2-repressed enhancers, which are a group of enhancers previously 
identified to be de-repressed in the absence of MeCP2 (see Chapter 2), there is a subtle, but 
significant increase in ChIP signal of NCoR1 (Figure 1D). Additionally, upon overexpression of 
MeCP2, we observe decreased ChIP signal (Figure 1D), suggesting that MeCP2 is not required for 




3.2.2 Loss of MeCP2 leads to alterations in accessibility and enhancer priming 
upstream of histone acetylation at MeCP2-regulated enhancers. 
We next sought to examine how disruption of MeCP2 affects each step in enhancer activation, in 
order to determine where in this process MeCP2 may collaborate with the independently recruited 
NCoR complex to repress activity. As previously mentioned, recent evidence suggests a role for 
NCoR-HDAC3 independent of deacetylase activity in neuronal gene regulation (Koerner et al., 
2018). In this way, the complex would not directly remove histone acetylation at enhancers to 
block gene activation, but instead may affect chromatin accessibility or early, priming histone 
modifications and/or the enzymes that deposit them. Regulation of these components could 
subsequently lead to changes in histone acetylation we and others observe. We therefore sought to 
investigate which steps in enhancer regulation MeCP2-NCoR may influence to control gene 
expression. 
 
To detect changes that occur early in the enhancer activation pathway, we performed ATAC-seq 
on Mecp2 knockout and MECP2 overexpression mice, assessing if changes in chromatin 
accessibility are driven by MeCP2 at enhancers (Figure 2A). Quantification of ATAC-seq signal 
within our enhancers defined by H3K27ac, illustrates a significant increase in MeCP2-repressed 
enhancers compared to non-misregulated enhancers in Mecp2 knockout mice, as well as a decrease 
in MECP2 overexpression compared to wild-type mice (Figure 2B). This trend was observed 
genome-wide as well, with changes in ATAC-seq correlating with total amounts of methylation 
(i.e. more MeCP2 binding sites) across all enhancers between Mecp2 knockout and wild-type mice 
(Figure 2C,  MECP2 overexpression not shown). These changes in ATAC-seq suggest that MeCP2 
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decreases chromatin accessibility at enhancers, showing MeCP2 has a repressive effect on 
enhancer activity upstream of H3K27ac. 
 
In order to get a refined measurement of changes in accessibility that occur directly at the core 
sequences of enhancers, we analyzed subnucleosomal regions as determined by ATAC-seq 
fragments less than the length of a mononucleosome (<100bp) (Figure 2A). Using this approach, 
we still found a significant change of ATAC signal at MeCP2-repressed enhancers, and highly-
methylated enhancers genome-wide, but to a lesser degree than all ATAC data (Figure 2D, E). 
Smaller magnitude changes of nucleosome-free ATAC signal suggest that the nucleosome-free 
region of enhancers may be less susceptible to reductions in accessibility driven by MeCP2 
compared to surrounding nucleosomal regions of enhancers. 
 
To assess the “priming” of enhancers for activation we next assessed how the H3K4me1 histone 
modification at these sites changes in response to loss of MeCP2. H3K4me1 has been described 
to be present at active regulatory elements as a precursor to H3K27ac (Creyghton et al., 2010; Lai 
et al., 2017). One potential mechanism of the effect of MeCP2 on enhancers is that it promotes 
demethylation of H3K4me1, which then causes a subsequent effect on enhancer-associated 
H3K27ac. Recent advances in genomic profiling have developed more sensitive techniques such 
as CUT&RUN and CUT&Tag that reduce background signal to measure protein binding with 
lower sequencing depth (Kaya-Okur et al., 2019; Skene and Henikoff, 2017). We have therefore 
implemented CUT&Tag to generate high signal-to-noise profiles for this modification genome-
wide to detect changes in H3K4me1 in Mecp2 knockout mouse cerebral cortex. Within MeCP2-
repressed enhancers, that are defined by their change in H3K27ac caused by mutation of MeCP2 
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(H3K27ac increases in Mecp2 knockout and decreases in MECP2 overexpression), we also 
observe increased H3K4me1 in the Mecp2 knockout and a decrease in MECP2 overexpression 
(Figure 2F, MECP2 overexpression not shown). Additionally, as previously observed for 
H3K27ac dysregulation by MeCP2, the enhancers with the most methylation exhibit the greatest 
upregulation of H3K4me1 signal in the Mecp2 knockout (Figure 2G). Notably, the effect size of 
H3K4me1 was more pronounced than H3K27ac, wherein for enhancers with the highest level of 
methylation, the change in H3K4me1 was greater in magnitude than the change in H3K27ac 
(compare Chapter 2 Figure 4F to Figure 2G).  
 
3.2.3 Loss of MeCP2 differentially affects cofactors associated with enhancer-
mediated promoter activation.  
The changes in H3K27ac observed at enhancers are likely to drive changes in downstream 
mechanisms in order to result in changes of gene activation. To investigate changes driven by 
MeCP2 mutations that may occur downstream of histone modifications, we measured how the 
presence of co-activators that mediate gene activation between promoters and enhancers are 
affected across MeCP2 mutants using ChIP-seq and CUT&Tag. We determined binding profiles 
of two complexes associated with enhancer activity, Mediator and Cohesin, across Mecp2 
knockout adult mouse cortex and found significant increases of Mediator in Mecp2 knockout 
compared to wild-type cortex at MeCP2-repressed enhancers compared to unaffected enhancers 
(Figure 2F). Conversely, ChIP-seq measurements of Cohesin identified only slight but significant 
increases in signal in Mecp2 knockout cortex compared to wild-type. In comparison to changes in 
Mediator, the changes in Cohesin at MeCP2-repressed enhancers are subtle. These findings 
suggest that loss of MeCP2 repression at enhancers leads to increased recruitment of Mediator, but 





Here we present initial analysis of the molecular mechanisms influenced by the mC-MeCP2-NCoR 
pathway to control enhancer activity. Contrary to a popularly proposed model for mC-MeCP2-
NCoR repression (Tillotson and Bird, 2019), we find that NCoR recruitment to the genome is 
independent of MeCP2 and that disruption of MeCP2 leads to dysregulation of multiple steps of 
the enhancer activation pathway, upstream and downstream of H3K27ac regulation.  
 
Given that we find that the NCoR complex does not require MeCP2 for recruitment, and this result 
is at odds with in vitro interaction assays, it will be important in future analyses to address antibody 
specificity for the NCoR complex in our genome profiling assays. Preliminary analysis of ChIP-
seq and CUT&Tag of a second component of the NCoR complex, TBLR1, indicates a high-degree 
of overlap between NCoR1 peaks and TBRL1 peaks, further supporting our NCoR findings (data 
not shown). Future experiments will expand on this TBLR1 data, allowing all conclusions to be 
based on two independent antibodies (NCoR1, TBLR1) and two methods (ChIP-seq and 
CUT&Tag) to assess NCoR complex binding. To further validate these results, we can use 
shRNAs to knockdown NCoR expression in vitro. ChIP-seq in control and NCoR-knockdown 
cells should show a measured depletion of NCoR signal in knockdown cells compared to control 
cells with normal levels. These control experiments will then provide further support for in vivo 




Because we observe changes in enhancer activation steps upstream of histone acetylation, our data 
support a mechanism through MeCP2 and NCoR that does not act through the HDAC3 component 
of this regulatory complex, but rather a yet to be defined role that drives these changes. We have 
identified steps upstream of histone acetylation in the enhancer activity pathway that are 
dysregulated through MeCP2 mutations that consist of increased chromatin accessibility 
surrounding enhancers and increased signal for the “primed” enhancer mark, H3K4me1. As these 
changes are canonically thought to occur upstream of H3K27ac modification, it may be feasible 
that these changes are driving the observed increases in H3K27ac upon MeCP2 loss. The greater 
effect size for H3K4me1 in MeCP2 mutants compared to H3K27ac changes suggests that 
H3K4me1 may be more directly affected by MeCP2. However, it is difficult to distinguish between 
technical differences (CUT&Tag vs ChIP-seq) or whether H3K4me1 is actually more affected by 
MeCP2 than H3K27ac. Distinguishing biological effects from technical differences will allow us 
to pinpoint a more direct target of MeCP2, where if H3K4me1 has a greater effect size, this 
suggests the changes in enhancer activity by H3K27ac are a downstream effect of MeCP2-
mediated regulation of H3K4me1. The same technical considerations are true for ATAC-seq as 
well. Therefore, while the cross-platform approach used for this study adds support for the findings 
on increased enhancer activity, it increases the difficulty of interpreting the magnitude of effects 
to identify the directly affected mechanism by the MeCP2-NCoR pathway. Finally, while increases 
in accessibility and H3K4me1 are thought to occur upstream of enhancer acetylation, it is possible 
that MeCP2-NCoR affect acetylation and that these changes feedback to affect accessibility and 
H3K4me1 in mechanisms that are not yet known. Future experiments measuring H3K27ac with 
CUT&Tag will add sensitivity to our previous ChIP-seq findings as well as be more directly 




While recruitment and binding of NCoR does not appear to be affected by the presence or absence 
of MeCP2, studies have begun examining if MeCP2 can regulate the activity of HDAC3 as a 
component of the NCoR complex. Mutations of the deacetylase activating domain (NS-DAD) 
cause a reduction in deacetylase activity of HDAC3, but fail to rescue phenotypes associated with 
MeCP2 overexpression (Koerner et al., 2018). To directly test the role of MeCP2 in HDAC 
activity, future experiments can measure NCoR-HDAC3 associated-deacetylase activity in vitro 
in the presence of wild-type MeCP2, NCoR-interacting deficient mutant MeCP2, or no MeCP2. If 
MeCP2 functions to control the activity of HDAC3, we would expect higher levels of deacetylase 
activity with wild-type MeCP2 compared to controls. Moreover, the presence of R306C mutated 
MeCP2 (which disrupts its ability to interact with the NCoR-TBL1-HDAC3 complex) should 
produce comparable deacetylase activity to the absence of MeCP2. Such an approach allows for a 
more direct measurement of the involvement in the interaction of MeCP2 with NCoR-TBL1-
HDAC3, and the results from these studies could corroborate the findings from Koerner et al. 
 
As much as upstream molecular mechanisms may be regulated through MeCP2, the changes in 
H3K27ac caused by MeCP2 mutations appear to lead to downstream effects on regulatory 
elements that recognize acetylated histone modifications. Our finding that Mediator shows a robust 
upregulation that is similar in magnitude to changes in H3K4me1 and H3K27ac at misregulated 
enhancers, suggests it is recruited to enhancers upon loss of MeCP2. MeCP2 may likely regulate 
the binding of other co-factors as well. In fact, a recent study of cultured human induced pluripotent 
stem cell neurons suggests that MeCP2 represses binding of BRD4 (Xiang et al., 2020), a co-
regulatory protein that forms condensates with acetylated enhancers to mediate gene activation 
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(Sabari et al., 2018). Future studies can examine if alterations in BRD4 occur downstream of the 
mC-MeCP2-NCoR pathway at enhancers in adult neurons. 
 
In contrast to our Mediator findings, we observed minimal changes in Cohesin at misregulated 
enhancers in MeCP2 mutant cortical tissue. In line with these limited changes in Cohesin are 
previous findings of 3C and Hi-C experiments in the same mouse model that did not identify 
significant changes in enhancer-promoter contacts (Boxer et al., 2020; Clemens et al., 2020). 
Alterations in Mediator binding, but not Cohesin, upon mutation of MeCP2 further suggests that 
the primary role of MeCP2 may be to control enhancer-associated modifications and cofactors (i.e. 
H3K4me1, H3K27ac, Mediator) but not enhancer-promoter looping. 
 
The identification of upstream and downstream effects on enhancer-associated histone 
modifications driven by MeCP2 has furthered the understanding of the role of MeCP2 in neurons. 
Future studies addressing potential additional downstream effects of H2K27ac dysregulation, like 
BRD4 recruitment at enhancers, may identify new functional consequences of MeCP2 mutations. 
For example, examination of MeCP2 in phase separating and condensate forming structures will 
show how the presence or absence of MeCP2 in condensates can influence mechanisms of 
molecular crowding and condensation of BRD4 (Bancaud et al., 2009) to affect other components 
from gaining access to these regions of high-regulatory activity. Continued studies could link 






3.4.1 Figure 1. NCoR binds to enhancers independent of MeCP2. 
A. Genome browser view of MeCP2-repressed genes illustrating H3K27ac and NCoR ChIP-seq 
between Mecp2 knockout and wild-type cortex as overlaid tracks. Below tracks are regions 
identified as enhancers from H3K27ac ChIP-seq and peaks of NCoR ChIP-seq signal. 
B. Pie chart of NCoR ChIP-seq peak distribution across regulatory and non-regulatory elements. 
C. Boxplot of quartiles of H3K27ac ChIP-seq quantified within NCoR ChIP-seq peaks. Spearman 
rho is shown as correlation between these two ChIP-seq marks. *** p<10-8. 
D. Boxplots of log2 fold changes in NCoR ChIP-seq in Mecp knockout (left) and MECP2 
overexpression mice (right) compared to wild-type at enhancers identified as misregulated by 




Data are from cerebral cortex 8-week-old wild-type, Mecp2 knockout, and MECP2 overexpression 







3.4.2 Figure 2. mC-MeCP2-NCoR drives changes in multiple steps of enhancer 
activation. 
A. Genome browser view of an MeCP2-repressed gene illustrating sequencing comparisons of 
H3K27ac ChIP-seq, ATAC-seq, and ATAC-seq filtered for nucleosome-free (NF) regions (sub 
100bp). Below the tracks are highlighted regions denoting peaks called as NF ATAC peaks. 
B. Boxplots of log2 fold-changes in ATAC-seq in Mecp2 knockout (left) and MECP2 
overexpression (right) mice compared to wild-type at misregulated enhancers identified by 
differential H3K27ac ChIP-seq. ***p<10-8, **p<10-3. 
C. Boxplots of log2 fold-changes in ATAC-seq across all enhancers genome-wide sorted into 
deciles based on total amounts of mCA per kilobase (left) and mCG per kilobase (right). Spearman 
correlations listed show the correlation between ATAC-seq fold-changes and levels of methylation 
at enhancers. ***p<10-8. 
D. Boxplots of log2 fold-changes in nucleosome-free (NF) ATAC-seq in Mecp2 knockout (left) 
and MECP2 overexpression (right) mice compared to wild-type that overlap with misregulated 
enhancers identified by differential H3K27ac ChIP-seq. ***p<10-8, **p<10-3, *p<0.05. 
E. Boxplots of log2 fold-changes in nucleosome-free (NF) ATAC-seq across all enhancers 
genome-wide that a NF ATAC peak overlaps. The enhancers are sorted into deciles based on total 
amounts of mCA per kilobase (left) and mCG per kilobase (right). Spearman correlations listed 
show the correlation between ATAC-seq fold-changes and levels of methylation at enhancers that 
the ATAC peaks overlap with. ***p<10-8. 
F. Boxplots of log2 fold-changes in CUT&Tag signal for H3K4me1 (left) and Mediator (MedI) 
(center) and ChIP-seq for Cohesin (Smc1) (right) in Mecp2 knockout compared to wild-type mice 
at misregulated enhancers identified by differential H3K27ac ChIP-seq. ***p<10-8, **p<10-3. 
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C. Boxplots of log2 fold-changes in H3K4me1 CUT&Tag signal across all enhancers genome-
wide sorted into deciles based on total amounts of mCA per kilobase (left) and mCG per kilobase 
(right). Spearman correlations listed show the correlation between CUT&Tag fold-changes and 
levels of methylation at enhancers. ***p<10-8. 
 
Data are from cerebral cortex of 8-week-old wild-type, Mecp2 knockout, and MECP2 
overexpression animals. n=2 for ATAC-seq and H3K4me1 CUT&Tag data; n=1 for Mediator 












Ongoing experiments and analyses discussed in this chapter were done as a collaboration between 
Dennis Wu (DYW), James Moore (JRM), and myself (AWC). AWC performed the ChIP-seq 
experiments and analysis, and DYW has been fundamental in furthering the understanding of 
neuronal patterns of mCH. JRM has pioneered the cell type-specific studies using the INTACT 
method and performed the RNA-seq experiments and analysis following isolation. AWC has 




Recent studies have discovered large quantities of mCH in neurons, defined cell-type specific 
profiles for this methyl mark, and linked it to the essential functions of MeCP2 (see Chapters 1-
3). These findings have demonstrated that mCH is a critical epigenetic component of the 
mammalian brain. However, important questions remain to be answered.  Progress has been made 
in identifying how chromatin architecture and gene expression states define mCH profiles in 
neurons, but insights into the molecular mechanisms that recruit and activate DNMT3A are still 
needed. Integrated methylomic, transcriptomic, and epigenomic studies have revealed strong 
candidate models for the long-enigmatic mechanism of MeCP2-mediated transcriptional control. 
However, rather than working through a previously proposed NCoR recruitment model, it appears 
that MeCP2 and NCoR may act to regulate early steps of enhancer activation and affect 
downstream recruitment of key coactivators. However, the precise site of direct action by MeCP2-
NCoR remains to be determined. Identification of this mechanism may also shed light on why 
intragenic enhancers are more affected than extragenic enhancers. Finally, accumulating evidence 
has implicated neuronal mC in diseases beyond MeCP2 disorders, suggesting other candidate 
genes for additional involvement exist that have not yet been tested. Here I discuss these 
outstanding questions, preliminary results addressing them, and future studies that can shed light 
on mechanisms of enhancer and gene expression control through the mC-MeCP2-NCoR pathway. 
 
4.2 Mechanisms of unique non-CG methylation patterns in 
the brain 
Our finding that the enhancers and genes most repressed by MeCP2 are not only enriched for mCH 
themselves, but are found within large megabase-sized regions of high CH methylation (Clemens 
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and Gabel, in press; Clemens et al., 2020) raises the question of how these large regions of 
methylation are put in place. DNMT3A is highest expressed at 2 weeks in mouse cortex, however, 
it is unknown what factors during this early timepoint determine how DNTM3A will deposit 
methylation across the neuronal genome. One candidate that is emerging from published studies 
and my preliminary work is the recruitment of DNMT3A to histone H3 methylated at K36. It has 
previously been shown that DNMT3A binds strongly to H3K36me3, and more recently has been 
identified to bind with greater affinity to H3K36me2 in embryonic stem cells (Rondelet et al., 
2016; Weinberg et al., 2019). Examination of the relationship between DNTM3A and H3K36me2 
within neurons will provide valuable information on the origin of neuronal mCH patterning. 
 
To understand if the affinity of DNMT3A to these histone modifications are relevant to the 
establishment of the neuronal epigenome, it will be interesting to assess the genomic profiles of 
H3K36me2 and DNMT3A in 2-week wild-type mouse cortex, when DNMT3A is at its peak 
expression. If H3K36me2 is a strong binding target of DNMT3A, we would expect that 
H3K36me2 would mark regions of the genome for DNA methylation deposition by DNMT3A and 
that regions with enriched ChIP-seq for H3K36me2 and DNMT3A at 2 weeks would correlate 
with enriched regions of mCH in adult, 8-week mouse cortex. To assess if this is the case, I 
performed ChIP-seq for DNMT3A and H3K36me2 in 2-week mouse cortex. This analysis shows 
a strong correlation of 2-week DNMT3A ChIP signal and 8-week mCH levels across TADs 
identified in mouse cortex that is consistent with our previous analysis (Clemens et al., 2020) 
(Figure 1A). Assessment of H3K36me2 indicates robust correlations between 2-week H3K36me2 
and DNMT3A in TADs, as well as 2-week H3K36me2 and 8-week mCH in TADs (Figure 1B, C). 
Together, these results may suggest that the mechanism of DNMT3A recruitment by H3K36me2 
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is conserved in neurons and that this facilitates the unique, broad domains of mCH deposition that 
occur in these cells. 
 
4.3 Understanding enhanced susceptibility of intragenic 
enhancers to repression by MeCP2 
A notable aspect of enhancer regulation by mC-MeCP2-NCoR that we have observed is that 
intragenic enhancers are more affected by MeCP2 repression and DNA methylation than 
enhancers found outside of genes. Classically, distance and position of enhancers has not been 
known to play a critical role in the capability of an enhancer to activate its target promoter (Nord 
and West, 2020; Schoenfelder and Fraser, 2019). However, we unexpectedly identified several 
location-dependent effects of MeCP2 on acetylation at enhancers and non-regulatory sequences: 
1) Enhancers that are located within a gene were more susceptible to dysregulation compared to 
enhancers outside of genes upon loss or overexpression of MeCP2 and loss of mCA from 
DNMT3A cKO. 2) Enhancers within a gene contact their promoter more than equal-distanced 
enhancers outside the gene. 3) Genes that contain more enhancers are more susceptible to 
regulation by MeCP2 than genes that contain fewer enhancers (Clemens et al., 2020). These 
findings indicate that intragenic enhancers may play a leading role in gene regulation through 
MeCP2.  
 
One possibility for the observed bias towards intragenic enhancers is the environment created by 
promoter-enhancer loops created during transcription. A recently-proposed model of 
transcriptional extrusion suggests that instead of polymerase progressing along the transcribed 
chromatin, polymerase machinery “reels-in” DNA, bringing the chromatin to the site of 
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transcriptional initiation (Zheng et al., 2019). In this scenario, intragenic enhancer-promoter 
contacts would be selectively increased compared to extragenic contacts as genes are transcribed 
and DNA is pulled in through the polymerase, creating more contacts. One newly proposed 
mechanism of regulation by MeCP2 depends on the formation of MeCP2 condensates within 
regions of high protein density (Fan et al., 2020; Li et al., 2020; Wang et al., 2020). For MeCP2 
bound to enhancers, if enhancer-promoter loops are being pulled towards the promoter during 
transcription, this could increase the number of contacts of loops with the promoter in a region of 
compacted chromatin. Thus, the collection of enhancers created at the promoter will also raise the 
density of MeCP2 and restrict the access of other coregulators within this region through molecular 
crowding (Bancaud et al., 2009). Enhancers outside of genes would not be exposed to this 
increased density as transcriptional extrusion would only occur within the gene itself, thereby 
allowing extragenic enhancers to escape high concentrations of MeCP2 and stronger repression by 
MeCP2. Comprehensive assessment of epigenomic changes in MeCP2 mutants and studies 
exploring how the role of MeCP2 in liquid-liquid phase separation or chromatin condensation 
contributes to its functions in gene regulation promise to further solidify our understanding of 
MeCP2. 
 
4.4 Understanding cell-type specific roles for mCH and 
MeCP2 
On a finer resolution than brain regions composed of heterogenous populations of cells, there exists 
a clear role for mCH and MeCP2 in cell-type specific gene regulation. Levels of mCH are highly 
cell type-specific, particularly methylation within gene bodies, which strongly correlates to cell 
type-specific gene expression (Lister et al., 2013; Luo et al., 2017; Mo et al., 2015; Stroud et al., 
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2017). However, systematic studies across cell types are needed to understand the relative 
importance of mCH in each cell type and to determine the complements of genes most impacted 
by its regulation. For example, there are large differences in total mCH levels across the genomes 
of neuronal subtypes, and it is possible that mCH and MeCP2 have larger impacts on gene 
regulation in high-mCH subtypes compared to lower-mCH subtypes. Therefore, loss of mCH or 
MeCP2 in disease may disproportionately impact these high-mCH subtypes, manifesting in 
specific circuit defects. Moreover, it has not yet been determined how the mechanism of MeCP2 
and DNA methylation identified in whole cortex to control enhancer function is utilized at a cell 
type-specific level. Studies using cell type-specific chromatin profiling, or single cell methods can 
identify how mCH and MeCP2 affect cell type-specific enhancers. 
 
In preliminary studies, we have begun to explore effects of cell type methylation within Mecp2 
knockout and MECP2 overexpression mice. Using the INTACT (Isolation of Nuclei Tagged in 
Specific Cell-Types) method (Deal and Henikoff, 2011; Mo et al., 2015) to isolate individual 
classes of neurons, we have initially profiled changes of gene expression and enhancer activity 
within Parvalbumin-positive (PV) interneurons isolated from MeCP2 mutant and wild-type 
cerebral cortex. PV+ neurons contain high levels of mCH compared to other neuronal classes, 
therefore providing a valuable substrate to detect mC-MeCP2 regulatory effects (Luo et al., 2017; 
Mo et al., 2015). In PV+ neurons, we found a significant overlap of misregulated genes and 
enhancers with whole cortex studies, as well as PV-specific changes mediated by MeCP2. 
Continued studies will profile Somatostatin-positive (SST) interneurons, another class with high 
levels of mCH (Luo et al., 2017; Mo et al., 2015), as well as two classes of excitatory neurons. 
These include layer V Rpb4+ neurons with relatively high levels of mCH and layer IV Nr5a+ 
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neurons with relatively low levels of mCH (Luo et al., 2017; Mo et al., 2015; Tasic et al., 2018). 
Results from these diverse classes of neurons with varying levels of CH methylation will provide 
valuable information for the biological function of mCH and MeCP2 within individual cell types. 
 
4.5 Disruption of mCH and MeCP2 in neurodevelopmental 
disease 
We now have evidence across multiple studies that MeCP2 does affect the transcription of many, 
if not all genes, within neurons. However, it has been difficult to identify the importance of any 
one gene due to the small degree to which most genes are affected. Notably, this pattern of gene 
dysregulation follows the developmental pattern of MeCP2 expression in neurons; gene expression 
studies in Mecp2 knockout and missense mutation mice have found that the classically observed 
changes of gene expression in adult mouse brain are not present early in development between 1-
4 weeks (Baker et al., 2013; Boxer et al., 2020). Because MeCP2 is very lowly expressed during 
this time period and there is no genome-wide change in gene expression, this highlights the 
importance MeCP2 plays in regulating the expression of these genes as it accumulates during 
neuronal maturation. The lack of gene dysregulation earlier in development corresponds with the 
delayed deterioration of neuronal function in individuals with Rett syndrome that occurs after 
largely normal development in the period prior to the buildup of MeCP2. As has been observed, 
Rett syndrome has a late onset after a seemingly normal development, which corresponds with the 
late onset appearance of mCH and MeCP2 in neurons. These events suggest that early neuronal 
maturation is affected when MeCP2 is disrupted. Critically, it has been shown in mice that re-
expression of MeCP2 between birth and 6-weeks can restore phenotypes back to wild-type state. 
This includes re-expression of MeCP2 after Rett-associated phenotypes manifest, suggesting a 
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reversible nature of this disease (Katz et al., 2016; Sinnett and Gray, 2017; Vashi and Justice, 
2019). These promising results in mice provide hope that an effective therapeutic can be used to 
treat children with Rett syndrome, even after symptoms arise. 
 
As discussed in Chapter 1, the balance of the mC-MeCP2-NCoR pathway has been shown to be 
essential for proper neuronal regulation, as mutations within this pathway drive 
neurodevelopmental disease, including Rett syndrome, MeCP2 duplication syndrome, autism 
spectrum disorder, and intellectual disability. We have also illustrated the sensitive nature of 
neuronal DNA methylation through studies of heterozygous disease-causing mutations of 
DNMT3A causing behavioral defects and recapitulating effects of neuronal enhancer 
dysregulation (Christian et al., 2020). 
 
The role of histone methyltransferases has also emerged as a critical factor in driving proper 
neuronal regulation. ASH1L and NSD1 are proteins responsible for H3K36 di-methyl 
modifications (Huang and Zhu, 2018; Weinberg et al., 2019), which our preliminary evidence has 
linked to patterning of mCH within neurons. If the DNA methylation regulatory system relies on 
H3K36me2 at an early stage in development, disruption of this histone methyl-mark should impact 
the ability of DNMT3A to deposit mCH. Disruption of ASH1L and NSD1 in neurons should 
prevent methylation of H3K36, which in turn may disrupt normal patterns of transcription and 
normal patterning and buildup of mCH by DNMT3A. These results would further support a 
connection between early postnatal patterns of H3K36me2 and adult patterns of DNA methylation 
and would raise the possibility that mCH is disrupted in neurodevelopmental disorders associated 




It will also be important to determine if mechanisms of DNA methylation deposition in neurons 
are specific to particular cell types or a common pan-neuronal mechanism. Studies identifying 
mechanisms that drive patterns of neuronal methylation and determining if disruption of molecular 
components involved in this process occur in disease may provide valuable information for 





4.6.1 Figure 1. Early developmental H3K36me2 distribution correlates with 
adult patterns of mCH. 
A. Comparison of TAD mCA/CA levels at 8 weeks and DNMT3A ChIP/Input in TADs at 2 
weeks. ***p < 10-8. 
B. Comparison of DNMT3A ChIP/Input at 2 weeks and H3K36me2 ChIP/Input in TADs at 2 
weeks. ***p < 10-8. 
C. Comparison of TAD mCA/CA levels at 8 weeks and H3K36me2 ChIP/Input in TADs at 2 
weeks. ***p < 10-8. 
 
Data are from cerebral cortex of 2- or 8-week-old wild-type animals. n=2 for DNMT3A and 
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